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Introduction to the thesis 
Introduction 
In the 90's the taxanes paclitaxel and docetaxel, both belonging to 
the so-called naturally occurring drugs, because of their origin from the yew 
trees Taxus brevifolia and Taxus baccata, respectively, were registered for 
clinical use in the treatment of cancer patients. Although their mechanism 
of action is the same, inducing cell death by promoting polymerization of 
tubulin into microtubules and particularly by inhibiting depolymerization of 
these microtubules (1-3), they are not simply two of a kind (4). Differences 
in activity, toxicity and pharmacokinetic behavior have been described over 
the last decade (5-10). In order to increase activity they have been 
combined with various other (anticancer) agents (4,11). To judge 
combination treatment on its merits, changes in the pharmaco-dynamics as 
well as modulations in the pharmacokinetics of the combined drugs have to 
be evaluated. This thesis explores the influence of other chemical entities 
on the pharmacokinetics of docetaxel and paclitaxel. Intended modulation 
of docetaxel by co-administration of a multidrug-resistance convertor is the 
topic of the first part of the thesis, the unintended and underestimated 
pharmacokinetic implications of the choice of Cremophor EL as the 
formulation vehicle of paclitaxel is the subject of the second part. 
Multidrug resistance is the phenomenon thought to be partly 
responsible for failure of cancer treatment with naturally occurring 
anticancer drugs such as taxanes (12-14). It is associated with 
overexpression of the transmembrane transport protein P-glycoprotein, 
which acts as an ATP-dependent drug efflux pump, yielding to a decrease 
in the intracellular concentrations of the substrate drugs (15-17). Abundant 
effort has been put into the development of agents that are able to inhibit 
P-glycoprotein, and when used in combination with anticancer drugs 
increase the intracellular exposure to these drugs (18-20). However, many 
clinical studies involving a wide range of P-glycoprotein inhibitors and co-
administered anticancer drugs have shown that these combination 
treatments almost always resulted in increased toxicity of the anticancer 
drugs particularly because of pharmacokinetic interaction between the two 
agents due to competition at the level of cytochrome-P450 3A isozymes 
(21,22), the major metabolic pathway of many drugs including docetaxel 
(23,24). Recently, a new 'second generation' P-glycoprotein inhibitor, 
R101933, has been developed which known major metabolic route is 
cytochrome-P450 unrelated. Since docetaxel is known to be a more pure 
substrate of P-glycoprotein than paclitaxel (25), it was obvious that co-
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treatment of docetaxel with R1 01933 could have great clinical importance. 
Therefore, we performed several pharmacokinetic and phase I studies with 
docetaxel combined with R101933, orally as well as intravenously. In order 
to determine the physiological and pharmacological consequences of 
inhibition of P-glycoprotein activity with respect to the disposition of 
docetaxel we monitored both plasma and fecal drug levels of docetaxel. 
Modulation of P-glycoprotein, particularly in the hepatobiliary tract, 
by Cremophor EL, the formulation vehicle of paclitaxel, was postulated as 
one of the explanations of the distinctly nonlinear pharmacokinetic behavior 
of this taxane (26-28). The operation of Michaelis-Menten kinetics, 
saturable distribution in combination with saturable elimination, was 
hypothesized as another cause of the nonlinear disposition of paclitaxel (26-
28). However, studies in mice demonstrated that in the absence of 
Cremophor EL the pharmacokinetic behavior of paclitaxel was linear (29). 
An explanation could be that, by its nature, Cremophor EL in blood is 
capable of forming micelles with a highly hydrophobic interior that can 
entrap the solubilised compound (30), consequently influencing the 
pharmacokinetic behavior of this drug. So we postulated that the nonlinear 
disposition of paclitaxel is caused by dose and time-related variations in 
Cremophor EL concentrations in the central compartment. To prove this 
hypothesis we performed a comprehensive pharmacokinetic analysis of 
paclitaxel and Cremophor EL in vitro and in patients, measuring paired whole 
blood and plasma levels of paclitaxel. Based on the results of these studies, 
we were able to develop and describe explicit modeling of the disposition of 
paclitaxel and free paclitaxel to permit a formal explanation of the observed 
phenomenon. 
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Chapter 1 
SUMMARY 
This review describes the clinical relevance of the two drug 
transporters P-glycoprotein (Pgp) and multidrug resistance-associated 
protein (MRP) and the in vitro phenomenon which is referred to as multidrug 
resistance (MDR). The attempts to try to block these resistance 
mechanisms are summarized with specific attention for the intentionally 
designed "second generation" MDR-convertors. Potential explanations of 
the limited clinical success rate are given and recommendations for the 
design of future studies provided. 
INTRODUCTION 
In vitro selection of tumor cells for resistance to so-called "naturally 
occurring" drugs, such as anthracyclines, vinca alkaloids, epipodo-
phyllotoxins, and taxanes, may result in the development of cross-
resistance to other, structurally and functionally unrelated natural 
compounds. This in vitro phenomenon is referred to as MDR and is 
generally regarded to be one of the major stumbling blocks to the efficacy 
of chemotherapy for human malignancies. A large variety of human cell 
lines displaying such an MDR phenotype have been identified. The MDR-
related anticancer drugs are derived from plants or micro-organisms, are 
structurally dissimilar and have different intra-cellular targets. What these 
drugs have in common is that they have a relatively low molecular weight 
and enter the cell by passive diffusion because they are preferentially 
soluble in lipids at physiological pH. 
Two different drug transporters, Pgp and MRP, have been identified, 
that can render cells multidrug resistant. Both have a broad substrate 
specificity and belong to the same large superfamily of transport proteins 
known as adenosine triphosphate (A TP) binding cassette (ABC) 
transporters. From a clinical point of view it is attractive to block these drug 
transporters in an effort to convert drug resistance into drug sensitivity. 
Indeed, there has been and still is, a very extensive research concerning 
such resistance converting agents, but the clinical success rate of their 
application has untill now been very limited. Underneath we will review the 
putative clinical involvement of the MDR phenotypes caused by Pgp and 
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MRP and we will discuss the limitations of the use of resistance converting 
agents, the difficulties encountered, and the potential future obstacles. 
PGP MEDIATED MDR 
The Pgp-mediated or so-called classical MDR phenotype is 
characterized by reduced intracellular drug accumulation through an energy-
dependent unidirectional drug-efflux pump (1). The energy required is 
supplied by A TP. This drug-efflux pump involves a transmembrane 
glycoprotein (referred to as Pgp) with a molecular weight of 170 kDa, and 
is encoded by the MDR1 gene on the long arm of chromosome 7. Pgp is 
approximately 1280 amino acids long, and is composed of two homologous 
halves; each half consists of six transmembrane domains and an 
intracellular loop with an ATP-binding motif (2). The precise mechanism by 
which Pgp exerts its effect is still a matter of debate. Pgp might extrude 
drugs directly from the plasma membrane even before they can enter the 
cytoplasm (model of "hydrophobic vacuum cleaner") (3). Another suggested 
mode of action is that a drug binds to a cytoplasmic region of Pgp, followed 
by an energy-dependent conformational change whereby the drug becomes 
transposed to the outside of the plasma membrane and is released (4-6). 
However, these models do not provide an explanation for the broad 
substrate specificity of the Pgp drug pump, which contrasts the new 
hypothesis recently formulated by Zhu. He proposed that Pgp functions as 
an energy-dependent efflux pump for certain conjugated metabolites 
(probably sulfates) of lipophilic anticancer drugs but not for the parent 
compounds (7). However, so far, data are lacking for in vitro conjugation of 
MDR-related anticancer drugs. 
Pgp expression is present in normal tissues, such as kidney (proximal 
tubule), adrenal gland, liver (biliary surface of hepatocytes), pancreas, 
intestinal tract (8), and in CD34 + hematopoietic stem cells (both in bone 
marrow and peripheral blood), lymphocytes (particularly CD56 +, natural 
killer cells), macrophages (9,10), and finally in capillary endothelium 
surrounding the brain and the testis. Although the physiologic role of Pgp is 
still speculative at this time, the anatomical sites of its expression suggest 
that Pgp is involved in general detoxification of xenobiotics in order to 
protect specific organs and cell types, and in transport of hormones. 
Experiments with Pgp-knockout mice have confirmed that a lack of either 
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one of the two murine drug-transporting Pgps (i.e. MDRl a or MDRl b) 
results in elevated drug levels in a wide variety of tissues and a reduced 
drug-tolerance (11,12). In other aspects these mice live quite normal 
showing that Pgp is not an absolute necessity for life (12,13). In line with 
this observation, an MDR 1 a Pgp-deficient sub population in the CF-1 mouse 
strain has been identified and breeding studies demonstrated that the 
inheritance of the markers follows a normal Mendelian autosomal pattern 
(14). 
MRP1 MEDIATED MDR 
The membrane-bound glycoprotein MRP1 has a molecular weight of 
190 kDa and is encoded by the MRP1 gene located on chromosome 16 
(15). It is also a member of the ABC superfamily of membrane transport 
proteins. MRP1 and Pgp only share 15% amino acid identity, even though 
they confer resistance to a similar, but not identical, range of cytotoxic 
agents (16). Whereas MRP1 expression also results in resistance to 
anthracyclines, epipodophyllotoxins, and vinca alkaloids, the resistance to 
taxanes, especially docetaxel, and mitoxantrone is significantly less than 
that observed in Pgp-mediated resistance (16,17). 
Despite the overlap in substrate specificity of Pgp and MRP1, it is 
very likely that their pump characteristics are very different. The available 
data strongly suggest that MRP1 is an ATP-dependent pump for glutathione 
(GSH), glucuronic acid and sulfate conjugates (18,19) of endogenous 
substances but also of xenobiotics, such as the anticancer drugs 
chlorambucil and melphalan (20). Interestingly, while the unmodified drugs 
are not transported by MRP1, GSH conjugates of doxorubicin and 
daunorubicin are (21). These data suggest that some cytotoxic drugs either 
first have to be metabolized by conjugation reactions in order to be 
transported by MRP1, although there presently is no conclusive evidence 
for this (22), or are involved in an MRP-related co-transport system 
involving GSH and unmodified (that is, not covalently bound) drug. The 
latter has yet only been suggested for vincristine (23). GSH-conjugate 
transporters have also been associated with the detoxification of heavy 
metals, which include cisplatin and this provides an interesting potential link 
between MDR and cisplatin resistance (24). 
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MRP1 is present in normal cells in liver, kidney (25,26), adrenal gland 
and testes (27,28). In normal brain, liver, small intestine and colon MRP1 
mRNA is present at low levels, while moderate levels of expression were 
found in lung, skeletal muscle, ovary and peripheral leukocytes (reviewed 
in: 29). The uniform expression pattern of MRP1 in normal tissues, 
suggests it may playa crucial role in normal cellular phvsiology, but much is 
yet unknown. MRP1 has been suggested to be involved in the regulation of 
intracellular redox potential and ion flux, in inflammatory responses, and in 
elimination of conjugated endo- and xenobiotics (30). Indeed MRP1 has 
been shown to protect the oropharyngeal mucosal layer and the testicular 
tubules against etoposide-induced damage (27). Much of the knowledge of 
the function of MRP1 is likely to result from investigations with specifically 
generated mutant mice lacking mrp 1 protein (31,32). 
PGP AND MRP1 EXPRESSION IN HUMAN TUMORS, AND THEIR 
POTENTIAL RELEVANCE 
Expression of MDR 1 has been detected in virtually all tumor types in 
man, ranging from almost absent to abundently present (Table 1) (8,33). 
The expression may be intrinsic or acquired. If normal cells are expressing 
high MDR1 levels tumors arising from such cells, such as colon and kidney 
cancer, usually also have relatively high intrinsic levels of MDR1 expression. 
Clinically, these tumors are all intrinsically drug resistant, i.e. have a very 
low response rate to chemotherapy. Other tumors, either initially sensitive 
(such as hematological malignancies, small cell lung cancer, ovarian 
cancer), less sensitive (breast cancer, some pediatric tumors) or insensitive 
(glioma) to chemotherapy, express no MDR1 before treatment, but high 
levels at relapse (acquired MDR) (36,38,39,44). The difference between 
these tumors in their initial sensitivity to chemotherapy, while negative for 
MDR1 expression, is one of the reasons to doubt the true relevance of Pgp 
in the occurrence of clinical drug resistance, even though several studies 
have reported a positive correlation between MDR1 gene expression and 
drug resistance in malignancies (45,46). Remarkably, consensus about 
elevated MDR 1 /Pgp levels and clinical drug resistance has been difficult to 
reach. This is probably due to differences in patient population, drug 
treatment and MDR 1 /Pgp detection methods. In the clinical correlation 
studies, MDR1/Pgp expression was estimated either by mRNA or protein 
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quantification. MDR1 mRNA expression was determined by PCR, Northern 
blotting, RNase protection assay or in situ hybridization. Pgp levels were 
quantitated by immunohistochemistry, flow cytometry or Western blotting. 
Except for in situ hybridization, flow cytometry and immunohistochemistry, 
all of these techniques were applied to RNA or protein fractions obtained by 
bulk destruction methods. Since tumors are heterogenous with regard to 
MDR1/Pgp expression and may contain a variable number of normal (matrix, 
epithelial and immune) cells, these assays mostly give an underestimation 
of the actual MDR1/Pgp levels. Despite all these difficulties, it is generally 
accepted now that Pgp is an adverse prognostic factor in childhood 
neuroblastoma, soft tissue sarcomas, colon cancer, locally advanced breast 
cancer and hematological malignancies (38,46-51). In osteosarcoma it is 
even a better prognostic marker than tumor necrosis after preoperative 
chemotherapy with high levels of Pgp predicting a higher relapse rate (52). 
The mechanisms responsible for malignant cells to increase expression after 
exposure to cytotoxic agents become more and more clear. In clinical 
samples, elevated MDR1/Pgp levels are not due to gene amplification. In 
acquired drug resistance alternatively, transcriptional activation (53), post-
transcriptional regulation leading to mRNA stabilization (54), and 
posttranslational modifications, such as glycosylation and phosphorylation, 
that can modify Pgp expression and function (55), might all be important. 
The in vitro identification of MRP1 as a drug-resistance gene for 
obvious reasons induced interest in its potential role in human tumors. 
MRP1 expression has been found in human tumors such as leukemias, Non-
Hodgkin's lymphoma (NHL), neuroblastomas, soft tissue sarcomas, and 
cancers of the lung, breast, colon and esophagus (Table 1). Also for MRPl , 
gene amplification is not likely to be a common mechanism of MRP1 
expression. In patients with squamous cell NSCLC, MRP1 expression was 
negatively correlated with treatment outcome (62). Analysis of paired tumor 
samples taken before and after chemotherapy in patients with squamous 
cell cancer of the esophagus showed significant increase in MRP1 
expression in post-chemotherapy tumor samples from patients with partial 
remission or stable disease, suggesting that chemotherapy selected out 
drug-resistant cell clones (60). In neuroblastoma increased levels of the 
MRP1 gene correlate with amplification and overexpression of the N-mvc 
oncogene, a negative prognostic indicator associated with a more 
aggressive and chemotherapy resistant phenotype (69). In breast cancer, 
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MRP1 expression may be of prognostic significance in the subgroups of 
patients with the more favorable prognosis, i.e. patients with small tumors 
and node-negative patients, as well as in the setting of adjuvant systemic 
chemotherapy (58). In patients receiving first-line chemotherapy for 
recurrent breast cancer, MRP1 was more often positive in non-responding 
tumors (50%) than in responding tumors (18%). Only 1 out of 8 (13%) 
MRP-positive tumors had an objective response, compared with 6 out of 15 
(40%) MRP-negative tumors. Patients with MRP-positive tumors had a 
shorter time to progression on first-line chemotherapy than those with MRP-
negative tumors. Apparently, MRP1 expression is a significant predictor of 
poor prognosis in patients with recurrent breast cancer (59). However, 
although several studies thus suggest a role of MRP1 expression, the 
significance in the clinical resistance of cancers is still under investigation. 
Table 1 Pgp and MRP expression in human tumors 
Tumor Pgp MRP Reference 
Colon cancer + + 34,56,57 
Breast cancer + + 35,37,58,59 
Ovarian cancer + + 36,37 
Esophageal cancer + 60,61 
Lung cancer (SCLC +NSCLC) + 62-65 
Neuroblastoma + + 38 
Glioma + + 39 
Osteosarcoma + 40 
Soft tissue sarcoma + + 41 
Melanoma + 66 
AML + + 42,67 
B-CLL + B-PLL + + 43,68 
NHL + + 43 
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IN VITRO MODULATION OF MDR 
As a consequence of its broad substrate specificity, the function of 
Pgp can be inhibited by non-cytotoxic compounds that also have a high 
affinity for the drug binding site on the Pgp molecule. Probably their binding 
to Pgp inhibits its ability to bind cytotoxics, resulting in less efflux of co-
administered anticancer agents from Pgp expressing cells (70,71). 
Structural similarities of these reversal agents include a ternary nitrogen, 
aromatic ring and amphipathic characteristics (72). 
Table 2 Recently developed 'second generation' MDR-convertors 
MDR-convertor Analogue of Inhibitor of Stage of devol. Reference 
SDZ PSC 833 Cyclosporin Pgp phase III 76 
GF 120918 Acridine- Pgp phase I 77,78 
carboxamide 
VX-710 Pipecolinate Pgp phase I 79,80 
R101933 Pgp phase I 81,82 
MS-209 Quinoline Pgp Preclinical 83 
N276-12 Imidazothiazole Pgp Preclinical 84 
N276-14 Imidazothiazole Pgp Preclinical 84 
N276-17 Imidazothiazole Pgp Preclinical 84 
LY335979 Pgp Preclinical 85 
XR9576(2) Anthranilamide Pgp Preclinical 86 
XR9051 Diketopiperazine Pgp Preclinical 87 
B9309-068 Pyridine Pgp Preclinical 88 
BIBW-22 Dipyridamole Pgp + MRP Preclinical 89,90 
MK571 L TD4 receptor MRP Preclinical 91 
Antagonist 
PAK-104P Pyridine MRP Preclinical 92 
In 1981, the calcium channel blocker verapamil was found to restore 
the in vitro sensitivity to vinca alkaloids in pgp-mediated MDR by 
competitive inhibition of the Pgp drug pump (73). Presently, a large number 
of such so-called MDR-reversing agents or resistance convertors have been 
reported, including other calcium antagonists, cyclosporin and its 
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analogues, steroid hormones, phenothiazines, quinidine, and qUinine 
(reviewed in: 74,75). New modulators were developed to specifically inhibit 
Pgp and to be more suitable candidates for further clinical use (Table 2) 
(3,71 ). 
The MOR modulator SOZ PSC 833 was reported to inhibit the 
development of Pgp-related drug resistance in vitro (93). It has therefore 
been suggested that clinical studies should be performed involving the early 
application of MOR-convertors in order to prevent Pgp-expression rather 
than inhibit Pgp-function. The assumption is that treatment of drug-
sensitive Pgp-negative cancers (e.g. in newly diagnosed patients with 
leukemias, lymphomas, or myeloma or as first-line treatment of metastatic 
breast cancer) with effective MOR modulators might suppress the 
appearance of resistant Pgp-expressing subclones and result in a prolonged 
time to progression and, perhaps, even in the cure of an additional subset 
of patients (94). The major clinical endpoint of such trials will have to be 
time to progression (94). However, this theory does not take into account 
the fact that many other resistance mechanisms exist, and that it has been 
shown that these may immediately take on an active role. For example, a 
myeloma cell line was generated with the specific aim to identify 
mechanisms of resistance that emerge with combined treatment with MOR-
convertors and cytotoxic drugs (95). In cells selected with doxorubicin only, 
drug resistance was mediated by over-expression of MOR 1 IPgp. In contrast, 
in cells selected with doxorubicin plus MOR-convertor (verapamil) resistance 
was mediated through decreases in topoisomerase II protein levels and 
catalytic activity, and not by Pgp expression. 
Drugs that modulate Pgp, affect MRP1 function in a much less 
potent way (16,96,97). In a search for agents specifically modifying MRP-
mediated MOR, it was reported that the isoflavonoid genistein increased the 
daunorubicin and etoposide accumulation in resistant cell lines that express 
MRP1, but not MOR1 (98,99). However, in view of the high concentrations 
required and the inherent toxicity of genistein, the success of its use as a 
clinical resistance modifier will be negligible. 
MRP1 transport of cysteinyl leukotrienes has led investigators to 
examine agents that can reduce cellular levels of GSH and ultimately 
modulate the MRP-mediated resistance phenotype. One such agent is 
buthionine sulfoximine (8S0), which depletes intracellular GSH by the 
inhibition of y-glutamylcysteine synthetase, an important enzyme in the 
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GSH synthesis pathway (1 00,101). Depletion of cellular GSH by incubation 
of cells with BSO reduces the activity of MRP1 against cytotoxic drugs 
(1 02, 1 03). However, one should be cautious when interpreting the effect 
of BSO on MRP1-mediated resistance, since depletion of GSH induces 
mUltiple cellular changes that may be influencing alterations in drug 
handling in MRP1-expressing cells. 
Other efforts to modulate MRP1 activity involve the use of organic 
ion transport inhibitors such as probenicid and the leukotriene L TC4 
receptor antagonist MK571 (4), the use of alternative substrates such as 
GSSG and Nonyl-GS, or use of the ATPase inhibitor sodium orthovanadate. 
Finally, MRP1 is a phosphoprotein, whose phosphorylation is regulated by 
protein kinases. Addition of protein kinase C inhibitors to MRP1 
overexpressing cells, resulted in reduced levels of MRP1 phosphorylation 
concomitant with an elevation in drug accumulation (1 04) and in reversal of 
MRP1-mediated cellular resistance (4). A new approach could be the use of 
antisense oligonucleotides for the inhibition of MRP1 or Pgp-expression 
(1 05,106). With improvements in the stability of antisense oligonucleotides, 
this approach may one day prove valuable in reversing both MRP1- and 
Pgp-mediated MDR. 
CLINICAL VERSUS PRECLINICAL 
It is obvious that there are many important theoretical and actual 
differences between in vitro and in vivo models of MDR and the situation in 
patients. In models cells are selected for resistance and therefore the 
potential effect of the modulator, if present, will be more outspoken. In 
vitro models usually have a homogeneous pattern of cells, whereas human 
tumors are known to be heterogeneous. Because of this, there will also be 
an inhomogeneous expression of mechanisms of resistance in human 
tumors and the expression will even differ between cells of the same tumor. 
As a resultant, MDR-convertors at best will have an incomplete effect even 
in Pgp-positive tumors. 
The limitations of presently available assays for Pgp detection in 
tumor cells and the variability observed in the results obtained seriously 
limit their use as a diagnostic tool. The apparent contradictory results of 
studies aiming to use Pgp expression as a marker for chemosensitiviy 
(44,107) can probably be explained by difficulties with the detection of Pgp 
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and MDR1 especially at low levels of expression in terms of reproducibility, 
sensitivity, and specificity of current assays, and the accessibility of tumors 
for biopsy (94). 
Another potential concern that has arisen in extrapolating in vitro 
results to the clinical situation relates to binding of compounds to proteins 
in plasma. In contrast to in vitro studies, where MDR-convertors are usually 
tested in a system containing low protein concentrations (typically :::;10% 
plasma), the modulators are clinically exposed to high concentrations of 
proteins with drug binding sites, particularly albumin, in the systemic 
circulation. Indeed, it has been reported that in model systems the ability of 
MDR modulators to inhibit Pgp activity in cell cultures is significantly 
decreased with increasing protein concentrations (88,108). Using 
monolayers of polarized LLC-PK 1 pig kidney cells transfected with 
complementary DNA containing either MDR1 or MDR1 a sequences, it has 
been shown, for example, that inhibition of paclitaxel transport under 
complete (i.e., 100%) plasma conditions by SDZ PSC 833 is - 8-fold less 
effective than in tissue-culture medium containing 10% plasma (109). 
Because of this, in vitro studies are thought by some authors to be 
misleading as far as the potential clinical activity of the agents is 
concerned. In addition, based on these findings, it has been suggested that 
protein binding of MDR-convertors in the systemic circulation can reduce 
drug availability of the (pharmacologically active) free drug fraction at the 
tumor site (108). However, this view is unnecessarily simplistic and does 
not justify the generally accepted physiologic concept of the extent of 
distribution of a compound within tissues, including a tumor, involving 
multiple equilibria. A large body of evidence exists that only in the case of 
agents with high binding affinity binding will be important in a practical 
sense, and will impact upon the pharmacokinetic behavior of drugs in the 
body. In attempting to extrapolate in vitro data to in vivo expectations, 
many investigators tend to lose sight of the fact that the plasma comprises 
a relatively small fraction of the total volume available for drug distribution, 
and that protein-drug complexes of rather extraordinary stability must be 
formed [e.g. cisplatin to human serum albumin or UCN-01 to u 1-acid 
glycoprotein (110)] to substantially reduce the amount of drug that exists in 
the body in the active, diffusible, unbound form. Far outweighing a 
potential importance of protein binding concerns the ability of modulators to 
reach their target in solid tumors at sufficiently high concentrations (and 
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achieve inhibition of Pgp activity), a process compromized by the high cell 
density in patient tumors (approx. 109 cells/ml) that are rarely used in tissue 
cultures (usually 105 to 106 cells/ml) (111). 
There has always been a concern that MDR modulation would reveal 
new side effects of the anticancer drugs due to the inhibition of Pgp in 
normal tissues. However, severe unexpected toxicity due to administration 
of MDR-convertors was never seen in patients. This is most likely because 
plasma levels of the MDR-convertors associated with their maximum-
tolerated dose, limited by intrinsic toxicity of the compounds, were fairly 
lower than those required for effective Pgp inhibition. Another major 
contributing problem, particularly with the early MDR-convertors, is their 
potential to competitively inhibit cytochrome P450 (CYP) isozymes (mainly 
CYP3A4) involved in the metabolism of anticancer drugs (112). For this 
reason alone, significant interactions at the level of drug metabolism can be 
anticipated, that can result in pharmacokinetic interactions between the 
MDR-convertors and the co-administered anticancer drugs, with 
concomitantly significantly increases in toxicity of the anticancer drugs 
(Table 3). The area under the plasma concentration - time curve of the 
cytotoxic drug increases and the cytotoxic drug is therefore effectively 
dose-intensified. Pharmacokinetic studies of cyclosporin A given in 
combination with doxorubicin, for example, have shown that cyclosporin A 
can significantly increase a patient's overall drug exposure necessitating 
dose reductions of the anticancer drug of 40-50% because of exacerbated 
toxicity (118-121). The plasma concentration of doxorubicinol, the major 
metabolite of doxorubicin, increases more than threefold when doxorubicin 
is given together with cyclosporin A (119). Because doxorubicinol is less 
potent as an anticancer drug but may be more cardiotoxic than its parent 
compound, proposed studies of agents that may reverse the MDR 
phenotype are not without risk (122). Based on these findings, it has been 
suggested that administration of MDR-convertors is unlikely to improve the 
therapeutic index of anticancer drugs unless such agents lack significant 
pharmacokinetic interactions (112) . Consequently, it can be postulated that 
in the human setting it will be very difficult for many of the MDR-convertors 
to reach adequate concentrations without severe toxicity. 
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Table 3 Pharmacokinetic interactions between 'second generation' MDR-convertors and anticancer drugs 
Anticancer drug MDR-convertor PK-effect on anticancer drug Toxicity/Dl T No. of patients 
(ref) 
Paclitaxel (70mg/m 2 , day 2) SDZ PSC 833 po Not measured Increased 61 
(5mg/kg qid, days 1-3) hematologic toxicity (113) 
VAD SDZ PSC 833 po Elevated AUC of doxorubicin, Increased 22 
(5-15mg/kg7days) doxorubicinol and vincrisitne Hematologic toxicity (114) 
Etoposide (75-100mg/m2, days 1-5) SDZ PSC 833 iv Elevated AUC Increased 35 
(1-15mg/kg, days 2-6) Hematologic toxicity (115) 
Mitoxantrone and etoposide SDZ PSC 833 iv Elevated AUC of etoposide Mucositis 10 
(3.25mg/m2 and 210mg/m2 (10mg/kg, days 2-6) PK of mitoxantrone variable (116) 
days 1 and 3-6/3-5) 
Doxorubicin (35-50mg/m 2 , day 3) SDZ PSC 833 po Elevated AUC Increased 42 
(2.5-25mg/kg, days 1-5) Hematologic toxicity (117) 
Paclitaxel (80mg/m 2 , day 1) VX-710 iv Elevated AUC Increased 25 
(120mg/m 2 /h, day 1-2) Hematologic toxicity (79) 
Adriamycin (45mg/m 2 , day 2) VX-710 iv None No change 17 
(120mg/m 2/h, day 1-4) (80) 
Doxorubicin (50-75mg/m2, day 3) GF120918 po Elevated AUC of doxorubicin Increased 46 
(400 mg bid, days 1-5) and doxorubicinol Hematologic toxicity (77) 
Doxorubicin (40mg/m2, day 3) GF120918 po Elevated AUC of doxorubicin Increased 51 
(1000 mg bid, days 1-5) and doxorubicinol Hematologic toxicity (78) 
Paclitaxel (200 mg/m2, day 3) Rl01933 po None No change 10 
(200 mg bid, days 1-5) (82) 
Docetaxel (100 mg/m2 , day 3) Rl 01933 po None No change 15 
(300 mg bid, days 1-5) (81 ) 
Chapter 1 
In recent years it became obvious that clinical drug resistance is a 
complex of many different mechanisms. For example, other M RP-related 
transporters have recently been identified, including cMOAT (also called 
MRP2), MRP3, MRP4, MRP5, and MRP6 (123), and may contribute to the 
resistance phenotype. The exposure of cells to particular drugs or drug 
combinations might induce specific patterns of resistance related to these 
different mechanisms. Clearly, drug resistance is multifactorial in human 
tumors while in models it is artificial made monofactorial by selection. As a 
consequence human tumors have many ways to escape the effect of 
cytotoxic agents and reversing one MDR-mechanism may not affect the 
many others and will thus not solve the problem of intrinsic or aquired 
resistance to many of the nowadays known anticancer agents. 
Table 4 MDR modulation in hematolymphatic malignancies 
Malignancy MDR-convertor Trial design Response Reference 
percentage 
Multiple Verapamil Phase II 3/8 patients 124 
myeloma 
Verapamil Phase III 36 vs 41% 125 
Cyclosporine Phase II 48% 126 
SDZ PSC 833 Phase I 8/22 patients 114 
Leukemia Cyclosporin A Phase 1/11 69% 118 
Cyclosporin A Phase III 24 vs 23% 127 
Quinine Phase III 52.8 vs 45.5% 128 
SOZ PSC 833 Phase I none 116 
SOZ PSC 833 Phase II 32% 76 
Lymphomas High-dose verapamil Phase II 72% 129 
Oexverapamil Cross-over 12% 130 
Quinine Phase 1/11 7% 131 
CLINICAL MODULATION STUDIES 
The initial encouraging results for MDR modulation were noted 
among the hematological malignancies: AML, lymphomas and multiple 
myeloma (Table 4). Three early studies of verapamil or cyclosporin A with a 
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regimen consisting of vincristine, doxorubicin and dexamethasone (VAD) in 
patients with drug-refractory mUltiple myeloma or NHL and overexpression 
of Pgp in tumor cells suggested that the modulator may be effective in 
overcoming drug resistance, with higher response rates than could be 
expected on the basis of historical data (124,126,129). Although a later 
phase III trial of VAD in combination with verapamil was negative in 
patients with refractory mUltiple myeloma this could largely be explained by 
fluctuations in serum levels of verapamil (125). 
A controlled cross-over trial of oral dexverapamil beginning 24 hours 
before and continuing for 24 hours past the infusion of etoposide, 
vincristine, and doxorubicin in patients with drug-refractory lymphomas 
showed only a modest response rate to the addition of dexverapamil. In this 
study there was no correlation between response and the AUC of 
dexverapamil, but a relation between response and Pgp-expression of tumor 
cells was observed (130). A modest increase in hematological toxicity was 
found, but pharmacokinetics of the cytotoxic agents were not performed. 
For patients with poor-risk acute myeloid leukemia a phase I1II trial 
was performed with a loading dose of cyclosporin A followed by continuous 
infusion given on days 6-8, administered concurrently with daunorubicin 
starting after cytarabine given on days 1-5 (118). A high rate of responses 
was seen, 62% of the patients achieved complete remisssion with a median 
remission duration of 13 months. Pgp expression was detected in tumor 
cells of 70% of the patients. Doses of cyclosporin A, yielding plasma 
concentrations capable of reversing Pgp-mediated anthracycline resistance 
in vitro, could be incorporated into this induction regimen with acceptable 
toxicity. However, mean daunorubicin concentrations were significantly 
higher in patients experiencing hyperbilirubinemia due to cyclosporin A. A 
phase III multicenter study for the same patient population with 
mitoxantrone, given on days 2-5, and high-dose Ara-C, given on days 1-5, 
with or without quinine at a dose of 30 mglkgld as a continuous Lv. 
infusion on days 1-6 showed no significant increase of the overall response 
rate by adding quinine, although there was a trend for quinine to improve 
the response rate in Pgp-positive acute leukemias (128). Possibly the 
achieved quinine concentrations were too low to efficiently inhibit Pgp, 
which explanation is supported by the low incidence of quinine-related side 
effects mostly seen among responding patients meaning a slight increase in 
hematological toxicity. Unfortunately, the pharmacokinetic parameters of 
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mitoxantrone were not determined. A non-randomized study in leukemia 
patients using mitoxantrone, etoposide and cytarabine (MEC), given on days 
1-5, with or without cyclosporin A, days 1-4, could not suggest any 
apparent benefit in response rate, remission duration, or survival of the 
addition of cyclosporin A, neither was there a relation between Pgp-
expression and response (127). Based on previously described drug 
interactions, reduced doses of mitoxantrone and etoposide were used but 
nevertheless excessive toxicity, in particular grade 4 stomatitis was seen. 
Again, appropiate pharmacokinetics were not performed in this study. 
For solid tumors, the results from clinical modulation studies are even 
less encouraging (Table 5). Two large, randomized studies, involving 
untreated small-cell lung cancer patients and breast cancer patients 
respectively, failed to demonstrate any benefit of adding verapamil or 
quinidine respectively, both in terms of response and survival (132,135). 
Significantly more dose reductions were necessary in the verapamil treated 
patients due to hematological toxicity, suggesting interactions with one or 
more of the anticancer drugs (132). However again, pharmacokinetics were 
not studied. Breast cancer patients randomised for epirubicin alone or in 
combination with quinidine did not show any evidence of increased toxicity 
with quinidine suggesting that there was no pharmacokinetic interaction 
between quinidine and epirubicin, which was confirmed from actual 
pharmacokinetic parameters, obtained in only 23 of the 233 patients (135). 
Table 5 MDR modulation in solid tumors 
Malignancy MDR-convertor Trial design Response Reference 
percentage 
SCLC Verapamil Phase III 82 vs 80% 132 
NSCLC Cyclosporin A Phase 1/11 22.7% 133 
Breast cancer r-Verapamil Phase I 134 
Quinidine Phase III 43 vs 44% 135 
Dexverapamil Phase II 10% 136 
Ovarian SDZ PSC 833 Phase II 7% 113 
cancer 
Colorectal Cyclosporin A Phase II 1/24 patients 137 
cancer 
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The modifiers used in these trials have been 'off the shelf' 
compounds, developed initially for other indications and were incidentally 
found to have resistance modifying properties. As outlined, they have 
considerable intrinsic toxicity at required concentrations and clinical 
application is further compromised due to the occurrence of profound 
pharmacokinetic interactions with the anticancer agent, which confound the 
interpretation of toxicity and response data, if any. Almost without 
exception studies have shown that at the maximum-tolerated dose 
modulators yielded serum concentrations considerably lower than the 
concentrations required to effectively inhibit Pgp in vitro (reviewed in: 4). 
Early clinical studies with either quinine or high-dose cyclosporin A and 
various cytotoxic drugs, disclosed two potential consequences of MOR 
modulation on the central nervous system: an increase in nausea and 
vomiting (possibly due to increased anticancer drug distribution to the brain) 
and greater than expected obtundation when lorazepam was used as an 
antiemetic (119,120,128,138). Because of these inherent problems 
associated with the early MOR-modulators, more recent studies have 
focussed on potentially less toxic 'second generation' modifiers, i.e. 
pharmaceutical agents developed specifically for their resistance modifying 
properties such as SOZ PSC 833, GF120918, VX-71 0, and R1 01933. 
SOZ PSC 833 (valspodar) is the non-immunosuppressive cyclosporin 
o analogue with increased inhibitory activity as compared to cyclosporin A. 
Currently, SOZ PSC 833 is undergoing phase II and III evaluation in drug 
resistant myeloma in combination with V AD since pilot experiments 
suggested promising results with this treatment approach in this tumor type 
(114). A multicenter phase II trial in patients with refractory or relapsed 
acute leukemia of the combination of SOZ PSC 833 given as a continuous 
infusion of 10 mg/kg/d on days 1-5 and mitoxantrone, etoposide, and 
cytarabine given on days 1-5 suggested encouraging antileukemic effects 
with a complete remission rate of 32 % (76). Despite the use of reduced 
doses of mitoxantrone and etoposide, the doses of the anticancer drugs had 
to be further reduced due to substantial hematological and gastrointestinal 
toxicity. In line with this, pharmacokinetic studies showed 57% decrease in 
plasma clearance of etoposide and a 1 .8-fold longer t1/2 of mitoxantrone as 
compared with historical controls without SOZ PSC 833. The combination 
of 3-weekly paclitaxel 70 mg/m2, day 2, and SOZ PSC 833 5 mg/kg given 
orally q.i.d. on days 1-3, yielded some responses in a few patients with 
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paclitaxel and cisplatin refractory ovarian cancer (113). The low paclitaxel 
dose was selected based on results from an unpublished phase I trial 
identifying this dose in combination with the MOR-convertor as having 
similar tolerability to standard single agent paclitaxel dosing. 
Pharmacokinetics were not performed in this study, but previously 3 phase I 
studies involving etoposide or doxorubicin demonstrated an increased 
toxicity of the anticancer drug due to a markedly decreased clearance of 
the agent (115-117). Although the exact mechanism responsible for the 
increased drug exposure in combinations with SOZ PSC 833 are not known, 
these studies strongly suggest that the pharmacokinetic interactions result 
primarily at the level of elimination pathways. These may involve inhibition 
of endogenous Pgp expressed in bile canaliculi and intestinal epithelial cells, 
although metabolic interference due to competitive inhibition of hepatic 
CYP3A4 can not be ruled out. Recent work has also raised important issues 
regarding the specificity of SOZ PSC 833 for Pgp, as the compound has 
been demonstrated to inhibit a bile-acid transporter in the canalicular 
membrane that may be involved in active secretion of anticancer agents 
(139). In addition, the pharmaceutical formulation vehicle Cremophor EL for 
Lv. use of SOZ PSC 833 in itself dramatically affects the pharmacokinetic 
behavior of numerous compounds, including paclitaxel, doxorubicin and 
etoposide (140), thereby potentially nonselectively increasing the incidence 
or severity of toxic side effects. As a consequence of all pharmacological 
issues associated with SOZ PSC 833, it is unlikely this MOR-convertor will 
improve the therapeutic index of any of the used anticancer drugs, unless 
the systemic exposure to the anticancer drug is monitored and adjusted to 
that obtained without SOZ PSC 833. 
VX-710 (biricodar), a pipecolinate derivative, is the prototype of a 
series of non-macrocyclic high-affinity ligands that are potent modulators of 
Pgp mediated MOR in vitro. A recent phase I study combined 3-weekly 
paclitaxel 3-hour iv infusions in increasing doses with increasing 
concentrations of VX-710 given as a 24-hour iv infusion, started 8 hours 
before the start of paclitaxel infusion (79). The overall qualitative toxicity 
profile was similar to the toxicitity profile of single-agent paclitaxel therapy 
and VX-710 was well tolerated, with minimal clinical toxicity. However, a 
major alteration of the pharmacokinetic parameters of paclitaxel was 
observed, characterized by a disproportional increase in AUC with 
increasing doses of VX-710, the mean paclitaxel AUC increased 
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disproportional. This pharmacokinetic interaction was speculated to be 
caused by inhibition of P-450-dependent processes that are responsible for 
the metabolism of paclitaxel. As expected based on the pharmacokinetic 
interaction, neutropenia was the principal DL T of the regimen already 
observed at a paclitaxel dose of 80 mg/m2 in combination with 120 
mg/m2/h VX-710. In contrast, a phase I study of the combination of 
doxorubicin at a dose of 45 mg/m2 given on day 2, with VX-71 0 given as a 
96-hour infusion on days 1-4, showed that the pharmacokinetics of 
doxorubicin remained relatively constant among the various VX-710 dose 
levels and that dose limiting toxicity at doses up to 120 mg/m2/h VX-710 
was not found (80). 
GF120918 (elacridarl, another novel agent derived from 
acridinecarboxamide, fully reverses Pgp-mediated resistance in vitro and 
restores sensitivity of various MDR tumors to doxorubicin in vivo without 
adverse pharmacokinetic interaction in mice (141). Based on these results, 
phase I trials of orally administered GF120918 at increasing doses twice 
daily, days 1-5, in combination with doxorubicin 50-75 mg/m2 given on day 
3, were performed (77,78). In line with the mouse-model, the pharmaco-
kinetic behavior of the anthracycline was not altered by GF120918, 
although in 3 of 47 patients (6%) a significantly increased exposure to 
doxorubicinol was observed, which was likely related to inhibition of 
reductive NADPH glycosidase and/or CYP-450-mediated demethylation 
(142). A significant relationship was established between the AUC of 
doxorubicinol and the decrease in neutrophils and platelets, that was 
identical in the presence and absence of GF120918, indicating no 
pharmacodynamic potentiation of the hematological toxicity. 
Recently, a new orally administered potent inhibitor of Pgp in vitro, 
R101933, was investigated in two phase I studies in combination with 
either docetaxel or paclitaxel (81,82). Interestingly, the major metabolic 
route of R101933 is CYP450 unrelated and in line with this, it was 
observed that the plasma pharmacokinetic characteristics of docetaxel and 
paclitaxel were not substantially influenced by R1 01933 enabling studies to 
investigate the contribution of the MDR-convertor to the toxicity and 
activity of an anticancer drug independent of pharmacokinetic interactions 
(81 ). 
Crucial for the effect of the MDR-convertors is that sufficient tumor 
levels are achieved. To assess this process, two elegant ex vivo methods 
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have been developed and used in various trials. (t) Tc-99m-sestamibi is a 
known substrate of Pgp and it can be used as a functional imaging agent 
for Pgp inhibition in vivo (143,144). In the phase I study of doxorubicin 
with biricodar Tc-99m-sestamibi scans suggested an in vivo inhibition of 
hepatic Pgp during biricodar infusion (80). A recent phase I trial of 
vinblastine in combination with SDZ PSG 833 demonstrated that sestamibi 
retention by tumor and liver was altered in the presence of the MDR-
convertor and that tumor visualization was enhanced (145). However, it is 
of importance to realise that Tc-99m sestamibi efflux was also shown to be 
influenced by MRP expression in vitro (146). (it) The GD56( +) subset of 
peripheral blood lymphocytes has been shown to express functional Pgp 
and has been suggested as a surrogate target for monitoring MDR-convertor 
activity ex vivo (147). A study with patients receiving SDZ PSG 833 
showed a decreased rhodamine efflux from GD56( +) cells ex vivo within 
15 minutes of treatment and with a clear dose-response relationship (148). 
In future studies, an effort should be made to relate the measured plasma 
levels of the MDR-convertor with the efficacy of the modulator on tumor by 
one of the two surrogate markers. This also could give an indication of the 
time needed to administer the MDR-convertor before and after treatment 
with the anticancer drug to reach the optimal effect of both. 
A t present, no specific, highly effective, non-toxic modulator of 
MRP1 is available yet for studies in patients, although some MDR-
convertors, such as biricodar, have been shown to inhibit both Pgp and 
MRP1 in vitro (149). 
CONCLUSIVE REMARKS 
More than two decades ago, the discovery of the MDR molecule Pgp 
was inducing great expectations. It was postulated that if the effects of 
this drug transporter could be reversed, many more cancer patients might 
benefit from treatment. Still, despite numerous studies there is no 
indisputable evidence about Pgp as a prognostic indicator of response and 
survival after treatment with cytotoxic drugs. In addition a plethora of 
clinical studies involving a wide range of MDR-convertors and co-
administered anticancer drugs have shown little convincing evidence for 
clinical benefit. The most plausible explanations for this failure include (I) 
insufficient local concentrations of the MDR-convertor, (it) the negative 
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impact of pharmacokinetic interactions, and (iii) the mUltiple other existing 
mechanisms of intrinsic or acquired clinical drug resistance that render it 
less likely that circumventing one of them would already restore drug 
sensitivity. 
So where do we go from here? Clearly we need to change gears. 
First of all we should be more selective in the choice of the cytotoxic 
agents. It has been shown that the taxane drugs are much better substrates 
for Pgp than any of the other cytotoxic agents known at present (150,151). 
Also they are among the most active anti-cancer agents in a wide variety of 
different tumors, so selecting taxane drugs for studies on MDR-modulation 
would make sense. 
Secondly, we should focus on those MDR-convertors that lack a 
pharmacokinetic interaction with anticancer agents. Pharmacokinetic 
interactions have frequently necessitated major dose reductions for the 
anticancer agents, thereby loosing all the potential benefits in terms of 
antitumor activity as compared to the normal doses given without the 
addition of the modulator. 
We will also have to be more restrictive in study design. Non-
controlled phase" studies will never provide an answer to the question if 
MDR-convertors have any value. Therefore there should be more focus on 
different designs. Phase I studies should without any exception include 
pharmacokinetic analyses of both the modulator and the anti-cancer drug 
involved, in order to exclude a potential pharmacokinetic interaction. The 
study design should aim for applying the anticancer agent at normal doses 
and adding escalating doses of the modifier. Alternatively, if a positive 
interaction could be exploited they should aim for at least achieving plasma 
levels of the anticancer agent that are similar to those achieved with the 
normal single agent dose. In other words, if the dose of the anticancer 
agent has to be tapered because of a pharmacokinetic interaction, this 
should not lead to a coinciding decrease in plasma levels. If such a decrease 
would be noted, development would better be stopped. Phase I studies 
should also if possible already include studies with surrogate markers of 
effect. Performing Tc-99m sestamibi scans or measuring rhodamine efflux 
from CD56( +) cells ex vivo are examples of tests that could provide 
evidence of an effect at Pgp level. One should also aim on involving these 
markers in pharmacokinetic/pharmacodynamics analyses. 
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As said, standard phase II studies are not informative. Only a phase II 
study using the combination of a modifier and an anticancer agent, 
performed in patients that have shown proven progression to the same 
dose of the anticancer agent previously, would provide useful information. 
However these studies have been proven difficult in accrual. Randomized 
phase II studies could provide some insight in differences in side effects as 
compared to the single agent anticancer agent, but can never be used for 
proof of concept. 
Because of the above in most instances adequately powered phase III 
studies should follow the phase I studies. Data on pharmacokinetic 
interactions should be taken into account. In preference only those 
modifiers lacking a pharmacokinetic interaction or where the systemic 
exposure to the anticancer drug is monitored and adjusted to that obtained 
without the modulator, should enter phase III studies. Specific attention 
should be given to adequate dosing. 
The early use of Pgp modifiers to prevent Pgp-expression rather than 
inhibit Pgp-function deserves further attention. However, we should keep a 
close eye on the obvious limitations related to modification of only one 
resistance mechanism in human tumors where tumor cells are known to 
escape the effect of anticancer agents by means of many different 
mechanisms of resistance. 
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ABSTRACT 
This phase I study was performed to assess the feasibility of 
combining docetaxel with the new P-glycoprotein inhibitor R1 01933 and to 
determine the dose limiting toxicity of this combination. Fifteen patients 
received oral R101933 alone at a dose escalated from 200 to 300 mg 
twice daily (cycle 0), an escalating i.v. dose of docetaxel (60, 75, 100 
mg/m2) as a 1-hour infusion (cycle 1), and the combination (cycle 2 and 
further). Dose limiting toxicity consisting of mucositis and neutropenic fever 
was reached at the combination docetaxel 100 mg/m2 and R 101933 300 
mg twice daily, and the maximum tolerated dose was established at 
docetaxel 100 mg/m2 and R101933 200 mg twice daily. Plasma 
concentrations of R1 01933 achieved in patients were in the same range as 
required in preclinical rodent models to overcome paclitaxel resistance. The 
plasma pharmacokinetics of docetaxel were not influenced by the R 101933 
regimen at any dose level tested, as indicated by plasma clearance values 
of 26.5 ± 7.78 Llh/m 2 and 23.4 ± 4.52 Llh/m 2 (P=0.15) in cycle 1 and 2, 
respectively. These findings indicate that the contribution of a P-
glycoprotein inhibitor to the activity of anticancer chemotherapy can now 
be assessed in patients for the first time independent of its effect on drug 
pharmaco kinetics. 
INTRODUCTION 
Acquired or intrinsic resistance of malignant cells to taxanes and 
other naturally occurring drugs has been linked to the so called "classical" 
mechanism of multidrug resistance (MDR) resulting in decreased 
intracellular concentrations of these anticancer drugs. This MDR phenotype 
is characterized by increased levels of P-glycoprotein, a member of the A TP 
binding cassette superfamily of transmembrane transport proteins with a 
molecular weight of 170 kD encoded by the MDR1 gene, and acting as an 
energy dependent drug efflux pump with broad substrate specificity (1,2). 
Since the first observation that verapamil could reverse MDR in vitro, 
similar properties have been shown for a wide range of drugs (3). These 
agents are thought to be competitive substrates for P-glycoprotein and thus 
can increase the intracellular concentration of a co-administered anticancer 
agent and consequently restore the antitumoral activity (4). Initially, a 
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number of drugs, marketed for other indications than inhibiting P-
glycoprotein, have entered clinical trials (5). However, it became evident 
that pharmacokinetic interactions occurred between these P-glycoprotein 
inhibitors and the co-administered anticancer drugs due in part to 
competitive inhibition of cytochrome P-450 enzymes resulting in 
significantly increased toxicity of the anticancer drug (6). By rational design, 
new modulators were developed to specifically inhibit P-glycoprotein and to 
be more suitable candidates for further clinical evaluations (7,8). The results 
of most of these clinical studies have been rather disappointing and the 
pharmacokinetic interaction between the cytotoxic and the P-glycoprotein 
inhibiting agent remains a confounding problem (6,9). 
N O-R 
1- Y N--/ \'0 
Figure 1 Structure of R1 01933 (R = CH 3 ) and its main metabolite R1 02207 (R = H) 
R1 01933 (Fig. 1) is a new orally administered compound that inhibits 
P-glycoprotein as demonstrated by various in vitro and in vivo models 
(10,11). The tolerability, cardiovascular and laboratory safety, and the 
pharmacokinetics were investigated in healthy subjects.' Nausea and 
vomiting were the dose limiting adverse events and were reported above 
400 mg single oral dose. Drowsiness was also mentioned as side effect. No 
clinically relevant changes in laboratory and cardiovascular safety 
parameters were observed. In vitro metabolism studies showed that the 
major metabolic pathway is not cytochrome P450 3A4 dependent.' Plasma 
1 Janssen Research Foundation, data on file 
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levels of R1 01933 at 200 mg b.i.d. are in the range of concentrations that 
are active in paclitaxel and adriamycin resistant human tumor xenograph 
rodent models. 1 
Docetaxel is a known substrate of P-glycoprotein and has shown to 
have higher affinity for the protein than the related compound paclitaxel 
(12,13). It also lacks the problems associated with i. v. use of paclitaxel 
caused by the presence of the formulation vehicle Cremophor EL, which is 
known to (a) alter the pharmacokinetics of the anticancer drug by 
entrapment in micelles (14) and (b) masks the effects, if any, of 
endogeneously expressed P-glycoprotein on the plasma levels of paclitaxel 
(15). Therefore, the development of agents that could reverse or prevent 
development of resistance to docetaxel is of great interest. 
The principal objectives of this phase I and pharmacokinetic study of 
R101933 and docetaxel were to determine the clinical utility of the 
combination and to investigate the potential lack of pharmacokinetic 
interactions. 
PATIENTS AND METHODS 
Eligibility 
Patients with a histologically confirmed diagnosis of a solid tumor for 
whom docetaxel as monotherapy was a viable therapeutic option or for 
whom other treatment options were not available, were candidates for this 
study. Additional eligibility criteria were: age ~18 and :0;75 years; Eastern 
Cooperative Oncology Group performance status < 3; life expectancy of at 
least 3 months; off previous anticancer therapy for at least 4 weeks; no 
previous treatment with taxanes or high dose chemotherapy requiring 
progenitor cell support; adequate bone marrow function (WBC count> 3.5 
x 109 /L, platelet count > 100 x 109 /L), renal function (serum creatinine :0;2 
times upper limit of normal), and liver function (bilirubin level normal, 
aspartate/alanine aminotransferase :0;2 times upper limit of normal and 
alkaline phosphatase :0;2.5 times upper limit of normal); and symptomatic 
peripheral neuropathy less than grade 2 (NCI criteria). Written informed 
consent was obtained from all patients, and the study was approved by the 
Rotterdam Cancer Institute Ethics Board. 
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Pretreatment and Follow-up 
Pretreatment evaluation consisted of recording the history of the 
patient, physical examination, laboratory studies, electrocardiography, and 
chest-X-ray. Computer tomographic scans were performed for tumor 
measurements. Laboratory studies included a complete blood-cell count 
analysis, and measurement of WBC differential, electrolytes (including 
sodium, potassium, chloride, calcium and inorganic phosphate), creatinine, 
urea, alkaline phosphatase, aspartate aminotransfer-ase, alanine 
aminotransferase, lactate dehydrogenase, bilirubin, total plasma proteins, 
serum albumin, glucose, uric acid, and urinalysis. History, physical 
examination, and toxicity scoring (according to the NCI Expanded CTC) 
were repeated once a week. Complete blood cell counts including WBC 
differential were performed twice a week, and the other laboratory tests 
were done once a week. Electrocardiography was repeated as clinically 
indicated. A final assessment was to be made after patients went off study. 
Formal tumor measurements and chest-X-ray were performed at 6-weeks 
intervals until documentation of progressive disease. Standard WHO 
response criteria were used. 
Drug Administration 
Docetaxel was administered every 3 weeks on day 3 as a 1-h 
infusion and was started 1 h after intake of R101933. All patients received 
pre-medication with dexamethasone orally 8 mg twice daily (b.Ld.), starting 
one day prior to each infusion of docetaxel for 5 days. R1 01933 (Janssen 
Research Foundation, Belgium) was supplied as a 1 O-mg/mL oral solution in 
15% hydroxypropyl-p-cyclodextrin. It had to be taken with water at least 1 
h after a meal. The drug was administered twice daily from days 1-5. From 
studies with healthy volunteers it was known that the terminal half-life of 
R1 01933 averaged about 24 h, with peak plasma concentrations attained 
within 2 h after intake. The maximum tolerated dose after 7-days b.Ld. 
dosing was 300 mg in healthy volunteers.' Seven days dosing at 200 mg 
b.i.d. appeared to be safe and well tolerated. Pharmacokinetic data revealed 
that plasma levels of R1 01933 at 200 mg b.Ld achieve concentrations that 
are in the same range as required in in vivo models to overcome paclitaxel 
resistance. Hence, the starting dose for our study was set at this dose 
level. In view of the terminal disposition half life of docetaxel, a 
simultaneous exposure to both R1 01933 and docetaxel for a 3-day period 
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was considered sufficient. This led to the choice of the 5 day R101933 
regimen. In the first stage of the study, the dose of docetaxel was 
escalated and the dose of R1 01933 was fixed. In the second stage of the 
study, the dose of docetaxel was fixed and the dose of R101933 was 
escalated. 
First, the patients received 5 doses of R101933 alone every 12 h 
(cycle 0) followed by a 48 h wash-out to allow assessment of the terminal 
half-life of R101933. One week later, cycle 1 was initiated with docetaxel 
alone. Thereafter, the combination was given 3-weekly until progressive 
disease (PO) or dose limiting toxicity (DL T) occurred. 
In each cohort 3 patients were treated unless DL Tc (DL T from 
chemotherapy) or DLTr (DLT from R1 01933) was observed. In that case, 
the accrual of 3 additional patients was required. DL Tc was defined as 
grade 3 non-hematological toxicity (with the exception of non-hematological 
toxicity that was still manageable in an out-patient setting, such as 
nausea/vomiting) or grade 4 neutropenia lasting > 8 days, grade 4 
thrombocytopenia or required delay > 2 weeks to a subsequent cycle due 
to toxicity. Febrile neutropenia and neutropenia with severe infection (~ 
grade 3 infection) was also considered as DL Tc. DL Tr was defined as any 
non-hematological toxicity > grade 2 in the first 2 days of treatment before 
chemotherapy was given. For dose-escalation decisions only DL Ts in cycles 
o and 2 were taken into account. The DL T of the combination of R 101933 
with docetaxel was reached when greater or equal to three of six patients 
experienced DL Tc. The DL T of R1 01933 alone was reached when greater 
or equal to one of three (or greater or equal to two of six) patients 
experienced DL Tr. The maximum tolerated dose (MTD) was defined as the 
dose level below DL T. 
Sample Collection and Processing 
Blood specimens were taken in all patients during the first, second 
and third courses of treatment. Blood volumes of 6 mL were drawn directly 
into Vacutainer tubes containing lyophilized sodium heparin (Becton 
Dickinson, Meylan, France) from a peripheral venous access device. In each 
patient, sufficient plasma was obtained before drug administration to 
evaluate possible interfering peaks in the chromatographic analysis. 
Samples for docetaxel analysis were collected immediately before infusion, 
and at 0.5, 1, 1.25, 1.5, 2, 3, 7, 11, 23, and 31 h after start of infusion. 
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For determination of R101933 concentrations, blood samples were 
obtained on day 1 (prior to the first dosing), day 2 (prior to the second 
dosing and 12 h thereafter), and day 3 (prior to the third dosing and 2, 4, 
8, 12, 24, 32, and 48 h thereafter). All blood samples were centrifuged 
immediately for 10 min at 1000 x g to yield plasma, which was stored 
frozen in polypropylene vials (Eppendorf, Hamburg, Germany) until the time 
of analysis. 
Analvtical Methods 
A pure reference standard of docetaxel (batch: 14PROC9230; purity: 
98.0% by reversed-phase HPLC) and the clinical docetaxel formulation in 
polysorbate 80 (Taxotere; 40 mg/mL) were kindly supplied by Rhone-
Poulenc Rorer (Vitry-sur-Seine, France), and were used as received. Plasma 
concentrations of docetaxel were determined by a validated liquid 
chromatographic/tandem mass spectrometric assay, with a lowest limit of 
quantitation of 1 ng/mL. Samples (200 I-lL) were pretreated by solid-phase 
extraction using endcapped Bond Elut nitrile micro-columns (Varian, Harbor 
City, CAl, based on an earlier procedure described for paclitaxel (16). A 
stainless steel analytical column (100 x 4.6 mm internal diameter) packed 
with 3 I-lm Hypersil BOS C 18 material (Alltech, Breda, The Netherlands) was 
used for chromatographic separation, and gradient elution was performed 
with a mixture of acetonitrile and 0.02 M ammonium acetate (pH 4.0) at a 
flow rate of 0.8 mL/min. Paclitaxel (50 I-lL of 20 I-lg/mL in acetonitrile) was 
used as internal standard. Triple quadrupole mass-spectrometric detection 
was performed with a turboionspray interface used in the positive ion mode 
with selective monitoring at m/z 808.5 (molecular ion docetaxel parent) and 
m/z 854.5 (molecular ion paclitaxel parent) and at m/z 527.0 (docetaxel 
taxane ring fragment) and m/z 569.0 (paclitaxel taxane ring fragment) in 
the first and third quadrupole, respectively. Calibration curves spanning a 
range of 1-5000 ng/mL were calculated by regression analysis of peak area 
ratios of docetaxel and the internal standard versus the spiked drug 
concentration of the standard. 
Blood samples collected and processed to plasma were also 
analyzed, as appropriate, for R1 01933 and its esterase-mediated carboxylic 
acid metabolite R102207 using a validated HPLC method. This assay used 
a selective solid-phase extraction with Bond-Elut Certify microcolumns 
(Varian). The columns were conditioned with 3 mL of ethanol, 3 mL of 
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deionized water and 1 ml of 1 M aqueous acetic acid. Plasma samples (1 
ml) were mixed with 3 volumes of 1 M acetic acid and 100 III of the 
internal standard (R 125026; 10 Ilg/ml in acetonitrile), and then loaded on 
the extraction columns. Consecutive washing steps with 3 ml of deionized 
water, 1 ml of 1 M acetic acid and 3 ml of ethanol were performed prior 
to elution in 3 ml of ethanol-ammonia (98:2, v/v). Samples were dried 
under nitrogen at 65°C and reconstituted in 100 III of 0.02 M ammonium 
formate (pH 4.0)-acetonitrile-ethanol (50:25:25, v/v/v). The analytes were 
separated on a 3-llm Hypersil 80S C8 column (100 x 4.6 mm internal 
diameter; Alltech) using a mobile phase comprising 0.02 M ammonium 
formate (pH 4.0), acetonitrile and ethanol, delivered with gradient elution at 
0.8 mL/min. Detection was performed by UV absorption measurements at 
270 nm. The concentrations of R1 01933 and R102207 were determined 
from calibration curves constructed in blank human plasma in the range of 
2-10,000 ng/mL. The ratio of the log-transformed peak areas of each of the 
analytes and the internal standard were plotted versus nominal 
concentrations for quantitative computations. 
Pharmacokinetic Data Analysis 
Individual plasma concentration-time profiles of R101933 and its 
inactive metabolite R102207 were analyzed model-independently using a 
validated macro in the EXCEL software package. The actual times of drug 
intake and blood sampling were taken into account. Peak plasma 
concentration (Cmaxl was determined by visual inspection of the data. The 
area under the plasma concentration-time curve (AUC) within a 12-hour 
dosing interval was calculated by the trapezoidal rule. In all cases, the AUC 
was extrapolated to infinity by addition of Clas/A, in which Clast is the last 
quantifiable concentration in the curve and A the terminal elimination rate 
constant, determined by linear regression analysis of the terminal points of 
the In-linear plasma concentration-time curve. The terminal disposition half-
life [t1/2(z,J was defined as In2/A. Individual plasma concentration-time curves 
of docetaxel were analyzed using the software package WinNonlin 
(Pharsight, Mountain View, CAl, by determination of slopes and intercepts 
of the plotted curves with mUlti-exponential functions. All curves were 
fitted using the actual infusion duration and blood sampling times. In all 
cases, concentration-time profiles of docetaxel were best fitted to a bi-
exponential equation after zero-order input with weighting according the 
58 
Phase I studv of docetaxel with R101933 
square of the model predictions of the concentrations. Final values of the 
iterated parameters of the best-fit function were used to calculate the 
pharmacokinetic parameters using standard equations (17). 
Statistical Considerations 
Pharmacokinetic parameters for docetaxel and R1 01933 are reported 
as mean values ± so. Variability in dose-normalized parameters between 
the various docetaxel dose levels was evaluated by the Kruskal-Wallis 
statistic followed, if required, by a Dunn's test to determine which group 
differed. To test pharmacodynamic and pharmacokinetic parameter 
difference for statistical significance among treatment courses, a two-tailed 
paired Student's t test was performed. Probability values of less than 0.05 
were regarded as statistically significant. All statistical calculations were 
performed using the Number Cruncher Statistical System version 5.X (Dr. 
Jerry Hintze, Kaysville, UT; 1992) or using Statgraphics Plus version 2 
(Manugistics Inc., Rockville, MA). 
Table 1 Patient characteristics 
Characteristic 
Patients included 
Sex 
Male 
Female 
Age, years 
Median 
Range 
Performance score (WHO) 
o 
1 
Primary tumor 
Urogenital tract 
Gastrointestinal tract 
Respiratory tract 
Melanoma 
Sarcoma 
Unknown primary 
Prior therapy 
Surgery 
Radiotherapy 
Chemotherapy 
None 
No. of patients 
17 
10 
7 
57.5 
42-72 
8 
9 
6 
5 
2 
2 
1 
14 
7 
11 
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RESULTS 
Seventeen patients were entered into this study. Patient 
characteristics are listed in Table 1; all patients were eligible. Two patients 
were considered not evaluable for toxicity and response. They did not 
receive the combination therapy, one because of unexpected rapid 
deterioration of the clinical condition and another because of development 
of liver enzyme abnormalities due to the malignant disease that would have 
precluded administration of docetaxel within normal safety limits. At the 
dose level R101933 300 mg b.i.d., one patient was not evaluable for 
pharmacokinetics, because it was not possible to take blood samples during 
the second cycle for technical reasons. 
Toxicity and Pharmacodynamics 
A total of 59 cycles, including 44 cycles of combined docetaxel and 
R1 01933, were given. Table 2 lists the number of cycles at each dose level 
and the main toxicities at each dose level. In the first part of the study, the 
dose of docetaxel was escalated and the dose of R1 01933 was fixed at 
200 mg b.i.d. Each dose level of docetaxel, 60, 75 and 100 mg/m2 
respectively, consisted of 3 patients and no DL T was experienced at this 
stage. One patient at the dose level 60 mg/m2 was hospitalized because of 
neutropenic fever after cycle 3, and was diagnosed to have pneumonia and 
sinusitis. Because of this clearly unrelated focus, the patient received 2 
further cycles which were uneventful. Two patients had grade 2 diarrhea 
starting one week after docetaxel infusion lasting not more than 4 days. 
Due to infection occuring in the area of the primary head/neck tumor after 
cycle 0, one patient treated with docetaxel at a dose level of 100 mg/m2 
was given prophylactic antibiotics during both cycles 1 and 2. From all 3 
dose levels of docetaxel studied with R101933 200 mg b.i.d., it was 
concluded that the combination was feasible with docetaxel given up to 
100 mg/m2 , which is the single agent MTD for docetaxel (12). 
In the second part of the study the dose of docetaxel was fixed at 
100 mg/m2 and the dose of R101933 was escalated to 300 mg b.i.d. 
Paired analysis of hematological pharmacodynamic parameters indicated 
that R 101933 co-administration had no significant influence of the 
observed myelotoxicity (Table 3), including the percent decrease in WBC 
and absolute neutrophil count. DL Ts were seen in four out of six patients, 
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Tab~e 2 Main toxicities (worst per cycle) at each dose level expressed in number of cycles in which they occurred 
Docetaxel R101933 Number Neutropenic Neutropenia Vomiting Mucositis Fatigue DLTc 
mg/m2 mg bid pts/cycles Fever CTC grade* CTC grade CTC grade CTC grade 
0 2 3 4 0 1 234 0 1 2 3 0 1 2 
60 200 3/11 4 - 5 - 2 10 - 11 6 5 0 
75 200 3/18 1 1 6 3 7 17 1 - - - 16 2 10 6 2 0 
100 200 3/7 2 2 - 5 7 - - - - 5 1 - 2 4 0 
100 300 6/23 4 1 1 2 3 16 20 - 1 - 2 17 3 2 1 12 7 4 4 
* NCI Common Toxicity Criteria 
Chapter 2 
but in two of these already with single treatment of docetaxel, and thus 
could not be attributed to the combination (Table 4). DL T consisted of 
neutropenic fever (n = 2), mucositis (n = 1) and vomiting (n = 1). 
Table 3 Summary of hematological pharmacodynamics * 
Parameter Cycle 1 Cycle 2 Mean 95% C.L.** P*** 
and further difference 
Leukocvtes 
Nadir (x 109 IL) 1.51±1.00 2.23±1.82 -0.72±0.35 -1.48,0.038 0.061 
(0.43-3.40) (0.20-7.30) 
%decrease WBC 75.2±18.0 70.9±17.7 4.28±4.41 -5.18,13.7 0.348 
(33.3-96.6) (37.9-96.9) 
Neutrophils 
Nadir (x1 09/L) 0.44±0.49 0.64±0.86 -0.20±0.17 -0.57,0.18 0.274 
(0.04-1.50) (0.05-2.60) 
%decrease ANC 90.6±9.48 88.6±15.7 2.06±3.89 -6.50,10.6 0.607 
•• 
• *. 
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(75.6-99.3) (44.8-98.7) 
Data were obtained from patients after treatment with a 1-h i.v. infusion of 
docetaxel at a dose level of 60, 75 or 100 mg/m2 given either alone (cycle 1) or in 
the presence of oral R1 01933 at a dose level of 200 or 300 mg b.i.d. (cycle 2 and 
further). The relative hematological toxicity (i.e., the percentage decrease in blood 
cell count) was defined as: % decrease [(pretherapy value - nadir 
value)/(pretherapy value)] x 100%. Data are presented as mean values ± SO, with 
the observed range shown in parenthesis. 
C.L., 95% confidence limits for the mean difference; ANC, absolute neutrophil 
count. 
Paired Student's t test . 
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Table 4 Neutropenia (highest eTe grade*) and DL T as per protocol in 
cycle 1 versus cycle 2 and further 
Taxotere R101933 C'icle 1 C'icle 2 and further 
(mg/m2) (mg bid) Patient Neutropenia DlT Neutropenia DlT 
60 200 2 0 
2 2 4 
3 2 0 
75 200 4 4 4 
5 4 4 
6 4 3 
100 200 7 4 4 
8 4 4 
9 4 2 
100 300 10 4 4 + 
11 4 4 
12 4 + 4 
13 0 4 + 
14 4 + 4 + 
15 4 4 
* NCI Common Toxicity Criteria 
DL Tr was not reached at any of the investigated dose levels. 
Nausea/vomiting and drowsiness, known to be side effects of R 101933 in 
healthy subjects 1, were not seen in our patients after administration of 
R 101933 alone. Fatigue was often mentioned as side effect after docetaxel 
but never exceeded grade 2. Nevertheless, for one patient given docetaxel 
at 100 mg/m2 and R101933 200 mg b.i.d., it was a reason to refuse 
further treatment after cycle 3, although an ongoing partial response was 
noted. Two patients at docetaxel100 mg/m2 and R101933 300 mg b.i.d. 
went off study after cycle 2 because of the observed DL T consisting of 
mucositis and vomiting, respectively. All other patients went off study 
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because of PD. Two patients achieved a partial response, and seven had 
stable disease. 
Plasma Pharmacokinetics 
For the evaluation of docetaxel pharmacokinetics, only the patients 
who had sampling and complete kinetic data during both treatment courses 
were included (n == 14 of 15). The results of paired plasma concentration-
time profiles of unchanged docetaxel given with and without co-treatment 
were remarkably similar for all patients studied (Fig. 2). 
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Plasma concentration versus time profiles of docetaxel in patients treated 
with 100 mg/m2 of docetaxel alone (0) or in combination with 300 mg 
b.i.d. oral R101933 (Et). Data are presented as mean values (symbols) ± 
SD (error bars). 
During both treatment courses, disposition phases appeared to be 
very typical of a bi-exponential profile, with plasma concentrations of 
docetaxel decreasing very rapidly immediately after cessation of the 
infusion, followed by a more prolonged terminal disposition phase of 
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approximately 11 h, in line with previous observations (18). The mean 
pharmacokinetic parameters of docetaxel for both treatment courses are 
summarized as a function of the study cohort in Table 5. The docetaxel 
total body clearance was normally distributed as judged by the 0' Agostino-
Pearson omnibus K2-test, and was independent of the administered dose 
(Kruskal-Wallis, P= 0.396), and averaged 26.5 ± 7.78 Llh/m 2 (mean±SO) 
without R101933 and 23.4 ± 4.52 Llh/m2 with R101933 (Kruskal-Wallis, 
P= 0.608), which is within the same range as described for this compound 
previously (18). There were no statistically significant differences in any of 
the studied docetaxel pharmacokinetic parameters, including the clearance 
(P= 0.15), between the two treatment courses (Table 5)' suggesting that 
R101933 administration did not influence the disposition of the taxane at 
the dose levels tested. At the final dose level, combining docetaxel at 100 
mg/m2 and R1 01933 300 mg b.i.d, statistical analysis indicated that a 1.3-
fold change in docetaxel clearance could have been detected with (1-
P) = 0.80 at the observed standard deviation of the mean difference 
between cycles (Sd= 3.13), and a calculated standardized difference of 20!Sd 
(19). 
Similarly, docetaxel did not significantly alter the absorption and 
elimination routes of R1 01933 (Table 6). In addition, dose-normalized AUC 
values for R 101933 were similar with or without docetaxel co-treatment. 
Overall, substantial interpatient variability in R 101933 kinetic parameters 
was apparent, with upto 10-fold variation in peak plasma levels. Over the 
total dose range studied, the peak plasma levels of R101933 did not 
increase with values of 133 ± 74 ng/mL (mean±SO; n = 10) and 136 ± 45 
ng/mL (n = 7) respectively, suggesting a dose-dependent kinetic behavior of 
the compound with saturable absorption characteristics. For this reason no 
attempt was made to further increase the dose of R1 01933. 
In all patients, there was extensive formation of the 
pharmacologically inactive compound R 102207, the principal circulating 
metabolite of R1 01933, reaching AUC values approximately 80-fold higher 
than that of the parent compound. Concentrations of this compound were 
also not substantially influenced by the administration of docetaxel at any 
dose level tested (Table 6). Of particular note, plasma levels of Rl01933 
capable of reversal of daunorubicin resistance in A2780 cell cultures with 
and without P-glycoprotein expression were achieved in all patients (20). 
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Table 5 Plasma pharmacokinetic parameters of docetaxel in the absence or presence of R 101933 * 
Cohort 
Docetaxel 60 mg/m2 (n=3) 
Without R 
With R 200 mg 
Docetaxel 75 mg/m2 (n=3) 
Without R 
With R 200 mg 
Docetaxel 1 00mg/m2 (n = 3) 
Without R 
With R 200 mg 
Docetaxel 1 00mg/m2 (n = 5) 
Without R 
With R 300 mg 
AUC** 
Iflg·h/ml) 
3.18±0.95 
2.88±0.52 
2.83 ± 1.03 
3.59±0.30 
3.93 ±0.67 
4.33± 1.13 
3.62±0.71 
4.04±0.84 
Cmax 
Ifl9/ml) 
2.06±0.58 
1.77±0.27 
1.68 ± 1.01 
2.20±0.53 
2.47±0.21 
2.95 ±0.26 
2.54±0.54 
2.86±0.55 
t'f2(a) 
(h) 
0.17±0.02 
0.20±0.01 
0.37±0.36 
0.32±0.12 
0.15±0.06 
0.24±0.06 
0.18±0.03 
0.23±0.07 
t 1/2(z) 
(hI 
12.5±3.8 
11.3±0.4 
12.0±2.4 
12.1 ±2.5 
11.1 ± 2.3 
9.4±4.4 
11.0±2.0 
10.9±4.8 
Vdss 
(l/m2 ) 
120±43 
119 ± 35 
253±227 
112± 29 
137±27 
86±41 
129 ±32 
104±50 
MRT 
(h) 
6.21 ±2.78 
5.54± 1.08 
7.49±3.34 
5.31 ± 1.22 
5.51 ± 1.92 
3.78±2.05 
4.59±0.95 
4.27±2.02 
Data were obtained from patients after the first (without R101933) and second treatment cycle (with R101933) of a 1-h infusion of 
docetaxel. The kinetic terms are mean values ± SO. 
AUC, area under the plasma concentration versus time curve; Cmax , maximum plasma concentration of drug; t1{2(i)' half life of the i-th 
disposition phase; VdSS' volume of distribution at steady state; MRT, mean residence time; n, number of patients evaluated at both 
treatment courses; R, R101933. 
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Table 6 Plasma pharmacokinetic parameters of R 101933 and its 
metabolite R1 02207 in the absence or presence of docetaxel* 
* 
200 mg R101933 (n=9) 300 mg R101933 (n= 5) 
Parameter Without D With D without D with D 
Rl01933 
Cmax * * (ng/mL) 120 ± 66 94.3 ± 26.9 127 ± 50 144 ± 42 
t 112 (z) (h) 19.6±7.4 NA 23.0 ± 9.2 NA 
AUC (~g.h/mL) 0.55 ± 0.24 0.53±0.15 0.91 ± 0.46 0.86 ± 0.49 
Rl02207 
AUC (~g.h/mL) 50.5 ± 14.2 52.4 ± 26.7 37.9 ± 20.2 45.7±11.0 
Data were obtained from patients after cycle 0 (without docetaxel) and after cycle 2 
(with docetaxel). The kinetic terms are mean values ± SO. 
** AUC, area under the plasma concentration versus time curve; Cm", maximum plasma 
concentration of drug; t 1l2(zl' terminal disposition half-life; n, number of patients 
evaluated; 0, docetaxel; NA, not available. 
DISCUSSION 
In the present study, we observed that the plasma pharmacokinetic 
characteristics of docetaxel were not substantially influenced by R101933, 
a new orally administered P-glycoprotein inhibitor. The lack of a 
pharmacokinetic interaction between docetaxel and R 101933 is an 
important finding, that makes it possible to study the contribution of an 
inhibitor of P-glycoprotein to the toxicity and activity of an anticancer drug 
independently of its effects on drug pharmacokinetics. Previous clinkal 
studies have shown that drug interactions between modulator and 
anticancer drugs occur (even with dose reductions of the anticancer drug), 
resulting in increased toxicity that can be accounted for by pharmacokinetic 
interactions alone (reviewed in Ref. 6). These clinical investigations indicate 
that P-glycoprotein inhibitors [verapamil, cyclosporin A, PSC833 
(valspodar), and VX-71 0 (biricodar) 1 increase the anticancer drug's systemic 
exposure, thereby potentially (nonselectively) increasing exposure to normal 
and malignant cells, resulting in increased severity or incidence of toxic 
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adverse effects. Based on these findings, it has been proposed that the 
administration of P-glycoprotein inhibitors is unlikely to improve the 
therapeutic index of docetaxel (or any other drug) without dose adjustment 
unless such agents lack a pharmacokinetic interaction (6,9). 
Our findings show that previously observed drug pharmacokinetic 
interactions between anticancer drugs and modulators, such as those 
between the docetaxel analogue paclitaxel and r-verapamil (21), cyclosporin 
A (22), PSC833 (23) or VX-71 0 (24), are most likely more related to an 
overlap in specificity of enzymes responsible for metabolism of the 
compounds, than to modulation of P-glycoprotein activity. Although few 
clinical data are available, several in vitro studies have shown that 
docetaxel is extensively metabolized in humans by the cytochrome P450 
3A4 system (25,26). The main pathway of docetaxel metabolism in 
humans consists of successive oxidations of the tert-butyl proprionate 
group on the C13 side chain, with spontaneous cyclization occurring for the 
putative aldehyde and acid derivatives. All metabolites so far characterized 
have been found to be many-fold less cytotoxic than docetaxel itself 
(27,28). In this context, it is noteworthy that R1 01933 did not influence 
the in vitro metabolism of docetaxel even at concentrations as high as 1 
Ilg/mL, and that the major metabolic route to R 102207 is cytochrome-P450 
unrelated. 1 Clearly, further experiments are needed to establish the 
relevance of this principle in humans, and to determine for what drugs it 
will apply. In addition, when given in combination with docetaxel, 
biologically relevant R 101933 concentrations could be achieved and 
sustained for several hours, similating optimal pharmacologic conditions 
required for complete reversal of the MDR phenotype in in vitro systems. 
Clinically, we observed that single treatment with R 101933 given 
orally at the tested dosages was associated with minimal toxicity. The 
toxicologic profile of the combination appeared to be very similar to that 
reported for docetaxel alone, and included neutropenic fever and mucositis 
as the principal dose limiting toxicities. Febrile neutropenia requiring 
hospitalization has been reported in approximately 1 5 % and severe 
mucositis in approximately 10% of cases treated with docetaxel alone (29). 
In fact, the incidence of neutropenia observed with other inhibitors of P-
glycoprotein in studies with anticancer drugs is greater than that observed 
with the cytotoxic agent alone (24). Fatigue was often mentioned by the 
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patients in this study as a side effect, but never after R1 01933 alone and 
asthenia is also a known side effect of docetaxel. 
In conclusion, we have shown that the studied combination of oral 
R101933 and i.v. docetaxel is safe, and at the achieved dose levels lacks 
the significant kinetic interaction with the anticancer drug as observed 
previously with other modulators. In case of a phase 11/111 study with the 
combination of R101933 and docetaxel 100 mg/m2, and in view of the 
pharmacokinetic data on R1 01933 presently presented, the recommended 
dose of R1 01933 will be 200 mg b.i.d. orally. 
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ABSTRACT 
MDR1 P-glycoprotein (Pgp) is a drug-transporting protein that is 
abundantly present in biliary ductal cells and epithelial cells lining the 
gastrointestinal tract. Here, we have determined the role of Pgp in the 
metabolic disposition of the antineoplastic agent docetaxel (Taxotere) in 
humans. Pharmacokinetic profiles were evaluated in five cancer patients 
receiving treatment cycles with docetaxel alone (100 mg/m2 Lv. over a 1-h 
period) and in combination with a new potent inhibitor of Pgp activity, 
R101933 (200-300 mg b.Ld.). The terminal disposition half-life and total 
plasma clearance of docetaxel were not altered by treatment with oral 
R 101933 (Pc:.0.27). The cumulative fecal excretion of docetaxel , however, 
was markedly reduced from 8.47±2.14% (mean±SD) of the dose with the 
single agent to less than 0.5% in the presence of R101933 (P= 0.0016). 
Levels of the major cytochrome P450 3A4-mediated metabolites of 
docetaxel in feces were significantly increased after combination treatment 
with R101933 (P= 0.01 0), indicating very prominent and efficient 
detoxification of reabsorbed docetaxel into hydroxylated compounds before 
reaching the systemic circulation. It is concluded that intestinal Pgp plays a 
principal role in the fecal elimination of docetaxel by modulating re-
absorption of the drug after hepatobiliary secretion. In addition, the results 
indicate that inhibition of Pgp activity in normal tissues by effective 
modulators, and the physiological and pharmacological consequences of 
this treatment, cannot be predicted based on plasma drug monitoring alone. 
INTRODUCTION 
Acquired or intrinsic resistance of malignant cells to taxanes and 
other naturally occurring anticancer drugs has been linked to the so called 
"classical" mechanism of multidrug resistance (MDR) which can cause 
cecreased intracellular concentrations of these drugs (1). This MDR 
phenotype is characterized by increased levels of Pgp, a member of the ATP 
binding cassette superfamily of transmembrane transport proteins with a 
molecular weight of 170 kD encoded by the MDR 1 gene, that acts as an 
energy dependent drug-efflux pump with broad substrate specificity (1). 
Pgp expression has been found in nearly all tumor types, ranging from 
leukemia to carcinoma, and it has also been reported in a number of normal 
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tissues, mainly in specialized epithelial cells with secretory functions 
including the apical biliary surface of hepatocytes and epithelial cells of the 
intestinal tract (2). The physiologic functions of Pgp are still speculative at 
this time, but possibilities include involvement in the protection of epithelial 
mucosal cells in the gastrointestinal tract from xenobiotics, in transport of 
steroids in the adrenals and bile salts in the liver, in protein secretion in the 
kidneys (3), and most recently discovered, in migration of dendritic cells 
and T -lymphocytes out of the skin (4). In addition, the expression of Pgp in 
the capillary endothelial cells forming the blood-brain and the blood-testis 
barrier apparently protects these organs from exogenous toxins, and thus 
contributes to the role of these anatomic sites as drug sanctuaries 
(reviewed in Ref. 5). 
Several studies have shown that Pgp-mediated MDR is of clinical 
significance, and this observation has stimulated a search for noncytotoxic 
agents that can reverse this resistance phenomenon (6,7). Clinical trials 
performed thus far with identified Pgp inhibitors given in combination with 
anticancer drugs, however, have raised important issues regarding the 
safety of the chemotherapeutic treatment because of drug interactions that 
increased or changed the spectrum of associated toxic side effects (8,9). 
The results of these clinical trials in combination with the poorly defined 
pharmacologic and physiologic function of Pgp in humans emphasize the 
need to perform studies to further evaluate the role of Pgp in the disposition 
of substrate drugs. The importance of these studies is further underscored 
by the previous use of anticancer drugs that are rather poor substrates of 
Pgp given with nonspecific inhibitors of Pgp (9). Thus, in the present study, 
we evaluated the role of Pgp in the plasma disposition and fecal elimination 
pathways of docetaxel, one of the best known substrates of Pgp (10), in 
humans using a combined treatment with the new orally administered Pgp 
inhibitor R 101933 as a model compound. 
MATERIALS AND METHODS 
Drug Administration 
Docetaxel (Rhone-Poulenc Rorer, Antony Cedex, France) was supplied 
as a concentrated solution in polysorbate 80 (40 mg/mL; Taxotere) and was 
administered to 5 cancer patients at a dose of 100 mg/m2 as a 1-h Lv. 
infusion. Three weeks later, the same dose was administered to each 
75 
Chapter 3 
patient 1 h after intake of R101933 on day 3. All patients received pre-
medication with dexamethasone (8 mg b.i.d.), starting 24 h prior to infusion 
of docetaxel and continuing for 4 days thereafter. R1 01933 (methyl 6,11-
dihydro-11-[ 1-[2-[ 4-(2-quinolinyl-methoxy) pheny/lethy/l-4-piperidinylidene1-
5H-imidazo[2,1-bH31benzazepine-3-carboxylate), an agent acting as a 
specific antagonist of Pgp, was supplied by Janssen Research Foundation 
(Beerse, Belgium) as an oral solution containing 10 mg/ml of the active 
compound in 15 % hydroxypropyl-p-cyclodextrin. The drug was 
administered orally twice daily for 5 consecutive days (i.e., days 1-5) with 
200 ml water, at least 1 h after a meal. The clinical protocol was approved 
by the institutional ethics committee, and signed informed consent was 
obtained from each participant prior to study entry. 
Sample Collection and Processing 
Blood specimens were acquired in all patients during both treatment 
courses. Sample volumes of - 6 ml were drawn directly from a peripheral 
venous access device into tubes containing lyophilized sodium heparin as an 
anticoagulant. Blood samples were collected immediately before infusion, 
and at 0.5, 1, 1.25, 1.5, 2, 3, 7, 11, 23, and 31 h after start of infusion. 
All samples were centrifuged immediately for 10 min at 1000 x g to yield 
plasma, which was stored frozen at -20°C in polypropylene vials until the 
time of analysis. 
Complete stool collections for docetaxel analysis were obtained for 
the duration of the study (i. e., up to 31 h after start of drug administration). 
This space of time was chosen based on previous fecal excretion studies 
with the structural related agent paclitaxel (11). Fecal specimens were 
collected in polystyrene containers and stored immediately at -20°C. 
Weighted feces samples were homogenized individually in 3 volumes of a 
phosphate buffer [containing 0.01 M potassium phosphate, 0.137 M 
sodium chloride and 2.7 mM potassium chloride in the presence of 0.05 % 
(w/v) glucose at pH 7.41 using five l-min bursts of an Ultra-Turrax T25 
homogenizer (lKA-labortechnik, Dottingen, Germany) operating at 20,500 
rpm. Aliquots of 500 III feces homogenates were diluted with human 
plasma (1:1, v/v) and stored frozen at -80°C prior to further processing. 
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Analvtical Methods 
A pure reference standard of docetaxel (batch: 14PROC9230; purity: 
98.0% by HPLC) was kindly supplied by Rhone-Poulenc Rorer, and was used 
as received. Plasma concentrations of docetaxel were determined by a 
validated HPLC assay with mass-spectrometric detection, with a lowest limit of 
quantitation of 1 ng/mL. Samples (200 /-!L) were pretreated by solid-phase 
extraction using endcapped Bond Elut nitrile micro-columns (Varian, Harbor 
City, CA). A stainless steel analytical column (100x4.6 mm, internal diameter) 
packed with 3 /-!m Hypersil BDS C18 material (Alltech, Breda, the Netherlands) 
was used for chromatographic separation, and gradient elution was performed 
with a mixture of acetonitrile and 0.02 M ammonium acetate (pH 4.0) at a flow 
rate of 0.8 mLlmin. Paclitaxel (Bristol-Myers Squibb, Wallingford, CT) was used 
as internal standard. 
Figure 1 
HO 0 
o 
Chemical structures of docetaxel (A) and its major cytochrome P450 3A4-
mediated metabolite M4 (3'-de-terl-butoxy-carbonylamino-3'-[3-(5,5-dimethyl-
2,4-dioxo-1 ,3-oxazoli-dinyl)]-docetaxel) (8). 
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Authentic reference standards of the docetaxel metabolites M 1, M2, 
M3 and M4 (Fig. 1) were obtained following isolation and purification of a 
patient fecal sample, as described (12), and their concentrations in feces 
homogenates were determined by reversed-phase HPLC with UV detection 
using a modification of a procedure described elsewhere (13). In brief, 
quantitative extraction was achieved by a single solvent extraction of 0.5-
mL samples with a mixture of acetonitrile-n-butyl chloride (1 :4, v/v). 
Chromatography was performed at 60°C using an Inertsil ODS-80A column 
(150x4.6 mm; 5 11m particle size; GL Science, Tokyo, Japan) protected by 
a Lichrospher 100 RP-18 endcapped-guard column (4.0x4.0 mm; 5 11m 
particle size; Merck, Darmstadt, Germany), and a 1-h exponential gradient 
elution (45 to 75 %; 1 mLlmin) of methanol in water-tetrahydrofuran-
aqueous ammonium hydroxide (97.4:2.5:0.1, v/v/v) at pH 6.0. The column 
effluent was monitored at a wavelength of 230 nm. 
Concentrations of R 101933 and its esterase-mediated carboxylic acid 
metabolite, R102207, were determined by a validated HPLC method 
involving solid-phase extraction on Bond-Elut Certify micro-columns 
(Varian). Standard curves were prepaired in drug-free human plasma and 
were expanded to encompass concentrations between 2 and 10,000 
ng/mL. A 1-mL aliquot of standard or plasma sample was mixed with 3-mL 
of 1 M aqueous acetic acid and 100 JiL of internal standard solution 
(R125026 in acetonitrile at 10 Jig/mL). Prior to loading, columns were 
preconditioned with 3 mL of ethanol, 3 mL of water and 1 mL of 1 M of 
aqueous acetic acid. Consecutive washing steps involved 3 mL of water, 1 
mL of aqueous acetic acid, and 3 mL of ethanol, and elution was performed 
with 3 mL of a mixture of ethnanol-ammonia (98:2, v/v). Samples were 
dried under nitrogen at 65°C and redissolved in 100 JiL of 0.02 M 
ammonium formate (pH 4.0)-acetonitrile-ethanol (50:25:25, v/v/v). 
Chromatography was performed on a column (100x4.6 mm) packed with 3-
Jim Hypersil BDS C8 material (Alltech), and gradient elution (0.8 mLlmin) 
with a mixture of 0.02 M ammonium formate (pH 4.0), acetonitrile and 
ethanol. UV absorption measurements were performed at a wavelength of 
270 nm. Determination of analyte concentrations was based on log-
transformed peak areas of R101933 and R102207 and the internal 
standard versus nominal concentrations by interpolation using linear 
regression analysis. 
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Pharmacokinetic Analysis 
Individual plasma concentration-time curves of docetaxel were 
analyzed by a two-compartimental model using the software package 
WinNonlin (Pharsight, Mountain view, CAl. All curves were fitted using the 
actual infusion duration and blood sampling times. Pharmacokinetic 
parameters were calculated by standard methods. To test parameter 
differences for statistical significance among treatment courses, a two-
tailed paired Student's t test was performed. Probability values of less than 
0.05 were considered statistically significant. 
In Vitro Studies 
A functional in vitro study was performed to evaluate whether oral 
R101933 in humans yields plasma levels which are capable of inhibiting 
Pgp function in tumor cells. The parental human ovarian carcinoma cell line 
A2780 (Pgp negative) and the derived anthracycline-resistant lines 
A2780Tloo and 2780AD (both Pgp positive), developed by transfection of 
Pgp and step-wise exposure to doxorubicin, respectively, were grown and 
maintained in colorless RPMI1640 medium (Brunschwig, Amsterdam, The 
Netherlands). Cells were kept in continuous logarithmic growth at 3JDC in a 
humidified atmosphere in 5 % CO 2/95 % air in medium supplemented with 
10% (w/v) heat-inactivated bovine calf serum (Hyclone, Logan, UTi, 
penicillin, streptomycin and L-glutamine. Exponentially grown cells were 
trypsinized, packed by centrifugation for 5 min at 1500xg and washed 
twice with medium. The cells were counted microscopically and transferred 
to protein-free RPMI to dilutions containing 4.0x 105 cells per mL. Inhibition 
of Pgp-mediated drug efflux in each of the cell lines was evaluated using a 
daunorubicin (final concentration, 1 ,ug/mL) retention assay, in the 
presence of various concentrations of R101933, ranging from 1 to 1000 
ng/mL. Preliminary time-course experiments revealed that at a given 
R101933 concentration, daunorubicin uptake in the cells did not change 
after 90 min, at which time equilibrium was reached. Thus experiments 
were carried out with a 2-h incubation period at 3JDC, using 0.5-mL 
aliquots of the cell suspension in 4.5-mL polypropylene screw-cap tubes 
(Greiner, Alphen aan den Rijn, The Netherlands). The addition of R101933 
was done following extraction of the compound from a human plasma 
matrix or patient sample using a mixture of acetonitrile and n-butyl chloride 
(1 :4, v/v), and reconstitution of dried extracts in neat medium by agitation. 
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During the incubation period, tubes were gently vortex-mixed at 30-min 
intervals to prevent clogging of the cells. Intracellular levels of daunorubicin 
were measured using flow cytometry with the aid of a fluorescence-
activated cell sorter. The fluorescence intensity in the resistant cell lines 
relative to that observed in the A2780 parental cell line in the absence of 
R101933, expressed as percentage, was plotted relative to the R101933 
concentration. 
RESULTS 
Plasma Pharmacokinetics 
The results of paired plasma concentration-time profiles of 
unchanged docetaxel given with and without co-treatment of oral R 101933 
were remarkable similar for all patients studied (Fig. 2). 
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Plasma concentration versus time profiles of docetaxel in 5 patients treated 
with docetaxel alone (100 mg/m2 as a 1-h Lv. infusion) (0) or in 
combination with oral R101933 (200 or 300 mg b.i.d.) (e). Data are 
presented as mean values (symbols) ± SD (error bars). 
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The mean pharmacokinetic parameters of docetaxel for both 
treatment courses are summarized in Table 1. There were no statistically 
significant differences in any of the studied docetaxel kinetic parameters, 
including the AUC and terminal disposition half-life, suggesting that 
R101933 did not influence the disposition of the taxane in the systemic 
circulation. The observed peak plasma concentrations of R1 01933 were in 
the range of 25.3 to 168 ng/mL and 83.1 to 142 ng/mL in the absence and 
presence of docetaxel, respectively. Concentrations of R 101933 in this 
range were observed to inhibit Pgp-mediated daunorubicin efflux in 2 cell 
lines with known expression of Pgp and resistance to anthracyclines (Fig. 
3). In a" patients, there was extensive formation of the pharmacologica"y 
inactive compound, R 102207, resulting from an ester hydrolysis, with peak 
levels approximately 75-fold higher (range, 33 to 124) than that of the 
parent drug. 
Table 1 
Parameter 
Plasma 
Docetaxel 
Disposition and elimination kinetics of docetaxel in the absence 
or presence of oral R 101933 * 
Without R101933 With R101933 P** 
AUC* * * (l-lg.h/mL) 3.62 ± 0.66 4.22 ± 0.97 0.33 
(3.04 - 4.50) (3.09 - 5.63) 
t 1/21PJ (h) 11.2±2.10 8.70 ± 4.80 0.27 
(8.60 - 13.3) (3.15 - 14.4) 
Feces 
Docetaxel 
fe t (%) 8.47±2.14 0.45 ± 0.24 0.0016 
(5.92 - 11.3) (0.13 - 0.72) 
M4 
fet(%) 
13.3±1.81 
(11.3 - 15.5) 
20.1 ± 4.39 0.010 
(16.8 - 27.4) 
* 
** 
*** 
Data were obtained from 5 cancer patients receiving a 1-h i.v. infusion of docetaxel 
at 100 mg/m2 either alone or in combination with 200 or 300 mg Rl01933 given 
orally. The kinetic terms are mean values ± SO, with ranges in parentheses. 
Probability value vs. control without R 1 01933 (paired two-sided Student's t test). 
AUC, area under the plasma concentration of docetaxel vs time curve; t1!2IPJ' terminal 
disposition half-life of docetaxel; fet, percentage of the absolute docetaxel dose 
excreted in the feces within 31 h after drug administration as indicated drug. 
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Modulation of cellular daunorubicin uptake by R1 01933 as measured by a 
change in the fluorescence intensity in the P-glycoprotein expressing and 
anthracycline-resistant cell lines A2780T100 (V) and 2780AD (A) relative to 
that observed in the A2780 parental cell line (CD) in the absence of 
R101933. Experiments were carried out with a 2-h incubation period at 
3]DC with R101933 present at various concentrations. Data points, 
expressed as percentage, are mean values of at least 3 independent 
experiments performed in duplicate, and bars represent standard errors. The 
grey box indicates the range of R101933 peak levels observed in the 5 
patients following treatment with an oral dose of 200 or 300 mg. Over the 
entire drug concentration range, substantial increases in intracellular 
fluorescence, induced by R 10 1933-mediated inhibition of P-glycoprotein 
activity, could be detected. 
Fecal Elimination 
In humans, excretion of docetaxel via the feces is a major route of 
drug elimination (12,14). To evaluate the effects of Pgp inhibition on 
elimination pathways of docetaxel, feces samples were collected over a 
period of 31 h from all 5 patients during both treatment courses with and 
without R1 01933. Preliminary insight obtained from work of our labaratory 
into the composition of docetaxel metabolites present in feces samples 
indicated that apart from docetaxel, 7 chromatographic peaks absorbed at 
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230 nm, the peak wavelength of taxane derivatives. Structural 
identification using HPLC and off-line mass spectrometry showed that the 
major peak was M4, a known metabolite of docetaxel resulting from 
hydroxylation reactions on the tert-butyl propionate side chain (15). Using 
reference standards, 3 of the minor peaks were identified as metabolites 
resulting from oxidation of one of the methyl groups on the tert-butyl 
propionate side chain (M2), and spontaneous cyclization of this alcohol 
derivative to the 2 diastereoisomers M 1 and M 3. 
In patients treated with docetaxel alone, 8.47±2.14% (mean±SD, 
n = 5) of the administered dose was excreted in the first 31 h as the parent 
drug, whereas 13.3±1.81 % of the dose could be accounted for by 
metabolite M4 (Table 1). The total fecal recovery of the metabolites M 1, 
M2, and M3 was very low in all patients (less than 0.5% of the dose; data 
not shown) and apparently the compounds play only a minor role in the 
overall drug disposition. In the same group of patients, co-administration 
with R 101933 resulted in markedly reduced fecal excretion of unchanged 
drug to less than 0.5% of the administered dose (P= 0.0016). In contrast, 
however, the excretion of metabolite M4 was significantly increased in all 
patients to 20.1±4.39% of the dose (P= 0.01 0). These data clearly show 
that R101933 administered orally causes a profound alteration of Pgp-
mediated intestinal re-absorption of docetaxel, without modifying the drug's 
kinetic behavior in plasma. 
DISCUSSION 
In the present study we have shown that intestinal Pgp plays a 
principal role in the fecal elimination pathways of docetaxel without 
modifying the pharmacokinetic behavior of the drug in the systemic 
circulation. Previous investigations have shown a major role of the 
cytochrome P450 3A4 isozymes in docetaxel metabolism. In humans, the 
principal biotransformation routes involve hydroxylation of the tert-butoxy 
function in the C13 side chain, followed by a spontaneous cyclization 
reaction (15). The 4 principal metabolites resulting from this pathway have 
substantially less cytotoxic activity on tumor and nonmalignant 
hematopoietic cells as compared to the parent drug (12). Fecal excretion of 
docetaxel and its metabolites has been previously reported in 2 other cases 
(14,15), and in both M4 was the main metabolite, very similar to our 
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current findings, and accounted for a larger fraction of the recovered dose 
than docetaxel itself. Interestingly, this metabolite can only be detected in 
the systemic circulation in about 30% of the patients treated with 
docetaxel at a dose of 100 mg/m2, and reaches peak plasma levels ranging 
from only 22-230 ng/mL (16). This makes it very likely that metabolite M4 
is very efficiently excreted through a biliary secretion pathway into the 
intestinal lumen immediately following its formation, and that re-absorption 
is low. In our patients, we observed that co-administration with R101933 
had a marked effect on the fecal elimination of docetaxel, changing from 
excretion partly as unchanged drug in case of single agent administration to 
almost exclusively through metabolic breakdown (mainly to M4) in the 
combination treatment. The similarity of the terminal disposition phases in 
plasma of docetaxel between treatment courses indicate that the reduced 
fecal excretion of the parent drug in the patients receiving R101933 is 
unlikely related to diminished (pgp-mediated) biliary secretion. This is also in 
line with recent preclinical studies performed in mice lacking MDR 1 (drug-
transporting) Pgp, indicating that these proteins are not essential per se for 
normal hepatobiliary secretion of the related compound, paclitaxel (17). 
Following biliary secretion of docetaxel given in combination with R1 01933, 
re-absorption of drug from the intestinal lumen appears to be a very 
efficient process. This does not, however, result in increased plasma levels 
due to a virtually complete first-pass extraction and/or docetaxel 
metabolism in the liver and intestinal mucosa, which also has significant 
expression of cytochrome P450 3A isozymes (9) (see Fig. 4 for a schematic 
representation of the role of intestinal Pgp in docetaxel metabolism and 
excretion). These findings lend further support to previous observations that 
the absorption of substrate drugs from the intestines can be increased by 
concomitant administration with Pgp inhibitors (reviewed in Ref. 18). 
The present data also raise important questions regarding the role of 
endogenously expressed Pgp (for instance in the bile canaliculi, kidneys and 
intestinal epithelial cells) in the pharmacokinetics of substrate drugs in 
plasma. It has been shown previously that R1 01933 does not interfere with 
docetaxel metabolism in preclinical systems, it does not induce cytochrome 
P450 isozymes, and the major metabolic routes of the modulator itself is 
ester hydrolysis, which is independent of cytochrome P450 activity 1. Our 
results of unaltered plasma concentrations of docetaxel in the combination 
1 Janssen Research Foundation, data on file 
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with R 101933 is consistent with the postulated concept that pharmaco-
kinetic interference between Pgp modulators and anticancer drugs is the 
result of competition for (cytochrome P450) enzymes involved in drug 
metabolism (8). This is also in keeping with previous knowledge from data 
generated in Pgp knock-out mice (5,17-19) and sheds light on some 
important mechanistic aspects of drug-drug interactions. Most importantly, 
our data clearly indicate that inhibiting Pgp function in normal tissues by 
administration of an effective modulator, the physiological and pharmaco-
logical consequences of this treatment cannot be predicted based on 
plasma drug measurement alone. 
o 
Figure 4 
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Schematic representation of the role of intestinal P-glycoprotein in 
docetaxel metabolism and elimination in humans. 
CD, model of the hepatic-cellular plate showing the bile collecting system 
with (0 hepatic metabolism of docetaxel from the systemic circuation or the 
portal vein after re-absorption following biliary secretion by cytochrome 
P450 3A4 isozymes into metabolite M4 and (Ii) its subsequent secretion in 
the terminal bile duct. 
@, model of the intestinal epithlium showing (0 re-uptake of docetaxel into 
the intestinal lumen, (iI) P-glycoprotein-mediated efflux of docetaxel and its 
inhibition by Rl01933 and (iii) intestinal metabolism by the cytochrome 
P450 3A4 enzyme system. 
*, sites of drug measurement. 
Abbreviations: doc, docetaxel; M4, 3' -de-tert-butoxy-carbonylamino-3' -[3-
(5, 5-dimethyl-2 ,4-dioxo-1 ,3-oxazolidinyl) ]-docetaxel; CYP3A4, enzymes of 
the cytochrome P450 family, isoform 3A4. 
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Given the dominant pharmacological role of intestinal Pgp activity in 
the efficiency and pattern of fecal excretion of docetaxel, we expect that 
the possibility to inhibit its activity completely with an orally administered 
Pgp modulator as demonstrated in this study can have important 
pharmacological applications. One of these applications is to increase the 
oral bioavailability of taxane drugs, which are known to display poor 
absorption characteristics following oral drug administration (19). Indeed, 
recent experimental data have shown that co-administration of oral PSC833 
or cyclosporin A (both substrates of cytochrome P450 3A4 isozymes) 
increased the AUC for paclitaxel in mice more than 10-fold (20), and 
preliminary findings from the same group indicate that the same applies to 
paclitaxel administered to cancer patients (21). Based upon our current data 
that show a very prominent and efficient detoxification of re-absorbed 
docetaxel into hydroxylated metabolites before it can reach the systemic 
circulation, we expect that this approach of increasing drug bioavailability is 
unlikely to succeed unless the modulator significantly interferes with 
docetaxel metabolism. 
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ABSTRACT 
Recently, a study of docetaxel in combination with the new orally 
administered P-glycoprotein (Pgp) inhibitor R 101933 showed that this 
combination was feasible. However, due to low oral bioavailability of 
R 101933 and high inter-patient variability, further attempts to increase the 
level of Pgp inhibition were canceled. Here, we assessed the feasibility of 
combining docetaxel with intravenously (i.v.) administered R101933, and 
determined the disposition of docetaxel with and without the Pgp inhibitor. 
Patients received R101933 i.v. alone at a dose escalated from 250 to 500 
mg on day 1 (cycle 0), docetaxel 100 mg/m2 as a 1-hour infusion on day 8 
(cycle 1) and the combination every three weeks thereafter (cycle 2 and 
further). Twelve patients were entered of whom 9 received the combination 
treatment. Single treatment with R1 01933 i.v. was associated with minimal 
toxicity consisting of temporary drowsiness and somnolence. Dose-limiting 
toxicity consisting of neutropenic fever was seen in cycle 1 and cycle 2 or 
further at both dose levels. The plasma pharmacokinetics of docetaxel did 
not change by the R1 01933 regimen at any dose level tested, as indicated 
by plasma clearance values of 22.5 ± 6.2 Llh/m 2 and 24.2 ± 7.4 Llh/m 2 
(P=0.38) in cycle 1 and 2, respectively. However, the fecal excretion of 
unchanged docetaxel decreased significantly after the combination 
treatment from 2.54 ± 2.05% to less than 1 % of the administered dose of 
docetaxel, most likely due to inhibition of the intestinal P-glycoprotein by 
R 101933. Plasma concentrations of R 101933 were not different in cycle 0 
or cycle 2 and the concentrations achieved in the first 12-hour period after 
i.v. infusion were capable of inhibiting Pgp in an ex vivo assay. It is 
concluded that the combination of docetaxel 100 mg/m2 i.v. and R101933 
500 mg i.v. is feasible, lacks pharmacokinetic interaction in plasma, and 
shows evidence of Pgp inhibition both in an ex vivo assay and in vivo by 
the indication of intestinal Pgp inhibition. 
INTRODUCTION 
One of the best described mechanisms of multidrug resistance 
(MDR), the in vitro phenomenon thought to be partly responsible for failure 
of cancer treatment with naturally occurring anticancer drugs such as 
taxanes, is associated with overproduction of the transmembrane transport 
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protein Pgp which acts as an A TP-dependent drug efflux pump and thus 
decreases the intracellular concentrations of these drugs (1,2). Abundant 
effort has been put in developing drugs which are able to inhibit Pgp and 
can be used in combination with anticancer drugs (3,4). However, it 
became evident that pharmacokinetic interactions occurred between the 
Pgp inhibitors and the co-administered anticancer drugs due to competitive 
inhibition of cytochrome P-450 enzymes resulting in significantly increased 
toxicity of the anticancer drugs (5,6). Recently, we described the results of 
a phase I and pharmacokinetic study with a new Pgp inhibitor, R101933, 
administered orally in combination with docetaxel i.v. (7). In this study the 
pharmacokinetic and clinical safety profiles of docetaxel were unchanged 
indicating a lack of pharmacokinetic interaction between the anticancer 
drug and the Pgp inhibitor. By means of a functional in vitro study it was 
shown that the achieved plasma concentrations of R 101933 were able to 
inhibit Pgp (8). However, due to a low oral bioavailability of R1 01933 and 
significant inter-patient variability in exposure to R 101933, further attempts 
to increase the level of Pgp inhibition by oral administration of R 101933 
were cancelled and a potential pharmacokinetic interaction with docetaxel 
at higher concentrations of R 101933 could not be excluded (7). Here, we 
performed a new phase I and pharmacokinetic study with docetaxel in 
combination with R 101933 given intravenously. Plasma samples as well as 
feces samples were collected. Earlier analysis of fecal excretion of 
docetaxel without and with oral R 101933 revealed that the physiological 
and pharmacokinetic consequences of inhibition of Pgp by effective 
modulators can not be predicted based on plasma drug monitoring alone 
and collecting feces samples can be an important element of the 
pharmacokinetic studies of anticancer drugs given in combination with a 
Pgp inhibitor (8). To confirm that the achieved R 101933 plasma levels after 
intravenous administration might be capable of inhibiting Pgp in tumor cells, 
we developed an ex vivo assay as a surrogate measure of Pgp antagonism. 
PATIENTS AND METHODS 
EligibilitV 
Patients with a histologically confirmed diagnosis of a solid tumor for 
whom docetaxel as monotherapy was a viable therapeutic option or for 
whom other treatment options were not available, were candidates for this 
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study. Additional eligibility criteria were: age :2:18 years; Eastern 
Cooperative Oncology Group performance status < 3; life expectancy of at 
least 3 months; off previous anticancer therapy for at least 3 weeks; no 
previous treatment with taxanes or high dose chemotherapy reqUlrrng 
progenitor cell support; adequate bone marrow function (ANC > 1.5 x 
109 /L, platelet count > 100 x 109 /Ll, renal function (serum creatinine s::2 
times upper limit of normal), and liver function (bilirubin level normal, 
aspartate/alanine aminotransferase s::2. 5 times upper limit of normal and 
alkaline phosphatase s::2.5 times upper limit of normal); and symptomatic 
peripheral neuropathy < grade 2 (NCI criteria). Written informed consent 
was obtained from all patients, and the study was approved by the 
University Hospital Rotterdam Ethics Board. 
Pretreatment and Follow-up 
Pretreatment evaluation consisted of recording the history of the 
patient, physical examination, laboratory studies, electrocardiography, and 
chest-X-ray. Computer tomographic scans were performed for tumor 
measurements. Laboratory studies included a complete blood-cell count 
analysis, and measurement of WBC differential, electrolytes (including 
sodium, potassium, chloride, calcium, magnesium and inorganic phosphate), 
creatinine, urea, alkaline phosphatase, aspartate aminotransferase, alanine 
aminotransferase, lactate dehydrogenase, bilirubin, total plasma proteins, 
serum albumin, glucose, uric acid, and urinalysis. History, physical 
examination, and toxicity scoring (according to the NCI Expanded CTC) 
were repeated once a week. Complete blood cell counts including WBC 
differential were performed twice a week. During cylce 0 
electrocardiographies were performed at baseline and approximately 1, 2, 
6, 24 and 48 hours after start of the infusion with R101933. The 
electrocardiography was repeated at the end of cycle 2 and further on 
when clinically indicated. A final assessment was to be made after patients 
went off study. Formal tumor measurements were performed at 6-weeks 
intervals until documentation of progressive disease. Standard WHO 
response criteria were used. 
Drug Administration 
First, the patients received R101933 alone (cycle 0) followed by a 
72-h wash-out period to allow assessment of the terminal half-life of 
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R101933. One week later, cycle 1 was initiated with docetaxel alone. 
Thereafter, the combination was given 3-weekly until progressive disease 
(PO) or dose limiting toxicity (OL T) occurred. Oocetaxel was administered 
every 3 weeks as a 1-h infusion and in the combination was started 
immediately after the end of the i. v. administration of R 101933. All 
patients received pre-medication with dexamethasone orally 8 mg b.i.d., 
starting one day prior to each infusion of docetaxel, and to be taken for a 
total of 3 days every course. R101933 (Janssen Research Foundation, 
Beerse, Belgium) was supplied as a 10-mg/mL solution in hydroxypropyl-
beta-cyclodextrin, hydrochloric acid, citric acid monohydrate, sodium 
hydroxide and mannitol. The drug was administered by a syringe infusion 
pump as a single 1-h infusion. The dose of docetaxel was fixed at 100 
mg/m2 and the dose of R 101933 was escalated. The first dose level of 
R101933 was set on 250 mg, a dose known to be capable of Pgp inhibition 
and to induce no toxicity in a simultaneous study with paclitaxel (9). 
In each cohort 3 patients were treated unless OLT of R101933 alone 
or OL T of the combination treatment was observed. In that case, the 
accrual of 3 additional patients was required. The occurrence of OL T during 
the first cycle with docetaxel alone led to a replacement of the patient in 
the same cohort to which the patient was assigned. OL T of R 101933 
(OL Tr) alone was defined as any non-hematological toxicity > grade 2 
before chemotherapy was given. OLT of the combination treatment (OLTc) 
was defined as grade 3 non-hematological toxicity (with the exception of 
non-hematological toxicity that was still manageable in an out-patient 
setting, such as grade 2 alopecia or nausea/vomiting) or grade 4 
neutropenia lasting more than 5 days, grade 4 thrombocytopenia or required 
delay > 2 weeks to a subsequent cycle due to toxicity with a reasonable 
possibility that the event could be attributed to the combined treatment 
with R 101933 and docetaxel. Febrile neutropenia and neutropenia with 
severe infection (> grade 2 infection) were also considered as OL T of the 
combination treatment. For dose-escalation decisions only OL Ts in cycles 0 
and 2 were taken into account. The OL T of R 101933 alone was reached 
when ~ lout of 3 (or ~ 2 out of 6) patients experienced OL Tr. The OLT of 
the combination of R 101933 with docetaxel was reached when ~ 3 out of 
6 patients experienced OL Tc. The maximum tolerated dose (MTO) was 
defined as the dose level below OLT. 
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Sample Collection and Processing 
Blood specimens were taken in all patients during cycle 0, 1 and 2. 
Blood volumes of 5-10 mL were drawn directly into Vacutainer tubes 
containing lyophilized sodium heparin (Becton Dickinson, Meylan, France) 
from a peripheral venous access device. In each patient, sufficient plasma 
was obtained before drug administration to evaluate possible interfering 
peaks in the chromatographic analysis. Samples for docetaxel analysis were 
collected immediately before infusion, and at 0.5, 1, 1.25, 1.5, 2, 4, 9, 24, 
and 48 h after start of infusion. For determination of Rl01933 
concentrations, blood samples were collected immediately before infusion, 
and at 0.5, 1, 1.5, 2, 3, 5, 10, 24, 48, and 72 h after start of infusion. All 
blood samples were centrifuged immediately for 10 min at 1000 x g to 
yield plasma, which was stored frozen in polypropylene vials (Eppendorf, 
Hamburg, Germany) until the time of analysis. 
Complete stool collections for docetaxel analysis were obtained in 
cycle 1 and 2 for the duration of the study U. e., up to 48 h after start of 
docetaxel administration). This interval was chosen based on previous fecal 
excretion studies with the structural related agent paclitaxel (10). Fecal 
specimens were collected in polystyrene containers and stored immediately 
at -20°C. 
Drug Analysis 
Plasma concentrations of docetaxel were determined by solid-phase 
extraction using Bond Elut nitrile microcolumns (Varian, Harobor City, CAl 
and a sensitive liquid chromatographic assay with tandem mass 
spectrometric detection, with a lower limit of quantitation of 1 ng/mL (200 
,uL-samples) (7). The analytical method for R101933 and its esterase-
mediated metabolite Rl02207 was based on solid-phase extraction with 
Bond-Elut Certify microcolumns (Varian) and high-performance liquid 
chromatography with UV absorption measurements at 270 nm, with a 
lower limit of quantitation of 2 ng/mL (l-mL samples) (7). Concentrations of 
docetaxel and its major hydroxylated metabolites M2, M3, and M4 in feces 
homogenates were determined by reversed-phase high-performance liquid 
chromatography with UV detection at 230 nm as described in detail earlier 
(8,11). This method employs 0.5-mL samples of feces specimens [first 
homogenized in 0.01 M potassium phosphate buffer (1 :3, w/v) and then 
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diluted (1:1, v/v) with human plasmal. with a lower limit of quantitation of 
2.0 j./g/mL. 
Pharmacologic Data Analysis 
Plasma concentration-time profiles of docetaxel, R101933 and its 
metabolite R102207 were pharmacokinetically analyzed by compartimental 
and noncompartmental models using the software package WinNonlin 
(Pharsight, Mountain View, CAl (7). The drug disposition half-lives, AUC 
extrapolated to infinity, plasma clearance, steady-state volume of 
distribution and percentage of the absolute docetaxel dose excreted in 
feces as parent drug or metabolite were determined using methods and 
equations as defined elsewhere (7,8). Hematological pharmacodynamics 
were evaluated by analysis of the absolute nadir values of blood cell counts 
or the relative hematological toxicity, i.e. the percentage decrease in blood 
cell count, which was defined as: 
% decrease = [(pretherapy value - nadir value) / (pretherapy value)] x 
100% 
Within each patient, myelosuppression was described either using 
continuous variables, consisting of the percentage decrease in WBC, 
absolute neutrophil count and platelet count or as discrete variables in case 
of NCI-CTC myelotoxicity grade. 
Ex Vivo Pharmacodynamics 
The expression of high levels of Pgp in the anthracycline-resistant cell 
line A2780T_100, obtained by transfection of Pgp, allowed us to use an ex 
vivo assay as a surrogate measure of Pgp antagonism in plasma samples of 
patients treated with R1 01933. The A2780T_100 cell line was maintained in 
RPMI1640 medium without I-glutamine and phenol red (Gibco, Amsterdam, 
The Netherlands) supplemented with 10% bovine calf serum, 
penicillin/streptomycin 50U/50 j./g/mL in a 5 % COz/95 % air atmosphere at 
3JDC. Cells were grown to 80 - 90% confluency and treated with trypsin-
EDT A before subculturing. On the day of the experiment, the cells were 
centrifuged at room temperature and resuspended in protein-free RPMI1640 
medium at a concentration of 80,000 celis/mL. Aliquots (500 j./L) of cell 
suspension were transferred to polypropylene tubes containing 250 j./L of 
incubation medium in the presence of daunorubicin and R 10 1933. 
Extraction of R 101933 was performed from 300-j./L plasma samples 
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(patients' samples or spiked calibration samples) using 1500 jJL acetonitrile-
n-butyl chloride (1 :4, v/v) in polypropylene microtubes (Eppendorf, 
Hamburg, Germany) by mixing for 30 seconds. After centrifugation for 5 
min at 23,000 g, 1300 jJL of the upper organic layer was transferred into a 
glass tube and evaporated to dryness at 50°C under nitrogen. R101933 
was reconstituted in 300 jJL RPMI1640 medium by agitation, and the 
sample was centrifuged again for 1 min at 3000 g. An aliquot of 250 jJL 
clear supernatant was added to the cell suspension. Next, cells were 
incubated for 120 min to assure maximal retention of daunorubicin (8). 
Preliminary experiments had shown that daunorubicin used at a final 
concentration of 1 jJg/mL provided reasonable fluorescence to distinguish 
differences between the various anticipated concentrations of R 101933, 
thus making this level suitable for the Pgp inhibition studies. Fluorescence 
measurements of individual cells were performF'ld with flow cytometry using 
a Becton-Dickinson FACS (San Jose, CAl equipped with an ultraviolet argon 
laser (excitation at 488 nm, emission at 530/30 and 570/30 nm band-pass 
filters). Analysis was gated to include single cells on the basis of forward 
and side light-scatter and was based on acquisition of data from 7500 cells. 
Log fluorescence was collected and displayed as single parameter 
histograms. Geometric mean fluorescence values of duplicate 
measurements were used for all patients' samples, and fluorescence data 
obtained from experiments done with the A2780 parental cell line (not 
expressing Pgp) were used as a positive control. Time-course studies were 
conducted with samples from the first treatment course in all patients using 
the fluorescence intensity in the resistant cells relative to a pretherapy 
plasma sample (i.e. in the absence of R1 01933), normalized to a value of 
1.0 (arbitrary units). Previous studies have shown that inactivation (with 
R 101933 in A2780T_100 cells) or complete preclusion of Pgp active-efflux 
function (in A2780 cells) is associated with a normalized fluorescence value 
of 2.5 on this scale (8). Therefore, the experimental set-up provides a 
factor that normalizes the degree of inhibition by R 101933 in each plasma 
sample relative to the total absence of Pgp function and allows for 
normalization of the results across sample sets both within and between 
patients. In each patient, the time to maximal inhibition of Pgp function 
following R 101933 administration was determined in addition to the 
duration above Ki, defined as the concentration required for half-maximum 
inhibition of Pgp-mediated daunorubicin efflux. 
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Statistical Considerations 
Parameters of all compounds are reported as mean values ± SO, 
except were indicated otherwise. The difference in pharmacokinetic 
parameters between the docetaxel administration days and between patient 
cohorts was evaluated statistically using a two-sided parametric matched-
pairs Student's t-test (after testing for normality) plus the 95 % confidence 
intervals. Probability values (two-sided) of less than 0.05 were considered 
statistically significant. All calculations were done on the Number Cruncher 
Statistical Systems v5.x software package (J.L. Hintze, East Kaysville, UT, 
1992). 
Table 1 Patient characteristics 
Characteristic No. of patients 
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RESULTS 
Twelve patients were entered into this study. Patient characteristics 
are listed in Table 1; all patients were eligible. Three patients were 
considered not evaluable for toxicity, response and pharmacokinetic 
analysis. In one patient the dose of docetaxel in cycle 2 and further was 
decreased to 75 mg/m2 because of disturbed liver function tests after cycle 
1. He received 7 cycles of the combination treatment without further 
deterioration of the liver function or other severe toxicities related to 
docetaxel or R101933. Two patients did not receive the combination 
treatment due to fatigue grade 3 and neutropenic fever related to chronic 
sinusitis, respectively, after treatment with docetaxel alone. The ex vivo 
assay was accomplished in all patients as all patients received cycle 0 with 
R1 01933 alone according to the protocol. 
Toxicity and Hematological Pharmacodynamics 
A total of 34 cycles docetaxel, including 25 cycles of combined 
docetaxel and R1 01933, were given. Table 2 lists the number of cycles at 
each dose level and the main toxicities at each dose level. At the first dose 
level of R1 01933, i.e. 250 mg, 3 patients were treated. Neutropenic fever 
in one patient after administration of docetaxel alone (cycle 1) led to the 
decision to provide prophylactic antibiotics (ciprofloxacine 500 mg b.i.d., 
day 4-15). Subsequently, this patient was treated with the combination 
therapy and experienced no further periods of neutropenic fever but ceased 
from treatment after cycle 3 due to neurotoxicity grade 3. Because of 
fatigue grade 4 and myalgia grade 3, another heavily pretreated patient at 
this dose level ended treatment after cycle 5. Since no DL Ts were seen in 
cycle 0 and 2, the dose of R1 01933 was escalated to 500 mg. At this dose 
level all patients experienced fatigue and myalgia from cycle 1 on but these 
and other toxicities never exceeded grade 2. At both dose levels most 
patients experienced grade 1-2 drowsiness and somnolence after the 
administration of R101933. Considering a simultaneously performed study 
of R 101933 i. v. combined with paclitaxel i. v. revealed a maximal tolerated 
dose of R 101933 alone of 500 mg (9), no attempt was made to further 
increase the dose of R101933 in the present study despite the fact that 
formally DLT was not reached. All patients without severe toxicity were 
treated until progressive disease. Partial responses were not seen 
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Table 2 Main toxicities (worst per cycle) at the two dose levels expressed in number of cycles in which the toxicity 
occurred 
R101933 Docetaxel 
** 
(mg) (mg/m2) 
Uk* 
* 
250 100 
500 100 2 
NCI Common Toxicity Criteria 
uk, unknown 
Neutropenia 
CTC grade* 
1 2 3 
3 2 5 
Somnolence 
CTC grade 
4 0 1 2 
10 5 2 3 
12 21 1 2 
Fatigue Myalgia 
CTC grade CTC grade 
0 1 2 3 4 0 1 2 3 
2 2 5 1 6 2 1 1 
15 1 8 11 10 3 
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Statistical analysis of paired hematological data, available in all 9 
evaluable patients, showed that R 101933 co-administration with docetaxel 
was not associated with a greater percentage decrease in WBC and 
absolute neutrophil count or lower mean blood cell count nadir (Table 3). 
This suggests that the observed myelotoxicity in treatment cycles with 
docetaxel combined with R 101933 is not attributable to inhibition of P-
glycoprotein in bone marrow precursor cells, and is consistent with our 
previous observations in patients treated with docetaxel and oral R101933 
(7). 
Table 3 Summary of hematological pharmacodynamics * 
Parameter Cycle 1 Cycle 2 
Leukocytes 
Nadir (x1 09/L) 1.63±1.01 1.97±1.47 
(0.66-3.20) (0.63-4.90) 
%decrease WBC 77.5±10.3 74.5±19.2 
(62.5-88.2) (45.2-94.2) 
Neutrophils 
Nadir (x1 09/L) 0.62±0.71 1.00±1.38 
(0.07-2.10) (0.12-3.70) 
%decrease ANC 91.2±9.96 87.8±15.9 
(72.5-98.3) (58.4-97.8) 
Difference 95% C.L. * * 
-0.37±0.71 -2.05,1.32 
3.04±6.95 -13.3,19.4 
-0.39±0.64 -1.95,1.19 
3.43±7.51 -14.9, 21.8 
p*** 
0.625 
0.675 
0.573 
0.664 
* 
** 
Data were obtained from patients after treatment with a 1-h i.v. infusion of 
docetaxel at a dose level of 100 mg/m2 given either alone (cycle 1) or the presence 
of Lv. R101933 at a dose level of 250 or 500 mg (cycle 2).The relative 
hematological toxicity (i. e., the percentage decrease in blood cell count) was defined 
as: %decrease = [(pretherapy value - nadir value)/(pretherapy value)] x 100%. Data 
are presented as mean values ± SO, with the observed range shown in parenthesis. 
C.L., 95% confidence limits for the mean difference; ANC, absolute neutrophil 
count. 
*** Paired Student's t test. 
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48 
Plasma concentration-time profiles of docetaxel in patients treated with 
docetaxel at a dose level of 100 mg/m2 given either alone (0) or in 
combination with R101933 given at 500 mg as a 1-h Lv. infusion (_). Data 
are presented as mean values (0, _) ± SO (error bars). 
Docetaxe/ Disposition 
Paired plasma concentration-time profiles of docetaxel given alone or 
in combination with R101933 were available in all 9 patients (Fig. 1). There 
were no statistically significant differences in any of the studied 
parameters, suggesting that R101933 at the dose levels tested did not 
influence plasma pharmacokinetics of docetaxel (Table 4). At the final dose 
level tested, combining docetaxel at 100 mg/m2 and R101933 at 500 mg 
(n = 6), docetaxel plasma clearance values averaged 22.4 ± 12.6 liters/h/m 2 
and 23.8 ± 7.9 Iiters/h/m2 in the absence and presence of R101933, 
respectively (P= 0.69). To test whether the pattern of drug excretion 
altered in the presence of R101933 administered as an Lv. infusion, we 
also studied the cumulative fecal excretion of docetaxel and its major 
hydroxylated metabolites over a period of 48 hours. In line with previous 
findings (8), a minor fraction of the administered docetaxel dose 
(2.54±2.05%) was recovered in the feces of patients as unchanged parent 
drug with single agent dosing (Fig. 2). In the presence of R101933, fecal 
excretion of unchanged drug was markedly reduced to less than 1 % of the 
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Table 4 Plasma pharmacokinetic parameters of docetaxel in the absence or presence of R1 01933* 
Cohort 
Docetaxel 
1 00mgim2 (n = 3) 
Without R 
With R 250 mg 
Docetaxel 
1 00mgim2 (n = 6) 
Without R 
With R 500 mg 
AUC** 
(ng.himL) 
4047±487 
4277±1233 
5559±2660 
4550±1317 
Cmax 
()lgimL) 
2699±699 
2628±819 
3407±1102 
3102±908 
T'/2Ia) 
(h) 
0.28±0.18 
0.17±0.02 
0.27±0.20 
0.20±0.02 
t ,/2Iz) 
(h) 
20.4±9.9 
13.1±0.9 
14.6±1.5 
16.1±4.1 
Vdss 
(L/m2) 
201±106 
117±57 
144±77 
176±107 
MRT 
(h) 
8.0±3.9 
4.6±1.2 
6.6±0.8 
7.0±2.0 
Data were obtained from patients after the first (without R101933) and second treatment cycle (with R101933) of a 1-h infusion of 
docetaxel. The kinetic terms are mean values ± SO. 
AUC, area under the plasma concentration versus time curve; CmaX' maximum plasma concentration of drug; t1!2U' half life of the ;-th 
disposition phase; VdSS' volume of distribution at steady state; MRT, mean residence time; n, number of patients evaluated at both 
treatment courses; R, R101933. 
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dose (P= 0.01, paired Student's t test). In contrast, however, the 
cumulative fecal excretion of the hydroxylated metabolites increased more 
than 2-fold (P=0.01). 
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Docetaxel M2+M3+M4 
Percentage of the absolute docetaxel dose excreted in the feces within 31 
hours after drug administration as unchanged drug or as the total of 
metabolites M2, M3, and M4. Data were obtained from patients treated 
with docetaxel at 100 mg/m2 given either alone (white bars) or in 
combination with R1 01933 given at 250 or 500 mg as a 1-h i.v. infusion 
(hatched bars). Data are presented as mean values (bars) ± SEM (error 
bars). 
R 101933 Plasma Levels 
No differences were observed in the pharmacokinetics of R 101933 
given either alone or in the presence of docetaxel (Fig. 3; Table 5). 
R 101933 peak plasma concentrations after 500 mg i. v. administration 
ranged from 2580 to 5328 ng/mL. Peak plasma concentrations of its acid 
metabolite R1 02207 were about 4 to 5 times higher. Plasma concentrations 
of R1 01933 and R102207 declined distinctly biphasically with time, with 
terminal disposition half-lives ranging from 4 to 36 hour and from 9 to 37 
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hour, respectively. The determination of the terminal disposition half-life 
was highly dependent on the ability to quantify R 101933 or R 102207 in 
the terminal phase. The AUC of R101933 ranged from 2.94 to 19.6 
Ilg.h/mL. The AUC of R102207 was about 20 to 25 times higher. Mean 
plasma clearance values of R101933 given alone were 52.7 ± 19.2Iiters/h 
(n = 5) and 58.5 ± 19.7 liters/h (n = 7) at dose levels of 250 mg and 500 
mg, respectively, suggesting a dose-proportional pharmacokinetic behavior. 
No differences were observed in R101933 plasma clearance given either 
alone or in the presence of docetaxel [mean values, 53.8 ± 18.4 liters/h 
(cycle 0) vs 57.2 ± 11.6 liters/h (cycle 2) (P=0.47j, indicating the absence 
of a pharmacokinetic interaction at these dose levels. 
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Plasma concentration-time profiles of R101933 (circles) and its acid 
metabolite R102207 (squares) in patients treated with R101933 given as a 
1-h i. v. infusion at a dose level of 500 mg either given either alone (open 
symbols) or in combination with docetaxel given at 100 mg/m2 (closed 
symbols). Data are presented as mean values (symbols) ± SO (error bars). 
Pharmacokinetic study of docetaxel with R 10 1933 i. v. 
Table 5 Plasma pharmacokinetic parameters of R 101933 and its 
metabolite R 102207 in the absence or presence of docetaxel * 
* 
250 mg R101933 (n=3) 500 mg R101933 (n=6) 
Parameter Without 0 With 0 without 0 with 0 
R101933 
Cmax ** 2.24±0.62 1.97 ±0.30 3.67±0.99 3.70±1.06 
(/lg/mL) 
tI12!z! (h) 12.9±1.4 24.2±12.6 10.5±8.4 7.5±1.8 
AUC 5.55±1.01 5.16±0.87 10.0±4.9 8.43±1.60 
(/lg.h/mL) 
R102207 
Cm,x (/lg/mL) 10.7 ±6.7 7.5±3.0 20.6 ±1.8 16.4±4.4 
t I12!z) (h) 15.6±5.3 13.0±4.1 21.3±8.5 15.5±2.8 
AUC 114±63 88.2±47.3 306±191 199±79 
(/lg.h/mL) 
Data were obtained from patients after cycle 0 (without docetaxel) and after cycle 2 
(with docetaxel). The kinetic terms are mean values ± SO. 
** AUC, area under the plasma concentration versus time curve; Cm,,' maximum plasma 
concentration of drug; t I12!z), terminal disposition half-life; n, number of patients 
evaluated; 0, docetaxel. 
Pgp Antagonism Following R 101933 
To determine whether infusion of Rl 01933 would be associated with 
systemic concentrations affecting Pgp activity in an ex vivo model based on 
daunorubicin retention in Pgp expressing A2780T_100 cells, plasma samples 
were obtained before and after drug infusion in the first treatment course. 
In this assay, fluorescence values have previously been shown to reflect the 
degree of inhibition of Pgp-mediated efflux (8). Control experiments 
conducted with the A2780 parental cell line provided a maximum 
fluorescence value of 2.50, whereas the fluorescence measured in the 
A2780T_100 will depend on the level of R101933 present in the patient's 
plasma. A total of 107 plasma samples from patients treated with R 101933 
(5 patients at 250 mg and 7 patients at 500 mg) were analyzed for 
pharmacologic activity in the assay. All pre-dose samples showed no 
measurable activity. Time-course studies with R 101933 administered at the 
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2 tested dose levels showed that following a single i.v. dose, substantially 
decreased daunorubicin efflux was found in plasma samples of all patients 
collected within 30 min of treatment (Fig. 4). 
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Time-course of R101933-mediated Pgp antagonism in patient samples 
obtained following R101933 administration as a 1-h i.v. infusion at dose 
levels of 250 mg (0) or 500 mg (.). Modulation of daunorubicin uptake in 
A2780T_100 cells (expressing Pgp) by plasma samples containing R101933 
were measured by a change in fluorescence intensity relative to that 
observed in the A2780 parental cell line in the absence of R101933. Data 
points are mean values ± SEM of duplicate measurements of plasma 
samples obtained from 3 patients (250-mg dose) or 7 patients (500-mg 
dose). The lower dotted line (fluorescence value of 1.0) indicates the base-
line fluorescence (i.e. lack of influence on Pgp-mediated efflux), whereas 
the upper dotted-line (fluorescence value of 2.5) indicates the maximum 
fluorescence (complete inhibition of Pgp-mediated efflux). 
Maximal inhibition of Pgp function was observed in all samples 
collected at times ranging from 30 to 60 min, with fluorescence increase 
values of 2.44±0.081 and 2.41±0.062 at R101933 dose levels of 250 and 
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500 mg, respectively, indicating near-complete reversal (i.e. > 97%) in the 
ex vivo assay. The duration above K;, defined as the concentration required 
for half-maximum inhibition of Pgp-mediated daunorubicin efflux, showed 
considerable interpatient variability (coefficient of variation, > 50%). Mean 
values of the duration above K; were 12.3±7.22 hours and 14.1±7.08 hours 
at dose levels of 250 mg and 500 mg, respectively (P= 0.709, unpaired 
Student's t test). Overall, the data indicate that plasma concentrations 
achieved in patients within 48 hours after single 250 or 500 mg Lv. 
administration of R1 01933 inhibit Pgp-mediated drug efflux in tumor cells 
ex vivo. Correlation of Pgp antagonism with R101933 plasma 
concentrations, as measured by high-performance liquid chromatography, 
indicated the occurrence of a plateau in efflux antagonism (not shown), in 
line with previous findings (8). This suggests that the plasma levels of 
R1 01933 achievable in patients result in ex vivo concentrations that reach 
a maximum inhibition of Pgp-mediated efflux, which begins at 
approximately 300 ng/mL, a plasma concentration well below that achieved 
at the MTD of the current combination. 
DISCUSSION 
MDR is generally regarded to be one of the major stumbling blocks to 
the efficacy of chemotherapy and since the discovery of the MDR product 
Pgp, many efforts were made to convert Pgp-mediated drug resistance into 
drug sensitivity (6). However, a plethora of clinical studies involving a wide 
range of Pgp inhibitors and co-administered anticancer drugs have shown 
that these combination treatments almost always resulted in increased 
toxicity of the anticancer drugs solely due to pharmacokinetic interaction 
between the two agents related to competition on the level of cytochrome-
P450 3A isozymes [reviewed in Ref. (5)). Therefore, it has been proposed 
that the administration of Pgp inhibitors is unlikely to improve the 
therapeutic index of anticancer drugs such as docetaxel unless such agents 
lack a pharmacokinetic interaction (5,6). In a previous study with orally 
administered R1 01933 in combination with docetaxel Lv. we have shown 
that R1 01933 did not influence the plasma pharmacokinetic characteristics 
of docetaxel knowing that the major metabolic route of R101933 is 
cytochrome-P450-unrelated (7). Due to low oral bioavailability of R 101933 
and significant inter-patient variability in exposure to R101933, further 
107 
Chapter 4 
increase of the plasma levels of R101933, in an attempt to achieve higher 
local concentrations of R1 01933, can be expected to be better reached by 
intravenous administration. In the present study this resulted, as expected, 
in significantly higher plasma levels of R1 01933 and reduced in inter-patient 
variability. Mean peak concentrations of R101933 after 500 mg Lv. 
infusion of R1 01933 were about 3500 ng/mL, while only 150 ng/mL after 
300 mg R101933 given as oral solution (7). Mean exposure (AUC) to 
R1 01933 was about 10-fold higher after i.v. infusion and a relatively lower 
exposure to the inactive metabolite R102207 was obtained. Furthermore, 
individual peak concentrations ranged only 2-fold after i.v. infusion 
compared to 10-fold after the oral solution, indicating a significantly 
reduced inter-patient variability. Notwithstanding the about 10-fold higher 
exposure to R101933 after Lv. infusion the plasma pharmacokinetics of 
docetaxel were still not influenced. The toxicologic profile of the 
combination treatment appeared to be very similar to that reported for 
docetaxel alone including neutropenic fever, neurotoxicity grade 3 and 
severe fatigue in combination with myalgia, all being reported in 
approximately 1 5 %, 5 %, and 6 %, respectively, of cases treated with 
docetaxel alone (12). Treatment with R 101933 i. v. at the tested dose 
levels was associated with minimal toxicity consisting of temporary 
drowsiness and somnolence beginning during the infusion and lasting for 
several hours. 
As we have postulated earlier, the physiological and pharmacological 
consequences of treatment with an effective Pgp inhibitor cannot be 
predicted based on plasma drug monitoring alone (8). So, we collected 
feces up to 48 hours after administration of docetaxel in cycle 1 and 2 to 
determine an often overlooked and sometimes underestimated parameter of 
drug disposition, the fecal excretion of the anticancer agent. The excretion 
of unchanged docetaxel proved to be decreased after co-administration with 
R101933 indicating biological activity of the Pgp inhibitor most likely at the 
level of intestinal Pgp. Inhibition of intestinal Pgp leading to modification of 
the enterohepatic cycle was postulated after treatment with R101933 
orally and now also seemed to be present after Lv. administration indicating 
sufficient concentrations of R101933 at the apical lumen side of the 
intestine. The re-absorption of docetaxel from the intestinal lumen did not 
result in increased plasma levels due to: i. the relative little fraction of 
docetaxel that is excreted via the feces (without R101933 only 2.5%), ii. a 
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virtually complete first-pass extraction and/or docetaxel metabolism in the 
liver and intestinal mucosa, which also has significant expression of 
cytochrome P450 3A isozymes (13). 
In the kind of studies as the present one, designed to overcome Pgp-
mediated MDR, measurement of the extent of in vivo inhibition of Pgp-
mediated drug efflux is deemed essential. To that end, we presented the 
results of an ex vivo assay developed as a surrogate measure of Pgp 
antagonism in the plasma samples of all patients receiving R1 01933. We 
deliberately decided on another approach compared to the two most well-
known surrogate assays to determine Pgp antagonism using the known Pgp 
substrates Tc-99m-sestamibi (sestamibi), a radionuclide imaging agent, and 
rhodamine 123 (rhodamine), a lipophilic dye. The first method determined 
the washout rates of sestamibi by scintigraphy indicating the presence of a 
functional efflux pump (14,15) and its efflux from tumor and liver has 
shown to be decreased in the presence of a Pgp inhibitor by enhanced 
tumor visualization (15-17). However, it is a time-consuming method in 
which patient compliance could be a restriction, it lacks a dose-response 
relationship between sestamibi uptake and the Pgp inhibitor levels (16), and 
establishment of the sensitivity of sestamibi scintigraphy as an adequate 
surrogate marker of Pgp inhibition is still needed. In this respect it is of 
importance to notice that a recent pilot study showed no correlation 
between sestamibi scintigraphy and the expression of Pgp determined in 
tumor tissue of patients with high-grade osteosarcoma (18). The second ex 
vivo method is based on the observation that hematopoietic cells, especially 
the CD56 + subset of peripheral blood lymphocytes, express functional Pgp 
(19). Plasma obtained from patients within 15 minutes after administration 
of the Pgp inhibitor SDZ PSC 833 showed ex vivo a decreased efflux of 
rhodamine from CD56 + cells with a clear dose-response relationship (20). 
However, accepting rhodamine-efflux from CD56 + cells as a surrogate 
marker requires the assumption that Pgp in CD56 + cells has identical 
substrate and antagonist specificities as Pgp in cancer cells. Moreover, 
both methods lack the possibility of interpatient comparison. An essentially 
different approach of evaluating the extent of Pgp inhibition has been the 
addition of plasma from patients treated with Pgp inhibitors and thus 
containing a certain concentration of this drug to an in vitro assay 
comprised of a known multidrug-resistant cell line and a detectable Pgp 
substrate such as radiolabeled daunorubicin or mitoxantrone (21). In the 
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present study we have favored this approach because this method allowed 
an interpatient and dose level comparison by the use of a cell line known to 
have a constant level of Pgp expression. Furthermore, this assay offered an 
easy possibility to confirm that pharmacologically and biologically relevant 
concentrations of R101933 were achieved over a distinguished period of 
time. Still, as with the other methods Pgp expression or the availability of 
the Pgp inhibitor in the tumor is not provided and the assay has to be 
performed in protein-free medium because it can be expected based on in 
vitro studies that protein binding of the inhibitor in the medium impaired the 
Pgp antagonism activity (21-24). Much concern has been raised from this 
experience because clinically Pgp inhibitors are exposed to high 
concentrations of drug-binding proteins and depending on the degree of 
serum protein binding (for R101933 more than 98%). this is thought to 
lead to significantly reduced drug availability of the (pharmacologically 
active) free drug fraction at the tumor site (24). However, this view does 
not justify the generally accepted physiologic concept of the extent of 
distribution of a compound within tissues, including a tumor, involving 
multiple equilibria, a situation never to be possible outside the body in in 
vitro as well as ex vivo experiments. 
An important finding of the present ex vivo study is the observation 
that a plateau occurred in the inhibition of the Pgp substrate efflux, 
suggesting that the achieved levels of R101933 in the assay reached a 
maximum inhibition of Pgp-mediated efflux and complete reversal could not 
be attained. The plateau phase was reached at ex vivo concentrations that 
correspond to a plasma concentration of R101933 of approximately 300 
ng/mL, a concentration well below that achieved at the maximal-tolerated 
dose level of R 101933 Lv. This result is in line with calculations using 
experimental models with high levels of Pgp expression suggesting that a 
single Pgp modulator cannot completely inhibit Pgp-mediated efflux (25). 
However, the indicated substantial (near maximal) reversal may be 
sufficient to improve drug efficacy. 
In conclusion, we have shown that the combination of R1 01933 Lv. 
directly followed by docetaxel infusion is safe lacking pharmacokinetic 
interaction in plasma and that at the plasma concentrations of R 101 933 
achieved within 48 hours after infusion are capable of inhibiting Pgp in an 
ex vivo assay. These findings justify further development of this 
combination treatment in which the recommended dose of Rl01933 Lv. 
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will be 500 mg. A phase II study is possible for example in patients with 
metastatic breast cancer failing on treatment with taxanes alone, but as 
these kind of studies have been proven difficult in accrual we propose 
adequately powered phase III studies (6). 
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SUMMARY 
The non-ionic surfactants Cremophor EL (CrEL) and Tween 80, both 
used as formulation vehicles of many (anticancer) agents including 
paclitaxel and docetaxel, are not physiological inert compounds. We 
describe their biological properties, especially the toxic side effects, and 
their pharmacological properties, such as modulation of P-glycoprotein 
activity. In detail, we discuss their influence on the disposition of the 
solubilized drugs, with focus on CrEL and paclitaxel, and of concomitantly 
administered drugs. The ability of the surfactants to form micelles in 
aqueous solution as well as biological fluids (e.g. plasma) appears to be of 
great importance with respect to the pharmacokinetic behavior of the 
formulated drugs. Due to drug entrapment in the micelles, plasma 
concentrations and clearance of free drug change significant leading to 
alteration in pharmacodynamic characteristics. We conclude with some 
perspectives related to further investigation and development of alternative 
methods of administration. 
INTRODUCTION 
After the identification of paclitaxel as the active ingredient in crude 
ethanolic extracts of the bark of the Western yew tree, Taxus brevifolia, 
against several murine tumors (1), the development of this promising drug 
was suspended for more than a decade due to problems in drug 
formulation. Paclitaxel is poorly soluble in water and in other common 
vehicles used for the parenteral administration of drugs. After investigation 
of a large variety of excipients to enable parenteral administration of the 
drug (reviewed in: Ref. 2), the formulation approach using 50% CrEL and 
50% dehydrated ethanol USP represented the most viable option. Currently, 
paclitaxel is commercially available as vials containing 30 mg of drug 
dissolved in 5 mL of CrEL:dehydrated ethanol USP (1: 1, v/v). CrEL is also 
being used as a vehicle for the solubilization of a wide range of other 
hydrophobic drugs, including anesthetics (e.g. propofol), photosensitizers, 
vitamins, immunosuppressive agents (e.g. cyclosporin A and tacrolimus), 
sedatives (e.g. diazepam), and (experimental) anticancer drugs (e.g. 
aplidine, clanfenur, didemnin B, halomon and teniposide). The amount of 
CrEL co-administered with these drugs varies up to about 5.5 mLlm2, 
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although paclitaxel is an exception as the CrEL content of the formulated 
preparation is much higher per dose, about 12 mLlm2 (3). 
A good 10 years after the identification of paclitaxel, docetaxel was 
developed from 10-deacetyl baccatin-III, a noncytotoxic precursor isolated 
from the needles of the European yew tree, Taxus baccata. This 
semisynthetic taxane analogue is formulated for clinical use in polysorbate 
80 (Tween 80), and the solution consists of 80 mg of docetaxel in 2 mL of 
Tween 80. Like CrEL, Tween 80 is used as a nonionic surfactant to 
solubilize several other anticancer drugs, including etoposide and the 
cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin. 
Both formulation vehicles are known as biologically and pharmaco-
logically active compounds. With a focus on CrEL and paclitaxel, we will 
describe in the present review the properties of CrEL and Tween 80 and the 
consequences of their intrinsic activity related to the formulated drugs and 
implications for other (anticancer) agents concomitantly administered. 
PHYSICOCHEMICAL PROPERTIES 
CrEL is a white to off-white viscous liquid with an approximate 
molecular weight of 3000 Da and a specific gravity (25°C/25°C) of 1.05-
1.06, and is produced by the reaction of castor oil with ethylene oxide at a 
molar ratio of 1: 35 (4). Castor oil is a colorless or pale yellow fixed oil 
obtained from the seeds of Ricinus communis (Fam. Euphorbiaceae), with 
an extremely high viscosity, and consists mainly of the glycerides of 
ricinoleic (12-hydroxyoleic acid), isoricinoleic, stearic and dihydroxystearic 
acids. The nonionic surfactant produced from castor oil is usually of highly 
variable composition, with the major component (about 87%) identified as 
oxyethylated triglycerides of ricinoleic acid (i.e. polyoxyethylene glycerol 
triricinoleate 35) (Fig. 1 A). CrEL is known to leach plasticizers, e.g. di(2-
ethylhexyl)-phthalate, from polyvinyl chloride (PVC) bags and polyethylene-
lined tubing sets, which can cause severe hepatic toxicity (5), and it is 
recommended to use PVC-free equipment for drug administration. 
In contrast to CrEL, Tween 80 is a relatively homogenous and 
reproducible, amber-colored, viscous liquid (270-430 centistokes) with a 
molecular weight of 1309.7 Da and a density of 1 .064 g/mL. The base 
chemical name of the major component of Tween 80 is polyoxyethylene 
sorbitan monooleate (Fig. 1 B), which is structurally similar to the 
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polyethylene glycols. Like most nonionic surfactants, CrEL and Tween 80 
are capable of forming micelles in aqueous solution, with critical micellar 
concentrations of 0.009% (w/v) and 0.1% (w/v), respectively. 
A 
CH2-0-(CH2-CHTO)x-CO-0-(CH2!?-CH=CH-CH2-CHOH-(CH2ls-CH3 
J -0-(CH2-CH2-0)y-CO-0-(CH2!?-CH=CH-CH2-CHOH-(CH2ls-CH3 
bH2-0-(CH2-CH2-0)Z-CO-0-(CH217-CH=CH-CH2-CHOH-(CH2ls-CH3 
(x + y + Z - 35) 
B 
0- ((C~l2- O)y - H 
0- ((C~l2-Olz-Co- (C~)-,-HC= CH- (C~)6- CH 
(w + x + y + z - 80) 
Figure 1 Chemical structures 
polyoxyethyleneglycerol 
of the major 
triricinoleate 35 
polyoxyethylenesorbitan monooleate (B) 
TOXIC SIDE EFFECTS 
Acute Hypersensitivity Reactions 
components of 
(A) and Tween 
CrEL, 
80, 
The most well known toxicity of CrEL is an acute hypersensitivity 
reaction, which is characterized by dyspnea, flushing, rash, and generalized 
urticaria (6). It has been described in the 80's after the use of teniposide in 
pediatric patients treated for neuroblastoma and lymphoid malignancies (7) 
and after the infusion of cyclosporin A in posttransplant patients (8). 
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Nowadays, it is a well known side effect associated with the use of 
intravenous paclitaxel. The mechanism of this hypersensitivity to CrEL has 
not yet been fully elucidated. Mostly, the hypersensitivity reaction occurs 
within the first two courses of paclitaxel and can be prevented by reducing 
the infusion rate which are the reasons of the general belief that it resembles 
a non-immunological reaction, based on degranulation of mast cells or 
basophils (9,10). On this hypothesis, the rationale for the current 
pretreatment schedules of paclitaxel with H2-receptor antagonists and high-
dose corticosteroids is based (9,11) . However, despite this extensive 
premedication, the overall frequency of minor reactions is estimated as high 
as 44%, with major reactions, necessitating discontinuation of paclitaxel 
therapy, still occurring in approximately 1.5 to 3% of patients (12,13). 
Already in the 70's, it was shown that Althesin and Stesolid MR, both 
compounds using CrEL as a vehicle, can activate C3 complement in vivo 
(14,15). Recently, it was postulated that complement activation is an 
important contributing mechanism to the hypersensitivity reaction from CrEL 
due to binding of naturally occurring anti-cholesterol antibodies to the 
hydroxyl-rich surface of CrEL micelles (1 6). Based on an elegant series of in 
vitro experiments, it was shown that CrEL-induced complement activation in 
human serum was clearly concentration dependent with a minimum activating 
CrEL level in the order of approximately 2 JlLlmL, a concentration readily 
achieved clinically in plasma following standard doses of paclitaxel (17). 
One of the constituents of CrEL, oleic acid, especially suspected for its 
histamine-releasing capability, is also present in Tween 80, and thus may be a 
cause of hypersensitivity reactions to docetaxel therapy (18). In addition, 
recent work performed has shown that allergens are present in Tween 80 
that elicit hypersensitivity reactions in guinea pigs, and that new allergens, 
including formaldehyde, are formed in an oxidation process after air exposure 
(19). 
NeurotoxicitV 
In contrast to the hypersensitivity reactions, it is less well known 
that CrEL can cause neurotoxicity, a toxicity known as one of the main side 
effects of paclitaxel. Electrophysiologic studies in patients with 
neurotoxicity after treatment with paclitaxel have shown evidence of both 
axonal degeneration and demyelination (11). One study performed with 
[3H]paclitaxel in rats did not reveal detectable levels of paclitaxel in the 
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peripheral nervous system, but paclitaxel in this study was solubilised in 
dimethyl sulfoxide instead of CrEL (20). This finding may suggest that the 
neurotoxicity of paclitaxel is probably caused by CrEL. 
Cyclosporin A (formulated in CrEL) administered intravenously has 
also been linked to nerve pathology, with approximately 25 % of patients 
experiencing neurotoxicity (21). In contrast, this side effect rarely or never 
follows oral administration of cyclosporin A, which is consistent with recent 
observations that CrEL is not absorbed when given orally (22,23), 
presumably as a result of acid-induced hydrolysis in the stomach and 
duodenum (24). Moreover, CrEL levels in plasma achieved with therapeutic 
doses of paclitaxel and i.v. cyclosporin A, have been shown to produce 
axonal swelling, vesicular degeneration and demyelination in rat dorsal root 
ganglion neurons exposed to the formulation vehicle (25). These authors 
speculated that residual ethylene oxide, a known potent neurotoxin, may be 
responsible for this phenomenon. However, an earlier in vitro study using a 
neuronal model by the differentiating N1 E.115 neuroblastoma cell line 
demonstrated that the neurotoxicity probably is unrelated to the residual 
ethylene oxide as toxic effects were unaffected after nitrogen-pretreated 
CrEL (26). Recent work indicated that the neurotoxic properties were 
induced by unsaturated fatty acids and preliminary evidence suggested that 
the changes were due to the appearance of peroxidation products (27). This 
suggests that the ethoxylated derivatives of castor oil, i.e. the primary 
constituents of CrEL, probably account for most of the neuronal damage 
observed (26). 
Vesicular degeneration is also produced by other solubilizing agents 
such as TWeen 80, a property which also depends on the polyoxyethylene 
substitutions produced by reaction of the parent compound with ethylene 
oxide. However, the incidence of neurotoxicity during treatment with 
docetaxel is much lower as compared to that with paclitaxel (28). 
Furthermore, the epipodophyllotoxin derivative etoposide which also 
contains considerable amounts of Tween 80, is not known to be 
neurotoxic. 
Miscellaneous Side Effects 
In animal models, it was shown that CrEL has acute but reversible 
cholestatic effects (29), although other data contradict this (30). 
Nephrotoxicity has also been linked to CrEL, as studies with rat kidney 
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models indicated that the addition of small quantities of CrEL resulted in 
marked renal vasoconstriction with decreased renal blood flow and 
deterioration in renal tubular function (31-33). Dermatitis is rarely observed 
after treatment with paclitaxel, but is a well known side effect of docetaxel, 
and Tween 80 has been known to cause this side effect (28,34). The rash 
primary involves pressure or trauma sites and resolves within two weeks, 
with skin biopsies revealing a non-specific perivascular lymphocytic 
infiltration. Cumulative fluid retention is another specific side-effect of 
docetaxel that can be dose-limiting. Tween 80 is known to alter membrane 
fluidity, leading to increased membrane permeability (35), and this may, at 
least in part, explain the observed reaction with docetaxel therapy. 
PHARMACOKINETIC CHARACTERISTICS 
Analytical Methods 
Clinical pharmacokinetic studies with CrEL and Tween 80 had not 
been performed until very recently, and at present a variety of analytical 
procedures are available for this purpose. The first assay developed for 
measurement of CrEL concentrations in plasma was a bioassay based on 
the ability of CrEL to modulate daunorubicin efflux in multidrug-resistant T-
cell leukemia VLB 100 cells (36). Alternatively, CrEL levels have been 
determined by measurement of ricinoleic acid after saponification of CrEL 
followed by precolumn derivatization and reversed-phase high-performance 
liquid chromatography (37). A method has also become available based on 
a selective binding of CrEL to the Coomassie brilliant blue G-250 dye in 
protein-free extracts (38,39), that has also been used succesfully for 
measurement of Tween 80 concentrations in murine and human plasma 
(40). Most recently, a potentiometric titration method for CrEL was 
developed for quantitative analysis in urine and plasma based on a coated 
wire electrode as end-point indicator with sodium tetraphenylborate at 20° C 
and pH 10 (41). Each of the available assays has its drawbacks and 
limitations, and the methodologic differences between them probably 
contribute to the evident differences in the measured concentrations of 
CrEL and thus the calculated pharmacokinetic parameters. 
In addition to the Coomassie brilliant blue G-250 colorimetric dye-
binding assay, various other analytical procedures are available for Tween 
80. Initially, attention was directed to measurement of the polyoxyethylated 
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portion of the molecule, since it would be impossible to distinguish the fatty 
acid moiety from endogenous compounds (42). The so-called polyol moiety 
is detectable by a wide variety of methods including a resorcinol-glucose 
precipitation, a colorimetric method using ammonium cobaltothiocyanate, 
turbidimetric or gravimetric procedures and complex formation with a 
barium phosphomolybdic reagent (43,44). The ammonium cobaltothio-
cyanate complexation has also been used in combination with high-
performance liquid chromatography and UV detection for analysis of Tween 
80 in urine and ascites fluid, using either post-column (45,46) or on-line 
complexation (47). 
Figure 2 
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Representative plasma concentration versus time profile of CrEL in a single 
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measured AUC in 23 patients with a 3-h intravenous infusion of paclitaxel 
(8) (data from: Ref. 50). 
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Plasma Pharmacokinetics 
Few studies have evaluated the pharmacokinetics of CrEL using the 
described various analytical methods, sometimes leading to differences in 
results and conclusions. Most of the available data indicate that CrEL 
delineates a linear pharmacokinetic behavior following 3-h paclitaxel 
administrations (Fig. 2), although with some other methods the kinetics 
were judged as non-linear with disproportional increases in systemic 
exposure with an increase in dose (48). With prolongation of the infusion 
duration from 1 to 3 and to 24 h, pharmacokinetic parameters have been 
found to change significantly; for example, after administration of paclitaxel 
(175 mg/m2) applying a 1-,3- or 24-h infusion schedule, the clearance 
increased from about 160 to 300 to 400 mLlh/m2 , respectively (17). It thus 
appears that CrEL shows dose-independent/schedule-dependent pharmaco-
kinetics with disproportional increases in systemic exposure of CrEL being 
associated with shortening of the infusion duration. 
The terminal elimination half-life of CrEL amounts to approximately 
80 h with a large range from 10 - 140 h, depending on the method used for 
measurement. In addition, the limited sampling used in one study with the 
application of the bio-assay method may have led to underestimation of the 
terminal elimination half-life (49). However, a study using the colorimetric 
assay demonstrated extended persistence of CrEL with detectable levels of 
the compound even at 1 week after initial treatment (50). In all studies the 
observed volume of distribution of CrEL was extremely low and not (much) 
higher than the volume of the central blood compartment, implying that 
tumor and tissue delivery of CrEL is insignificant. 
Not much is known about elimination routes of CrEL in humans. The 
results of a study in patients with hepatic dysfunction treated with 
paclitaxel suggested that hepatobiliary elimination of CrEL is not of primary 
importance, because severe impairment of the hepatic function did not 
reduce the clearance but, on the contrary, lead to increase of the clearance 
compared to historical controls (51). A possible explanation of this can be 
that the enzymes for which CrEL is a substrate (such as serum esterases) 
may be elevated in patients with severe hepatic dysfunction, leading to an 
accelerated rate of metabolism of CrEL within the systemic circulation. 
However, thus far there is no evidence that these mechanisms may playa 
role in the clinical situation (51). Despite its relatively high hydrophilic 
nature, the renal elimination of CrEL seems to be almost negligible 
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according to preliminary findings indicating that the cumulative urinary 
excretion of CrEL is very low, accounting for less than 0.1 % of the 
administered dose (52). CrEL pharmacokinetics in a patient with predialysis 
renal impairment treated with paclitaxel were not significantly different from 
historic controls (52). CrEL may be largely degraded in the blood 
compartment although the pathway of its elimination is currently unknown. 
It is possible that elimination pathways for CrEL are mainly dictated by 
serum carboxylesterase-induced degradation causing release of ricinoleic 
acid. Given the long terminal half-life of CrEL, this metabolic route occurs at 
a low rate and the involved enzymes may be easily saturated, which may 
explain the peculiar schedule-dependent clearance of the compound. 
The pharmacokinetic behavior of Tween 80 is very different from 
that of CrEL. In mice a rapid decline of the concentration was shown after 
bolus injection, with plasma concentrations decreasing to < 0.05 JiLlmL (i.e. 
the lower limit of quantitation of the analytical method) within 1 5 min after 
drug administration (40). Observations in 5 patients treated with docetaxel 
(100 mg/m2) as a 1-h infusion showed peak plasma levels of Tween 80 of 
0.16±0.05 JiLlmL, and in plasma samples collected after 1 h the levels had 
already fallen below the detection limit of the assay. In vitro experiments 
have shown that this rapid elimination is caused by a rapid 
carboxyl esterase-mediated hydrolysis in the systemic circulation, catalyzing 
the cleavage of the oleic acid side chain from the molecule (40). Earlier 
studies with Tween 20 and Tween 40 performed in rats and humans have 
shown the same pattern of metabolism with ester bond cleavage and 
subsequent oxidation of the fatty acid moiety (53,54). After intravenous 
administration in adult rats, most of the polyoxyethylene moiety appeared in 
the urine (about 86% within the first 12 h), while some was present in 
feces, indicating a minor role of biliary secretion (55). Following oral 
administration, Tween 80 is known to be metabolized in the intestine by 
pancreatic lipase (56) into oleic acid and polyoxyethylene sorbitol (57), with 
only 3.2% of the administered dose being excreted unchanged into the 
urine (58). 
MODULATION OF DRUG DISPOSITION 
It is likely that CrEL in blood is capable of forming micelles with a 
highly hydrophobic interior, which can entrap the solubilised compound as 
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well as other co-administered compounds. As indicated, in aqueous solution 
the critical micellar concentration of CrEL is 0.009%, although the actual 
value in plasma may be higher due to the presence of proteins and 
interference by other macromolecules. It can be speculated that the 
pharmacokinetic behavior of the drugs using CrEL as a formulation vehicle 
will be influenced by CrEL, especially those which are highly hydrophobic as 
most of the newly developed anticancer drugs are. It can also be 
anticipated that CrEL may alter the distribution of compounds co-
administered with the drugs using CrEL as a formulation vehicle. 
Although Tween 80 will also be able to form micelles in the systemic 
circulation after intravenous administration, it is unlikely that it will playa 
role in the disposition of docetaxel or compounds co-administered with 
docetaxel based on its rapid decline in plasma. 
Figure 3 
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Effects on Paclitaxel Pharmacokinetics 
Initially, the effect of CrEL on the disposition of paclitaxel was 
studied in female FVB mice that received the drug by intravenous injection 
at dose levels of 2, 10 and 20 mg/kg by appropriate dilution of the 
commercially available drug formulation (59). The paclitaxel clearance of 
2.4 Llh/kg at the lowest dose level was reduced to 0.33 and 0.15 Llh/kg at 
the 10 and 20 mg/kg dose levels, respectively. However, if administered at 
10 mg/kg in Tween 80-ethanol or at 2 and 10 mg/kg in dimethylacetamide, 
the clearances were 2.66, 2.57 and 2.62 Llh/kg, respectively (Fig. 3), 
indicating that the nonlinearity of paclitaxel disposition resulted exclusively 
from CrEL. Despite that much higher plasma levels of paclitaxel are reached 
when given in the CrEL-containing formulation, the tissue levels were 
essentially similar with all tested drug preparations, suggesting that the 
profound influence of CrEL on paclitaxel pharmacokinetics is taking place in 
the central blood compartment. More recent in vitro work from our group 
has confirmed this hypothesis, by analyzing the effects of CrEL on cellular 
partitioning and the blood:plasma concentration ratio of paclitaxel in human 
samples (60). These experiments revealed a significant decrease in the 
blood:plasma concentration ratio of paclitaxel from 1.07±0.004 
(mean±standard deviation) to 0.690±0.005 (P < 0.05) up to concentrations 
corresponding to peak plasma levels of CrEL achieved after the 
administration of paclitaxel (175 mg/m2 Lv. over a 3-h. period; i.e. 5.0 
flLlmL). There was a clear concentration-dependent effect of CrEL on this 
ratio, with maximal inhibition of cellular paclitaxel uptake at a CrEL total 
blood concentration of 10 flLlmL, at which concentration the blood:plasma 
ratio averaged 0.625 ± 0.008, suggesting a distribution of paclitaxel merely 
outside blood cells (Fig. 4). These effects on the blood:plasma ratio were 
not seen with castor oil but were primarily caused by polyoxyethylene-
glycerol triricinoleate along with fatty acid esters of polyoxyethylene glycol. 
Additional experiments were carried out with artificial binary mixtures 
relating washed erythrocytes to a buffer, figuring as a model excluding the 
influence of the plasma proteins, or plasma in which concentration ratios 
were determined after addition of paclitaxel in the absence or presence of 
CrEL. In both mixtures, paclitaxel in the presence of CrEL was only 
distributed in the water or plasma phase with ratios of 0.649 and 0.664, 
respectively. This shows that CrEL causes a profound alteration of 
paclitaxel accumulation in erythrocytes in a concentration-dependent 
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manner by reducing the free drug fraction available for cellular partitioning. 
Since this effect was also observed in the absence of plasma proteins, it 
was not caused by altered protein binding or an increased affinity of 
paclitaxel for protein dissociation products that are produced by the action 
of CrEL on native lipoproteins (61,62). Overall, the data suggested that 
drug trapping occurs in micelles composed primarily of polyoxyethylene-
glycerol triricinoleate and that these micelles act as the principal carrier of 
paclitaxel in the systemic circulation. Not much later, our findings were 
indepently confirmed in two other publications (63,64). 
Figure 4 
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Effect of CrEL concentration on blood:plasma concentration ratios of 
paclitaxel (data from: Ref. 60) 
The findings described above have serious implications for the 
interpretation of paclitaxel pharmacokinetics and for strategies attempting 
to find kinetic correlates that would assist in prediction of hematological 
toxicity. Previously, paclitaxel disposition in cancer patients has been 
reported to be nonlinear, with disproportional relationships between 
changes in the dose and the resulting plasma AUCs and peak plasma 
concentrations (65,66). This nonlinearity, particularly evident with the 3-h 
infusion schedule, has been speculated to result from two separate 
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saturable processes, one in distribution and one in elimination (65-68). By 
prospectively measuring whole blood and plasma concentrations of 
paclitaxel in a group of patients treated with consecutive dose levels of 
135, 175 and 225 mg/m2, we recently demonstrated the relevance in vivo 
and showed its importance related to the apparent nonlinear 
pharmacokinetics of paclitaxel (69). The plasma clearance of paclitaxel 
turned out to be dose-dependent decreasing from 16.7±2.53 Llh/m 2 at 135 
mg/m2 to 9.75±2.78 Llh/m 2 at 225 mg/m2 (P=0.030). This was shown to 
be caused by a CrEL-concentration dependent decrease in uptake of 
paclitaxel in the erythrocytes, with blood:plasma concentration ratios 
altering significantly from 0.83±0.11 (135 mg/m2) to 0.80±0.18 (175 
mg/m2) and 0.68±0.07 (225 mg/m2), at which most of the drug was 
distributed outside the blood cells. Calculating the clearance of paclitaxel in 
whole blood samples showed that this was clearly dose-independent 
(P=0.063) and averaged 17.5±3.43 Llh/m 2 • Like our in vitro findings, these 
in vivo results also indicate that the operation of Michaelis-Menten kinetics, 
the postulated cause of nonlinear paclitaxel disposition in plasma, is not 
related to saturable tissue binding or disproportional elimination kinetics, but 
appears to be an artifact caused by paclitaxel dose-related levels of CrEL in 
blood. 
Based on the premise that paclitaxel can be included in micelles and 
thereby undergo a change in pharmacokinetic properties, a pharmacokinetic 
model was developed to predict the free fraction ratio of paclitaxel at any 
CrEL concentration (69). An example of the course of paclitaxel 
concentration versus time for the different forms of paclitaxel existing in 
blood based on this model is shown in Fig. 5. Pharmacokinetic/pharmaco-
dynamic analysis of CrEL concentrations and corresponding blood 
distribution of paclitaxel showed that the disproportional accumulation of 
paclitaxel in plasma in a 3-h schedule is not seen in this manner with 
alternative infusion durations (17). This paradox can be understood in view 
of the fact that the high CrEL concentrations achieved early into the 1-h 
infusion produce only a low relative net change in the paclitaxel 
blood:plasma ratio (between 0.545 and 0.650), although the absolute 
quantitative effect is large already at low-dose input. Measurement of 
plasma concentrations of CrEL may, therefore, not be the exclusive 
indicator of the importance of the vehicle-drug interaction, but rather the 
combination of dose delivered and input-rate applied (17). 
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The above mentioned results were in line with previous findings that 
in spite of nonlinear paclitaxel kinetics in plasma, tissue levels of the parent 
drug and its known metabolites in mice have a linear relationship with the 
dose administered (70). The paradox of disproportional increases in plasma 
concentrations and linear distribution processes in tissues thus seems to be 
caused by the fact that the plasma comprises a relatively small fraction of 
the total volume available for paclitaxel distribution and that, 
simultaneously, the CrEL-drug complex is not stable enough to substantially 
reduce the amount of drug that exists in the body in the active, diffusible, 
unbound form. 
Recent work using the isolated perfused rat-liver model to investigate 
the influence of CrEL on the hepatobiliary elimination pathways of paclitaxel 
can also be explained by the principle of CrEL modulating the distribution of 
paclitaxel (71). It was found that CrEL caused a dose-dependent inhibition 
of paclitaxel elimination from the isolated perfused rat liver as can be 
explained by micellar entrapment of paclitaxel at the high dose of CrEL, 
thereby preventing paclitaxel from reaching sites of metabolism and 
excretion. 
Effects on Pharmacokinetics of Other Agents 
The existence of CrEL in blood as large polar micelles with a highly 
hydrophobic interior also raises the possibility of additional complexities in 
case of combination chemotherapy regimens with paclitaxel. For example, 
fluorescence studies on the interaction between anthracycline drugs and 
different surfactants indicated that daunorubicin, although relatively 
hydrophilic, is readily incorporated into CrEL micelles (72). Thus, in the 
systemic circulation, micellar incorporation of anthracyclines may result in 
altered cellular distribution and a concomitantly increased plasma 
concentration. In this respect, it is interesting to note that clinically 
significant pharmacokinetic interactions between paclitaxel and doxorubicin 
have been reported (73) as well as between CrEL alone and the 
anthracycline in both rodents and humans (74-76). By co-administration 
with CrEL, the apparent clearance of both doxorubicin and its metabolite 
doxorubicinol were significantly decreased (74). A murine pharmacokinetic 
study confirmed this finding, showing that both paclitaxel and docetaxel 
modified the distribution and metabolism of doxorubicin and that CrEL alone 
also showed this effect in contrast to Tween 80 alone (76). It can be 
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postulated that this pharmc:cokinetic interaction, at least partly attributable 
to CrEL, may contribute to the greater than expected toxicity of the 
combination treatment in which paclitaxel precedes doxorubicin with both 
agents given as prolonged infusion (77). Combining paclitaxel as a 3-h 
infusion with doxorubicin as a bolus infusion showed measurable 
pharmacokinetic differences between the sequences given although no 
pharmacodynamic differences were found (73). A more prolonged 
distribution and elimination phase of doxorubicin and its metabolite 
doxorubicinol was seen when the bolus infusion of doxorubicin was 
immediately followed by paclitaxel infusion leading to high concentrations 
of both agents at the same time. The overall pharmacokinetic results 
indicated that the dose of paclitaxel and doxorubicin, the duration of their 
infusion, and the interval between their administration were associated with 
nonlinear anthracycline disposition. A recent phase I study of paclitaxel and 
doxorubicin administered as concurrent 96-h infusions showed no change in 
the pharmacokinetics of both agents (78). Consequently, differences in the 
plasma concentration-time profile of CrEL, conditional to the paclitaxel 
administration schedule, account for the apparent sequence and schedule-
dependent effect of paclitaxel on doxorubicin pharmacokinetics as is in line 
with our findings with paclitaxel, and it can be speCUlated that doxorubicin 
will also be encapsulated in CrEL micelles if administered in combination 
with 3-h infusions of the taxane. 
Similarly, the elimination of etoposide is inhibited by CrEL in the 
isolated perfused rat-liver model through decreased total and biliary 
clearance from the liver (79). It can be postulated that the same 
phenomenon occurred as with paclitaxel in the same model, i.e. entrapment 
of etoposide in the micelles. Unpublished results in patients treated with the 
combination of paclitaxel (3-h infusion) and intravenous etoposide 
confirmed these observations (AS and JV). Similar pharmacokinetic 
interactions as described for CrEL and paclitaxel have also been reported for 
the photosensitizer C8KC (80), cyclosporin A (81) and the anesthetic 
induction agent propofol (82). 
Tween 80 can also influence the pharmacokinetics of other drugs, 
but the reports in the literature on the effects of Tween 80 on drug 
distribution and elimination are conflicting. In the isolated perfused rat liver 
it decreases the clearance and volume of distribution of etoposide (79), but 
it increases the renal and biliary excretion of methotrexate (56). In mice, it 
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increases plasma levels of doxorubicin by decreasing the plasma volume as 
a result of the osmotic effect of high-dose Tween 80 when injected 
intraperitoneally (83). However, in patients who received the same amount 
of Tween 80 as is present in 100 mg/m2 of etoposide, both the volume of 
distribution and the clearance of doxorubicin were increased due to reduced 
plasma concentrations of doxorubicin during the early phase of its kinetics 
(84). The effect of docetaxel on doxorubicin pharmacokinetics has not been 
reported, but initial results of a phase I trial of this combination did not 
indicate a greater than expected doxorubicin toxicity, suggesting that there 
is no major pharmacokinetic or pharmacodynamic interaction (85). Likewise, 
there is no apparent pharmacokinetic interaction between epirubicin and 
docetaxel in rats (86) and breast cancer patients (87), although AUC values 
of the 7-deoxydoxorubicinone metabolite were 1.9-fold higher in the 
presence of docetaxel as compared to single agent epirubicin treatment 
(87). Phase I clinical trials of combinations in which docetaxel was used 
together with vinorelbine, ifosfamide, 5-fluorouracil or cisplatin have shown 
also no evidence of relevant pharmacokinetic interactions (88). 
There have been many reports highlighting the ability of Tween 80 to 
increase the absorption in animals and humans of various drugs, including 
steroids (89)' phenobarbital (90), sulphonamides (91) and methotrexate 
(58), mainly by increasing biomembrane permeability. Furthermore, Tween 
80 has been shown to induce significant increases in peak plasma levels 
and AUC values following intravesical instillation of thiotepa in patients 
with recurrent transitional cell carcinoma of the bladder (92)' which 
contrasts recent work by Knemeyer et al (63) indicating that CrEL 
substantially reduces paclitaxel penetration into the bladder wall during 
intravesical treatment, most likely as a result of paclitaxel's affinity for the 
hydrophobic interior of CrEL micelles. 
PHARMACODYNAMIC CHARACTERISTICS 
Modulation of P-glycoprotein Activity 
While examining in vitro the multidrug resistance-reversing potential 
of compounds dissolved with CrEL, it was observed that CrEL itself was 
able to modulate P-glycoprotein, the drug-transporting membrane protein 
elevated in tumor cells showing multidrug resistance in vitro (93-97). This 
effect of CrEL seems to be either due to a direct interaction with P-
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glycoprotein (95,98), or the result of a general membrane perturbation 
affecting the function of the protein pump (99,100). CrEL at concentrations 
2': 0.1 IlLlmL increased the sensitivity of multidrug resistance cells, with 
approximately 50% reversal at 1.0 IlLlmL and complete reversal occurring 
at concentrations of 1.5-2.0 IlLlmL in vitro (36,101). In solid tumors the 
significance of these in vitro findings is controversial, because the 
extremely low volume of distribution of CrEL suggests that concentrations 
necessary to affect reversal of the multidrug resistance phenotype (ranging 
from 0.3 to 1.0 IlLlmL, depending on the cell lines tested) are probably not 
attained in vivo (50). Recent pharmacokinetic results from experiments 
conducted in MDR 1 a P-glycoprotein knock-out mice (102) and studies in 
tumor-bearing mouse models (103,104) support the conclusion that CrEL is 
not a very effective multidrug resistance modulator in solid tumors, because 
no enhancement of drug-induced antitumor activity was found in 
combination with CrEL, despite peak plasma levels of CrEL > 40 IlLlmL. In 
contrast, the pharmacokinetic selectivity of CrEL for the central blood/bone 
marrow compartment can be an advantage to hematological malignancies, 
in which the expression of P-glycoprotein is known as a factor contributing 
to resistance to chemotherapy (reviewed in: Ref. 105). Indeed, it was 
shown that CrEL functions independently as a modulator of the multidrug 
resistance phenotype displayed in blast cells obtained from previously 
untreated patients with acute myelogenous leukemia at concentrations as 
low as 0.12 IlLlmL (106). The strategy of adding CrEL as a P-glycoprotein-
modulating agent to chemotherapy in the treatment of hematological 
malignancies may also be of interest in view of recent findings that indicate 
that P-glycoprotein function in normal hematopoietic cells (i.e. CD3( +) 
lymphocytes) is less susceptible to CrEL than P-glycoprotein in leukemic 
myeloid cells (107). This selectivity in P-glycoprotein inhibition appears to 
be unique for CrEL, and suggest the possibility of targeted P-glycoprotein 
modulation in some malignancies with this agent. 
Tween 80 has also shown to be a multidrug resistance modulator in 
vitro, even more potent than CrEL with approximately 50% reversal 
occurring already at levels between 0.2 and 0.3 IlLlmL (94,95). Tween 80 
has recently also been shown to increase etoposide cellular accumulation 
and potentiate cytotoxicity against various human lung adenocarcinoma cell 
lines by an unknown mechanism independent of P-glycoprotein (108). 
However, in cancer patients the plasma concentrations of Tween 80 
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measured following docetaxel infusion were only about 0.10 f.tLlmL, and 
thus too low to reverse the multidrug resistance phenotype or affect cellular 
accumulation at the tumor site (40,101). In addition, the very short terminal 
half life of Tween 80 does not contribute to the probability that these in 
vitro properties will have clinical ramifications. 
Intrinsic Effects on Hematological Pharmacodynamics 
Increase in circulating platelet levels was recorded following 
prolonged administration of high doses of CrEL in dogs (109). In contrast, in 
mice it was shown that peripheral blood cell parameters, including white 
blood cell count, reticulocyte and platelet counts were unaffected by CrEL 
administration (110; observation AS and JV). However, intravenous 
administration of CrEL in mice was associated with a decrease in bone 
marrow cellularity, an upregulation of 8220 (8-cells) and 7/4 surface 
antigen expression (neutrophil and activated macrophage) in the marrow 
and an increase in the incidence of progenitors (110). Furthermore, CrEL 
protected mice from irradiation-induced death if administered prior to the 
dose (110). These intriguing effects are consistent with the interpretation 
that CrEL activates accessory cells, and modulates accessory factors 
regulating hematopoietic progenitor cells through the operation of cytokine 
cascades. The induction of histamine release may also playa role in the 
hematopoietic response to CrEL administration (18,111,112). In mice, no 
evidence was obtained of localized toxicity or marrow destruction as a 
result of CrEL injection (110), which is consistent with flow cytometric 
studies demonstrating that even very high concentrations of CrEL (> 10%) 
did not lyse mammalian cell membranes (94). 
Recently, in 5 patients with ovarian cancer treated with paclitaxel, 
rouleaux formation of red cells was found within 24 h after infusion (113). 
In vitro experiments with samples of whole blood revealed the same finding 
after addition of both paclitaxel and CrEL, which makes it likely that CrEL is 
responsible for the phenomenon. This experience suggests caution in the 
use of automated blood cell analyzers in patients receiving paclitaxel. 
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INFLUENCE ON ANTICANCER DRUG PHARMACODYNAMICS 
Paclitaxel 
Various hypotheses regarding the relationship between the plasma 
pharmacokinetics and the hematological toxicity of paclitaxel have been 
postulated, including those using a step function (threshold model) 
(114,115) and more general models that used a nonlinear continuous 
function for the time-dissociated component (116,117). However, since the 
nonlinear pharmacokinetics of paclitaxel in plasma can be explained by CrEL 
concentration-dependent changes in drug movement within the central 
compartment, the effects of entrapment of paclitaxel in the plasma 
compartment will be less with prolonged infusion schedules associated with 
lower concentrations of CrEL (17,69). Thus, total plasma levels of 
paclitaxel measured in these schedules will represent a higher fraction of 
free paclitaxel, and this may, in part, explain the increased incidence of 
severe hematological toxicity seen in the 24-h infusion schedules as 
compared with infusion of the same dose over 3 h (69). 
Some studies suggested that CrEL and Tween 80 may enhance 
taxane cytotoxicity (118-120), and might have a cytotoxic effect of their 
own (121,122), although this could not be confirmed by others (123). 
Furthermore, some investigators observed that high levels of CrEL 
antagonized the in vitro cytotoxicity of paclitaxel at concentrations > 1 .35 
JlL/mL (124). This was shown to be related to a CrEL-mediated G1-phase 
arrest of the cell cycle, thereby preventing cells from entering mitosis in a 
phase where paclitaxel is most cytotoxic (125,126). This disruption of the 
cell cycle is likely to be one mode of action through which CrEL antagonizes 
paclitaxel cytotoxicity, in addition to the observation that high levels of 
CrEL reduced the rate of cellular accumulation of paclitaxel (126). This 
observation can also be related to micellar formation and subsequent drug 
encapsulation, and can be regarded as a confirmation of our above 
described findings on the clinical pharmacokinetic behavior of paclitaxel. 
Although CrEL (or Tween 80) concentrations have not yet been measured 
in tumor tissues in any study, it is unlikely that any potential difference in 
antitumor activity between various formulations is caused by direct 
cytotoxic effects or cell cycle arrest by the surfactants, because of their 
pharmacokinetic selectivity for the blood compartment and the undetectable 
CrEL levels in normal tissues of treated mice (59). Notwithstanding these 
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observations, it is of interest to note that in early studies conducted by the 
National Cancer Institute, paclitaxel was not effective in several tumor 
models when given intravenously as a solution in polyethyleneglycol 400 or 
10 to 15% Tween 80-ethanol, suggesting that the CrEL-based vehicle is 
essential for in vivo antitumor activity (127). Furthermore, Fujimoto et al 
showed significantly higher in vivo antitumor activity of paclitaxel against 
P388 leukemia when formulated in CrEL as compared to drug dissolved in 
dimethylacetamide (128). Similar differences for a vehicle-dependent 
antitumor activity have been observed in vitro using clonogenic assays 
(129,130). Taken together, these data suggest a rather complex interaction 
between the vehicle and the drug that is not yet completely understood. A 
recent study on some cell lines exhibiting varying MDR-1 mRNA expression 
levels with CrEL concentrations corresponding to those used in clinical 
formulation of paclitaxel revealed that there was not an independent effect 
on cell survival (1 31 ). 
AnthracyC/ines 
As discussed, CrEL affects the plasma pharmacokinetics of 
doxorubicin in both rodents and humans, and thus can be a critical 
determinant in the toxicity of this anticancer drug (74-76). This is of 
potential clinical interest in view of the fact that combinations of paclitaxel 
and anthracyclines were reported to be highly effective in the treatment of 
breast cancer (132-134). Several studies provided evidence that when 
paclitaxel as a 24-h infusion preceded doxorubicin greater toxicity was seen 
in the combination treatment (77,135). The dose-limiting toxicity, including 
stomatitis of the upper gastrointestinal tract, occurred at doses of both 
paclitaxel and doxorubicin that were approximately 30% less than when 
doxorubicin preceded paclitaxel. In contrast, no significant increase of 
hematological and gastro-intestinal toxicities were observed when paclitaxel 
as a 3-h infusion was given before doxorubicin, and it can be concluded 
that there exists no detectable sequence-dependent effect when both 
agents are administered as short infusions with the exception of cardiac 
toxicity (132). The risk of cardiac toxicity was found to be much higher 
than with other regimens including anthracyclines. A study in mice 
demonstrated that CrEL increased the tissue levels of doxorubicin due to an 
unknown mechanism, but it deserves attention that especially the most 
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vascularized tissues showed the most outspoken change of doxorubicin 
disposition (76). 
Platinum Analogues 
Clinical combination chemotherapy studies with paclitaxel or 
docetaxel in combination with cisplatin revealed important sequence-
dependent differences in frequency and severity of toxicities, with less 
severe myelotoxicity when the taxane was given before cisplatin 
(136,137). In the sequence of docetaxel followed by cisplatin it was 
demonstrated that the reduced leukocytopenia was accompanied by a 
significant inhibition of cisplatin uptake and DNA-adduct formation in 
peripheral blood leukocytes as compared to the alternate sequence 
(138,139). The fundamental mechanism turned out to be not related to the 
taxanes themselves, but to their formulation vehicles (140). Both CrEL and 
Tween 80 selectively inhibit cisplatin uptake in human peripheral blood 
leukocytes and rat bone marrow cells. In case of CrEL, there was a clear 
concentration-dependent effect with maximal inhibition of approximately 
50% achieved at an extracellular CrEL concentration of 10 JiL/mL, but also 
a mere 25 % decrease in cisplatin-uptake at concentrations of CrEL as low 
as 0.0001 JiL/mL. However, the biochemical mechanism of the dose-
dependent interaction of CrEL with the cellular uptake of cisplatin is not 
clear, but it has been speculated that inhibition of protein kinase C by CrEL 
(141) could playa role leading to decreased diffusion of cisplatin into the 
cells. It can be concluded that the extended exposure of normal 
hematopoietic cells to levels of CrEL achieved in patients after paclitaxel 
treatment might result in a selective protection against cisplatin 
accumulation in peripheral blood leukocytes (140). As such, the use of CrEL 
as a formulation vehicle may be an important determinant in the reduced 
cisplatin-associated myelotoxicity observed in clinical combination 
chemotherapy studies with paclitaxel (136,142). In vitro, the same studies 
revealed a lack of interaction between CrEL and the cisplatin analogue 
carboplatin, which is in line with previous clinical observations 
demonstrating a sequence-independent effect on the myelotoxicity of the 
combination paclitaxel and carboplatin in cancer patients (143,144), and a 
lack of effect of CrEL (equivalent to a paclitaxel dose of 175 mg/m2 ) on the 
pharmacokinetics and hematologic toxicity of carboplatin (target AUC, 6.0 
mg.min/mL) (145). 
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Miscellaneous 
Sequential dependency was also seen in two phase I trials of 
paclitaxel administered as a 3-hour or prolonged intravenous infusion and 
cyclophosphamide in which the hematologic and gastro-intestinal toxicities 
were more severe when paclitaxel preceded cyclophosphamide (146-148). 
However, in these studies no alterations of the pharmacokinetics of both 
compounds were seen, and the mechanism underlying the 
pharmacodynamic interaction, and the role of CrEL therein, have not yet 
been elucidated. 
CONCLUSIONS AND PERSPECTIVES 
Paclitaxel and docetaxel are hydrophobic antineoplastic agents 
demonstrating significant antitumor activity against a broad range of human 
malignancies. The enthusiasm evoked by some exciting clinical results of 
these agents has also led to the publication of a substantial number of 
papers addressing the role of pharmaceutical vehicles in their pharmacologic 
behavior. The investigations have yielded fundamental insight into modes of 
action, pharmacokinetic profiles, and considerations of dosage and schedule 
and route of drug administration. The current paclitaxel formulation vehicle 
CrEL presents a number of serious concerns, including a wide variety of 
intrinsic toxic side effects that limit the amount of drug that can be safely 
administered. Modulation of the drug disposition profiles by alteration of the 
blood distribution resulting from entrapment of this compound in circulating 
micelles have been documented, and CrEL also seems to playa crucial role 
in changes of the pharmacokinetics and -dynamics of several other 
compounds co-administered or those using CrEL as a formulation vehicle. It 
can be anticipated that tremendous (therapeutic) advantage could be 
obtained from the use of a clinically useful formulation vehicle in which 
CrEL is absent. This is particularly evident from recent data of a dose-
finding study with an albumin stabilized, CrEL-free, nanoparticle formulation 
of paclitaxel, which suggest a considerable increase in maximum tolerated 
dose of paclitaxel and a lack of hypersensitivity reactions in spite of the 
absence of premedication and a 30-min infusion (149). A dose-finding 
study with a new submicronic, Tween 80-free dispersion formulation of 
docetaxel, suggested a lower incidence and severity of hematological and 
non-hematological toxicity (including fluid retention and skin rashes) at 
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equimolar doses as a compared to the currently used preparation (150). 
Several other strategies are in progress to develop a CrEL-free and Tween 
80-free formulation of paclitaxel and docetaxel, respectively, including the 
use of alternative formulation vehicles (e.g. co-solvents, emulsions, 
liposomes, cyclodextrins, nanocapsules and microspheresl. development of 
more water-soluble derivatives or prod rugs, and alternative administration 
routes (e.g. local treatment and oral administration). Details of these 
strategies are discussed by Nuijen et al and Malingre et ai, respectively, in 
the current issue of this journal. Continued investigations into the role of 
pharmaceutical vehicles in taxane-related drugs, coupled with new 
approaches in taxane drug design and formulation, should eventually lead to 
a more rational and selective chemotherapeutic treatment with these 
agents. 
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ABSTRACT 
We have determined the in vitro and in vivo cellular distribution of 
the antineoplastic agent paclitaxel (Taxo!) in human blood and the influence 
of Cremophor EL (CrEL), the vehicle used for Lv. drug administration. In the 
absence of CrEL, the blood/plasma concentration ratio was 1.07±0.004 
(mean±SD). The addition of CrEL, at concentrations corresponding to peak 
levels in plasma achieved after administration of paclitaxel (175 mg/m 2 i.v. 
over 3 h; i.e. 0.50%), resulted in a significant decrease in the concentration 
ratio to 0.690±0.005 (P<0.05). Kinetic experiments revealed that this 
effect was caused by reduced erythrocyte uptake of paclitaxel by 
polyoxyethyleneglycerol triricinoleate, the major compound present in CrEL. 
Using equilibrium dialysis, it was shown that the affinity of paclitaxel for 
tested matrices was in decreasing order CrEL> plasma> human serum 
albumin, with CrEL present at or above the critical micellar concentration 
(approx. 0.01 %). Our findings in the present study demonstrate a profound 
alteration of paclitaxel accumulation in erythrocytes caused by a trapping of 
the compound in CrEL micelles, thereby reducing the free drug fraction 
available for cellular partitioning. It is proposed that the nonlinearity of 
paclitaxel plasma disposition in patients reported previously should be re-
evaluated prospectively by measuring free drug fractions and whole 
blood/plasma concentration ratios. 
INTRODUCTION 
A substantial number of clinical studies with the antineoplastic agent 
paclitaxel (Taxo!) have been performed to date, and have revealed a 
nonlinear disposition of the drug, which may have significant implications in 
that greater than expected increases in systemic exposure may result from 
a given increase in dose (1). For example, 3-h infusions of paclitaxel at 135 
mg/m2 resulted in a mean Cmax of 3.3 JiM and a mean AUC of 10.4 JiM.h, 
while at 175 mg/m2 the mean Cmax and AUC values were 5.9 JiM and 18.0 
JiM.h, respectively (2). Thus, a 30% increase in dose results in an 80% 
increase in Cmax and a 75% increase in AUC. In line with results from dose 
escalation studies in humans, paclitaxel disposition in mice also increased 
disproportionally with doses increasing from 2 to 10 or 20 mg/kg (3). 
Subsequent studies have demonstrated that both distribution and 
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elimination appeared to be linear processes in the absence of CrEL, the 
formulation vehicle used for i. v. drug administration (4). Because plasma 
concentrations of CrEL in mice and humans are within the same range, it is 
very likely that CrEL also plays an important role in the nonlinear paclitaxel 
disposition in humans (5,6). At present, the biochemical mechanisms 
responsible for the dose-dependent interaction of CrEL with the 
pharmacokinetics of paclitaxel remain unclear. It has been suggested that 
CrEL might interfere with P-glycoprotein-mediated biliary drug secretion, 
thereby influencing paclitaxel elimination (7). Recent studies, however, 
indicate that drug-transporting P-glycoproteins are not essential per se for 
normal hepatobiliary secretion of paclitaxel (8,9), and that the disposition of 
CrEL itself limits the potential to modulate P-glycoprotein activity in vivo 
(10,11). In the present study, we have determined the in vitro and in vivo 
cellular distribution of paclitaxel in human blood in an effort to extend our 
insight into the role of CrEL in the pharmacokinetics of paclitaxel. 
MATERIALS AND METHODS 
Chemicals and Reagents 
Paclitaxel powder and a sterile solution of paclitaxel formulated in a 
mixture of CrEL and dehydrated ethanol USP (1: 1, v/v) at 6 mg/ml were 
obtained from the Bristol-Myers Squibb Company (Wallingford, CT). Stock 
solutions of paclitaxel at 1 mg/ml in dimethylsulfoxide were stored at _80°C, 
and diluted further in methanol-dimethylsulfoxide (1: 1, v/v) prior to use. 
CrEL, pure castor oil and human serum albumin (fraction V) standards were 
obtained from Sigma Chemical Co. (St. Louis, MO), and Coomassie brilliant 
blue G-250 from Bio-Rad Laboratories (Munich, Germany) as a concentrated 
solution in 85% (w/v) phosphoric acid-ethanol (2:1, v/v). Five reversed-
phase HPLC fractions of crude CrEL, each with progressively increased 
hydrophobicity were kindly donated by Dr. David Kessel (Wayne State 
University, Detroit, MI) (12). Miscellaneous chemicals and reagents were of 
the highest grade available and originated from Rathburn (Walkerburn, 
United Kingdom). Purified water was obtained by filtration and deionization 
using a Milli-Q-UF system (Millipore, Bedford, MAl, and was used 
throughout. 
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Experimental Techniques 
Samples of human blood were obtained from four healthy volunteers 
in glass vials containing lyophilized sodium heparin as anticoagulant, and 
were used within 1 hour after collection. Aliquots of the blood were 
centrifuged for 5 min at 3000 x g (4°C) to separate plasma, which was 
transferred to a clean polypropylene tube and then stored frozen at _20°C 
until used. Erythrocyte suspensions were prepared with freshly donated 
heparinized blood from which plasma and buffy coat were removed by 
aspiration. The cells were washed twice, each time with 3 ml ice-cold 
phosphate-buffer (containing 0.01 M potassium phosphate, 0.137 M 
sodium chloride and 2.7 mM potassium chloride) in the presence of 0.05% 
(w/v) glucose at pH 7.4, and resuspended in the same buffer to give the 
desired hematocrit. For preparation of platelet-rich plasma, heparinized 
blood was centrifuged at 200 x g for 20 min at room temperature to pack 
down erythrocytes and leukocytes. The resulting supernatant, with very 
low contamination from red cells and leukocytes, was used as platelet-rich 
plasma. 
Blood/plasma ratio experiments were conducted using aliquots (2 ml) 
of the various matrices, which were placed in a 37°C-shaking water bath for 
5 min prior to addition of paclitaxel in the presence or absence of CrEL. At 
the time required for maximal cellular paclitaxel uptake at equilibrium, 
duplicate aliquots of 250 Vi were withdrawn from the incubation tubes 
(Eppendorf, Hamburg, Germany), and kept at -80°C for 5 min to achieve 
complete hemolysis. The remaining blood fraction was centrifuged, and the 
supernatant diluted 3-fold with drug-free human plasma to determine 
plasma concentrations as described above. 
Equilibrium dialysis was accomplished at 37°C in a humidified 
atmosphere of 5 % CO 2 using test cells made from 1.5-ml polypropylene 
microtubes (Eppendorf) carrying a 250-VI inside recess in the lids. The 
experiments were carried out with 250-VI aliquots of paclitaxel-containing 
(1 vg/ml) plasma or a 40 mg/ml solution of human serum albumin in 0.01 M 
phosphate buffer (pH 7.4) against an equal volume of the same buffer. 
Spectra/Por 3 dialysis tubing with a 12,500 molecular weight cut-off 
(Spectrum Medical, Kitchener, Canada) were soaked in 0.9% (w/v) sodium 
chloride solution prior to use. The time to reach equilibrium was determined 
in preliminary experiments and ranged between 5 and 24 h, depending on 
the composition of the fluid in the receptor compartment. The ratio of drug 
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concentrations measured by HPLC in the buffer and plasma or serum 
albumin solution after dialysis was taken as an estimate of the unbound 
(free) fraction of paclitaxel. Because the volume shift during dialysis was 
negligible « 1 0%), the results were used directly without applying a 
correction factor. In both the blood/plasma ratio and equilibrium dialysis 
experiments, it was confirmed that the total drug recovery from all the 
fractions was equal to the amount of paclitaxel added to blood, plasma or 
buffer mixtures. 
Clinical Pharmacokinetics 
The patient studied was a 65-year old female suffering from 
recurrent ovarian cancer after earlier cisplatin-containing chemotherapy. She 
received paclitaxel formulated in CrEL-ethanol at an absolute dose of 256 
mg supplemented with 100 /JCi of [G-3 H)paclitaxel (specific activity: 2.4 
Ci/mmol; radiochemical purity: 99.7% by HPLC; Moravek Biochemicals, 
Inc., Brea, CAl. The majority of the tritium is in the m- and p-positions of 
the aromatic rings, with minor amounts in the 10-, 3'-, and 2-position of 
the taxane ring system. The dose was administered as a 3-h Lv. infusion in 
500 ml of sterile and isotonic sodium chloride, after a standard 
premedication comprising dexamethasone (10 mg i. v.J, clemastine (2 mg 
i.v.) and ranitidine (50 mg Lv.). Blood samples (approx. 5 mil were obtained 
in glass tubes with lyophilized sodium heparin at the following time points: 
immediately before dosing; at 0.5, 1, 1.5, 2, 2.5, and 3 h after start of 
infusion; and at 5, 15, 30, and 45 min, and 1, 2, 4, 6, 8, 12, and 24 h 
after end of infusion. One-ml aliquots of whole blood were stored frozen 
immediately at -20'C, and the remaining blood was centrifuged at 4000 x g 
for 5 min to separate plasma. The clinical protocol was approved by the 
Rotterdam Cancer Institute Ethics Board, and the patient signed informed 
consent prior to study entry. Concentrations of paclitaxel were measured 
using an isocratic reversed-phase HPLC method with UV detection at 230 
nm as described previously (13). The analytical procedure for CrEL was 
based on a colorimetric dye-binding assay using Coomassie brilliant blue G-
250 (14), with modifications as described (6). 
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RESULTS 
In Vitro Partition in Blood Fractions 
The time to equilibrium of paclitaxel between whole blood and 
plasma, determined by measuring the concentration on blood cells at 
several time points at 37°C, and calculating the rate of migration, was 
reached within 15 min of pooling cells and plasma. At this time point, a 
blood/plasma ratio of 1.07±0.004 (mean±SD) was observed, which was 
independent of the paclitaxel concentration, indicating that the cellular 
concentration is proportional to the concentration in plasma water. This 
shows that the rate of exchange between blood cells and plasma water is 
effectively instantaneous on the time scale of paclitaxel disposition, and 
that the steady-state load on cells represents approximately half of the total 
blood concentration. The addition of CrEl, at concentrations corresponding 
to peak levels in plasma achieved after administration of paclitaxel (175 
mg/m2 i.v. over 3 h; i.e. 0.50%) (10), resulted in a significant decrease in the 
blood/plasma concentration ratio to 0.690±0.005 (P<0.05). 
Further experiments revealed a clear concentration-dependent effect of 
CrEl on this ratio, with maximal inhibition of cellular paclitaxel uptake at a 
CrEl total blood concentration of 1.0% (Table 1). At this concentration, the 
blood/plasma ratio averaged 0.625±0.008, suggesting a distribution of 
paclitaxel merely outside blood cells, with approximately 88% of total 
paclitaxel associated with the plasma fraction, assuming a mean hematocrit 
of 0.45. Incubation of paclitaxel in whole blood with castor oil, the major 
component in the CrEl vehicle prior to polyoxyethylation, showed no 
evidence of significant alterations in cellular uptake with a mean 
blood/plasma ratio of 1.23±0.17 (P> 0.05). Experiments with reversed-phase 
HPlC fractions of CrEl indicated that the effect of the unfractionated vehicle 
was not observed with the hydrophilic components present in the first 
fractions, mainly containing polyethylene glycol and oxyethylated glycerol 
(Table 1)' but are primarily caused by compounds from fraction 4, e.g. 
polyoxyethyleneglycerol triricinoleate along with fatty acid esters of 
polyethyleneglycol. 
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Table 1 Blood/plasma concentration ratio of paclitaxel in the absence 
and presence of various concentrations of CrEL, castor oil and 
HPLC fractions of CrEL * 
Compound added (%) Blood/plasma ratio % change vs. Control P** 
None 1.07±0.004 
CrEL (0.01) 1.09±0.009 + 1.83 0.387 
CrEL (0.05) 0.990±0.015 -.35 0.012 
CrEL (0.10) 0.901±0.017 -15.8 0.003 
CrEL (0.50) 0.690±0.005 -35.5 <0.0001 
CrEL (1.0) 0.625±0.008 -41.6 <0.0001 
Castor oil (0.50) 1.23±0.171 + 13.0 0.061 
CrEL fraction 1 (0.50) 1.06±0.008 -0.94 0.520 
CrEL fraction 2 (0.50) 0.926±0.018 -13.5 0.043 
CrEL fraction 3 (0.50) 0.763±0.055 -28.7 0.010 
CrEL fraction 4 (0.50) 0.645±0.051 -39.7 0.003 
CrEL fraction 5 (0.50) 0.943±0.039 -11.9 0.103 
* Paclitaxel was used at an initial concentration of 1 tlg/ml, and incubated in whole 
blood for 15 min at 37'C prior to fractionation and HPLC analysis. Ratio data are 
presented as mean values ± SD of (at least) triplicate measurements. 
** Probability value vs. control (unpaired two-sided Student's t test). 
The distribution of paclitaxel within an artificial mixture of washed 
erythrocytes, occupying 45% of the total volume, and buffer indicated red 
cell/buffer concentration ratios of 3.70±0.061 and 0.649±0.014 in the 
absence and presence of CrEL, respectively, further indicating that, in the 
latter case, paclitaxel is only distributed in the water phase (Table 2). The 
apparent contradiction between the low blood/plasma ratio and high 
accumulation into erythrocytes was shown to be due to the compensating 
effect of plasma protein binding, which has been observed previously for a 
diversity of other drugs (for an overview, see: Ref. 15), including paclitaxel 
(16). This is borne out by the finding that in the presence of plasma 
proteins, cellular partitioning of paclitaxel in erythrocytes was markedly 
impaired (Table 2). Surprisingly, paclitaxel accumulation in platelets was 
less affected by CrEL than erythrocyte uptake (Table 2), with a 
platelet/plasma ratio in the order of approximately 300, taking into account 
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the low total platelet volume in blood (approx. 4 fll/ml blood). As suggested 
recently by Wild and co-workers, this high degree of platelet uptake likely 
reflects a tight binding of paclitaxel to the intracellular tubulin/microtubule 
system, and has previously been shown to occur with other tubulin-
interactive drugs, such as the vinca alkaloids (17). 
Table 2 Distribution of paclitaxel in artificial binary mixture systems of 
the main blood fractions in the absence and presence of CrEL * 
Binary system CrEL (%) Total/extracellular ratio % change vs. control p* * * * 
Erythrocytes/buffer* * 
None 3.70±0.061 
0.50 0.649±0.014 -82.5% <0.001 
Erythrocytes/plasma * * 
None 1.03±0.021 
0.50 0.664±0.007 -35.5% 0.002 
Platelets/plasma * * * 
None 1.33±0.037 
0.50 1.26±0.024 -5.26% 0.018 
* Paclitaxel was used at an initial concentration of 1 Jlglml, and incubated in whole 
blood for 15 min at 37°C prior to fractionation and HPLC analysis. Ratio data are 
presented as mean values ± SD of (at least) triplicate measurements. 
** Hematocrit, approx. 0.45 
*** Platelet count, approx. 750 x 109(L 
**** Probability value vs. control (unpaired two-sided Student's t test). 
Binding Interactions 
In order to gain insight into the mechanism underlying this 
phenomenon, equilibrium dialysis was used to determine the effects of CrEL 
on the fraction unbound paclitaxel. Preliminary experiments verified that 
CrEL could not cross the semipermeable dialysis membrane, as was 
indicated by the absence of detectable levels in the buffer compartment 
after dialysis. As predicted by earlier experiments (5), paclitaxel was found 
to bind extensively to human plasma (89.1±O.595%, mean±SD; n = 3) in 
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the absence of CrEL, with human serum albumin accounting for 
approximately 50% of the total binding. In the presence of CrEL (0.50%), 
however, a clear and statistically significant decrease in the free (unbound) 
drug fraction of up to 66% (P= 0.013) and 92% (P= 0.002) was seen for 
plasma and human serum albumin, respectively. Interestingly, equilibrium 
dialysis experiments performed with CrEL in the absence of any plasma 
proteins revealed that at a spiked concentration of 0.50%, a free drug 
fraction of only 0.044 was observed, suggesting that paclitaxel affinity for 
CrEL is substantially greater than for either plasma or human serum 
albumin. This binding affinity for CrEL was distinctly concentration-
dependent, with no change in the free fraction of paclitaxel at CrEL 
concentrations below 0.01 % [i.e., the amount of surfactant corresponding 
to the critical micellar concentration in aqueous solutions (18) and maximal 
binding (at a free drug fraction of approx. 0.017) in the presence of CrEL at 
a concentration of 1.0%. Equilibrium dialysis of paclitaxel-containing plasma 
against a buffer with CrEL resulted in a virtually quantitative shift of drug 
(90.1 ±1.09%) to the receptor fluid, further pointing to a preferential binding 
to the surfactant. 
Figure 1 
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Concentration VS. time curves of paclitaxel in whole blood (0) and plasma 
(e) [panel AJ and of CrEL (II1II) in plasma [panel 8]. Pharmacokinetic data 
were obtained from a female patient receiving the drug formulated at 6 
mg/ml in a mixture of CrEL-dehydrated ethanol USP (1: 1, v/v) at an 
absolute dose of 256 mg. 
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In Vivo Pharmacokinetics 
Figure shows the logarithmic concentration-time curves of 
paclitaxel in whole blood and plasma (Le. the unbound ultrafiltrate fraction 
plus the protein/CrEL bound blood fraction) [panel A], and of CrEL in plasma 
[panel B], after an Lv. dose of 256 mg to a female patient with advanced 
ovarian cancer. Similar to our in vitro partition experiments, a distinct CrEL-
concentration dependency was noted for the whole blood/plasma 
concentration ratio and the unbound drug fraction (Table 3). This suggests 
that erythrocytes form a secondary transport system in whole blood, which 
becomes less significant as the CrEL concentration increases, and hence, 
the unbound drug concentration decreases. In all, these data appear to 
indicate that CrEL micelles act as the principal carrier of paclitaxel in the 
systemic circulation. 
Table 3 
Time (h)* * 
0.50 
1.0 
1.5 
2.0 
2.5 
3.0 
CrEL concentration-dependent blood/plasma ratio and unbound 
paclitaxel fraction in plasma of a patient* 
CrEL (%) Bloodlplasma ratio Unbound fraction 
0.039 1.02 0.076 
0.122 0.795 0.057 
0.157 0.851 0.038 
0.215 0.749 0.028 
0.300 0.737 0.022 
0.335 0.623 0.016 
* Paclitaxel was administered as an Lv. infusion over a 3-h period at an absolute dose 
of 256 mg to a single female with advanced ovarian cancer. 
** Sample collection time point after start of a 3-h i.v. infusion of paclitaxel. 
DISCUSSION 
In the present study we have shown that CrEL, the formulation 
vehicle used for Lv. drug administration, causes a profound alteration of 
paclitaxel accumulation in erythrocytes, by reducing the free drug fraction 
available for cellular partitioning. This effect was also observed in the 
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absence of plasma proteins, indicating that it was not caused by altered 
protein binding, or an increased affinity of paclitaxel for protein dissociation 
products which are produced by the action of CrEL on native lipoproteins 
(12,19). The data indicate that erythrocytes form a secondary transport 
system in whole blood, which becomes less significant as the CrEL 
concentration increases, and hence, the free drug fraction decreases. 
Current data suggest that drug trapping occurs in micelles composed 
primarily of polyoxyethyleneglycerol triricinoleate, and that these micelles 
act as the principal carrier of paclitaxel in the systemic circulation. 
The findings of extensive red cell uptake of paclitaxel at low CrEL 
levels, and the high binding to plasma proteins and CrEL micelles may have 
a substantial impact on the interpretation of the drug's pharmacokinetic 
behavior that has not been fully appreciated. Previously, paclitaxel 
disposition in animals and humans has been reported to be nonlinear, with 
disproportional relationships between changes in the dose and the resulting 
plasma AUCs and peak plasma concentrations. This nonlinearity has been 
speculated to result from two separate saturable processes, one in 
distribution and one in elimination and both described by Michaelis-Menten 
kinetics, based on the usefulness of complex mathematical pharmacokinetic 
models to accurately describe plasma profiles of paclitaxel over a wide 
dosage range (1,2). The authors have generated estimates of the maximal 
process rate (i.e., V ma) and the paclitaxel concentration associated with 
O.5xVmax (i.e., Km), and observed that the Km estimate for the distribution 
process is much smaller than that for elimination. This suggested that 
distribution should be the first process to exhibit saturation. Our present 
data indicate, that the resulting disproportional accumulation of paclitaxel in 
plasma, which is most pronounced with the drug administered by the 3-h 
infusion schedule (1), is related to a CrEL-mediated alteration of drug 
distribution within the circulation during paclitaxel infusion. This is exactly 
what is observed clinically in our patient, and is supported by our previous 
finding that, in spite of nonlinear paclitaxel kinetics in plasma, tissue levels 
of the parent drug and its known mono- and dihydroxylated metabolites in 
mice are linear with the dose administered (3). The paradox of 
disproportional increases in plasma concentrations and linear distribution 
processes in tissues is likely caused by the fact that the plasma comprises a 
relatively small fraction of the total volume available for paclitaxel 
distribution and that, simultaneously, the CrEL-drug complex is not stable 
159 
Chapter 6 
enough to substantially reduce the amount of drug that exists in the body in 
the active, diffusible, unbound form. In addition, it is also possible that the 
equilibrium between blood and tissues is not solely based on paclitaxel 
dissolved in the plasma water phase, but also on direct drug transport from 
loaded erythrocytes to tissues (15). This hypothetical transport may be of 
great importance for paclitaxel in cases of low concomitant CrEL levels that 
are associated with low dose schedules. Regardless of the tissues uptake 
processes, our current findings indicate that the operation of Michaelis-
Menten kinetics, the postulated cause of nonlinear paclitaxel disposition in 
plasma, is not related to saturable tissue-binding or disproportional 
elimination kinetics, but appears to be an artifact caused by paclitaxel-dose 
related levels of CrEL in the blood. We are currently prospectively re-
evaluating the linearity of paclitaxel pharmacokinetics in humans using 
different infusion schedules by measuring free drug fractions and 
blood/plasma ratios, based on the expectation that if the fraction of drug 
which is bound changes appreciably with concentration in the concentration 
range of interest, then the AUC of free (unbound) paclitaxel should be a 
linear function of the dose administered. 
The existence of CrEL in blood as large polar micelles with a highly 
hydrophobic interior also raises the possibility of additional complexities in 
case of combination chemotherapy regimens with paclitaxel. For example, 
fluorescence studies on the interaction between anthracycline drugs and 
different surfactants indicated that daunorubicin, although relatively 
hydrophilic with an octanol-water partition ratio of approximately 3.5, is 
readily incorporated into CrEL micelles (18). Thus, in the systemic 
circulation, micellar incorporation of anthracyclines may result in altered 
cellular distribution and a concomitantly increased plasma concentration. In 
this regard, it is interesting to note that both paclitaxel (in the clinical 
formulation) and CrEL alone strongly affect the plasma pharmacokinetics of 
another anthracycline antineoplastic agent, doxorubicin, in both rodents and 
humans (7,20). Similarly, CrEL is known to decrease etoposide clearance in 
rats (21), and preliminary findings in humans treated with the combination 
of paclitaxel (~175 mg/m2 over 3 h) and Lv. etoposide confirmed these 
observations'. At present, we are investigating the effects of micellar 
incorporation in the biodistribution and pharmacokinetics of doxorubicin and 
etoposide, and the role of CrEL as a determinant in the increased incidence 
1 Sparreboom A and Verweij J, unpublished observations 
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and severity of hematological toxicity in clinical trials (7) with the 
combination of paclitaxel and doxorubicin2 • 
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Chapter 7 
Cremophor EL (CrEL) is a castor oil surfactant used as a vehicle for 
formulation of a variety of poorly water-soluble agents, including paclitaxel. 
Recently, we found that CrEL can influence the in vitro blood distribution of 
paclitaxel by reducing the free-drug fraction, thereby altering drug 
accumulation in erythrocytes. The purpose of this study was to investigate 
the clinical pharmacokinetics of CrEL, and to examine interrelationships of 
paclitaxel disposition, infusion duration and CrEL kinetics. The CrEL plasma 
clearance, studied in 17 patients for a total of 28 courses, was time-
dependent and increased significantly with prolongation of the infusion 
duration from 1 to 3 to 24 h (P<0.03). An indirect response model, applied 
based on use of a Hill function for CrEL concentration-dependent alteration 
of in vivo blood distribution of paclitaxel, was used to fit experimental data 
of the 3-h infusion (1'=0.733; P=0.00001). Simulations for 1- and 24-h 
infusions using predicted parameters and CrEL kinetic data revealed that 
both short and prolonged administration schedules induce a low relative net 
change in paclitaxel blood distribution. Our pharmacokinetic/pharmaco-
dynamic model demonstrates that CrEL causes disproportional accumulation 
of paclitaxel in plasma in a 3-h schedule, but is unlikely to affect drug 
pharmacokinetics in this manner with alternative infusion durations. 
INTRODUCTION 
Paclitaxel, a natural product first isolated from the Western Yew tree, 
Taxus brevifolia, acts by stabilizing the microtubule cytoskeleton, and 
possesses antitumor activity against a relatively broad spectrum of 
malignancies (reviewed in 1). The variability in clinically tested treatment 
schedules of this drug is enormous, ranging from short i.v. infusions of less 
than 1 h to 10-day or even 7-week continuous-infusion administrations (2-
4), with large differences in experienced toxicity profiles and with fortuitous 
implications for the pharmacokinetics of paclitaxel. The latter refers to the 
experience of nonlinear plasma disposition, which appears to be most 
pronounced with the drug administered as a 3-h infusion, the most 
frequently used schedule nowadays (5-7). The mechanisms underlying the 
nonlinearity of paclitaxel disposition are not yet completely understood, 
although it has been shown that distribution and elimination appear to be 
linear in the absence of CrEL, the non ionic castor oil vehicle used in the 
clinical formulation (8,9). We have shown recently, that in vitro CrEL 
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causes a profound alteration of paclitaxel accumulation in erythrocytes in a 
concentration-dependent manner, by reducing the free drug fraction 
available for cellular partitioning (10). In this report, we (i) evaluated the 
importance of this in vitro observation for cancer patients treated with i.v. 
administered paclitaxel, (if) describe the clinical pharmacokinetics of CrEL 
administered with a 1-h, 3-h and 24-h i.v. paclitaxel infusion, and (iii) 
propose a pharmacokinetic/pharmacodynamic model to describe the 
pharmacokinetic profiles of CrEL for these three treatment groups and the 
relationship between CrEL plasma concentrations and the paclitaxel blood 
distribution. 
MATERIALS AND METHODS 
Patients and Treatment 
A total of 1 7 patients enrolled in Phase I trials performed in 
Rotterdam (the Netherlands; n = 5), Milan (Italy; n = 6) or Freiburg im 
Breisgau (Germany; n = 6) was studied during treatment with paclitaxel as a 
single agent for a variety of malignant solid tumors refractory to standard 
therapy. They represented either newly recruited patients (Rotterdam) or 
those for which plasma samples had been previously collected and detailed 
clinical profiles documented elsewhere (5,11). Paclitaxel was administered 
as a 1-h (6 courses), 3-h (13 courses) or 24-h (9 courses) i.v. infusion 
every 3 weeks at doses ranging from 135-225 mg/m2 • The drug was 
formulated in a mixture of CrEL and dehydrated ethanol USP (1: 1, v/v) 
(Taxol; provided by Bristol-Myers Squibb) and diluted further into isotonic 
sodium chloride or dextrose prior to dosing. 
Sample Collection and Drug Analysis 
For CrEL, pharmacokinetic evaluation was performed in all patients 
for a total of 28 courses. Heparinized blood samples of 5 mL were obtained 
at the following time points: before dosing and at 0.5, 1, 4, and 24 h after 
infusion (1-h schedule) or at 1, 2, 3, 3.08, 3.25, 3.5, 3.75, 4, 5, 7, 9, 11, 
15, and 24 h after infusion (3-h schedule) or at 1, 22, 23, 23.92, 24, 
24.08, 24.15, 24.5, 25, 26, 27, 30, 36, and 45 h after infusion (24-h 
schedule). One-mL aliquots of whole blood were snap-frozen at -20°C (3-h 
schedule only at 1, 2, and 3 h after infusion), and plasma was separated by 
centrifugation for 5 min at 4000 x g (all schedules). 
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Concentrations of paclitaxel in whole blood and plasma were 
determined using a validated isocratic reversed-phase high-performance 
liquid chromatography (HPLC) procedure with UV detection (A = 230 nm), as 
reported (12). The analytical method for CrEL was based on binding of the 
surfactant to Coomassie Brilliant Blue G-250 in protein-free plasma extracts 
by measuring the change in ratio of absorbances at 595 nm over 450 nm 
(13,14). 
Pharmacokinetics 
The CrEL plasma concentration-time curves were analyzed using the 
software package Siphar v4 (SIMED, Creteil, France) by determination of 
slopes and intercepts of the plotted curves with a bi-exponential function 
(15). Initial parameter estimates were obtained by an automated peeling-
algorithm procedure, with an integrated numerical algorithm based on the 
Powell method and a weighted-least squares operation. The area under the 
plasma concentration-time curve of CrEL was determined on the basis of 
the best fitted curves from time zero up to the last sampling point with 
detectable levels (AUCo_t ) (lower limit of quantitation: 0.5 f.tL/mL). 
Extrapolation to calculate AUCo_'" was not performed because based on the 
limited sampling procedure, half-life estimates of the terminal disposition 
phase [reported previously to be > 80 h with 3-h paclitaxel infusions] (15) 
and subsequent determinations of total clearance and volume of distribution 
could not be done with sufficient precision [i.e. the extrapolated part 
represents a significant amount (> 20%) of the AUCo "']' Therefore, the 
apparent plasma clearance of CrEL was estimated by dividing the delivered 
volume (expressed in mL per m2 body-surface area) by the observed AUCO_tt 
to allow evaluation of the impact of infusion duration on the 
pharmacokinetic behavior. Peak plasma concentrations (Cm.xl of CrEL and 
paclitaxel were determined graphically by visual inspection from scattered 
plots of concentration-time profiles. 
For pharmacodynamic analysis, paclitaxel concentrations were 
considered as 'total paclitaxel', because an acetonitrile/n-butyl chloride 
extraction was applied to separate paclitaxel from its binding proteins and 
CrEL micelles for the assay (12). Based on our previous in vitro partitioning 
experiments (10), we assumed that CrEL can decrease the unbound fraction 
in serum in vivo with subsequently decreased erythrocyte binding in a 
concentration-dependent manner, whereas the elimination rate of paclitaxel 
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from the central compartment remains unchanged (16). An indirect 
response model based on the premise that inhibition of paclitaxel uptake by 
erythrocytes will change the blood to plasma [(B/P)l concentration ratio was 
applied as follows: 
where (B/P)o is the paclitaxel blood:plasma concentration ratio in the 
absence of CrEl, (B/P)min is the minimum paclitaxel blood:plasma ratio that 
can be achieved, [CCrELl is the CrEl plasma concentration, which is a forcing 
function defined by the kinetic analysis, [CCrELl50 is the CrEl plasma 
concentration producing 50% of maximum decrease of the paclitaxel blood 
to plasma ratio, and y is the slope coefficient for the Hill function describing 
the sigmoidity of the fit. 
Statistics 
All pharmacokinetic parameters are reported as mean values ± SO. 
Intra patient differences between the first and second course in dose-
normalized parameters were assessed by the coefficient of variation, 
expressed as the ratio of the SO and the observed mean. Pharmacokinetic 
variability between the various dose levels and infusion duration was 
evaluated by the Kruskal-Wallis statistic and Dunn's multiple comparison 
test, if necessary. Pharmacodynamic parameters [(B/P)o, (B/P)min, [CCrELl50 
and yl were estimated by the maximum likelihood method using the Siphar 
program, and the model evaluated for goodness of fit by minimization of 
sums of squared residuals and by reduction of the estimated coefficient for 
fitted parameters. Significance of the relationship was assessed by 
construction of contingency tables with subsequent X2 analysis. Statistical 
analysis was performed using the NCSS software (v5.X; Dr. Jerry Hintze, 
Kaysville, UT). All test were two-tailed, and the level of significance was 
set at a=0.05. 
RESULTS 
CrEL Kinetics 
Mean pharmacokinetic parameters of CrEl at each of the dose levels 
tested are listed in Table 1 as a function of the infusion duration. In all cases, 
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CrEL plasma concentrations increased progressively and mono-exponentially 
throughout the infusion in a first-order fashion (Fig. 1), most likely because 
the fractional term associated with the terminal phase is approximately 0.97 
(9), causing spontaneous CrEL distribution in the circulation relative to 
elimination. Both Cmax , observed immediately after cessation of the infusion, 
and AUCo_t were significantly higher at an increased dose with all three 
schedules (P<0.04). The plasma clearance was independent of the dose 
within each infusion duration (P> 0.44), although with the 24-h infusion there 
was a trend toward slower clearance with an increase in dose (Table 1). 
Table 1 Effect of dose and infusion duration on CrEL pharma-
cokinetics * 
Tint * * Paclitaxel dose CrEL dose n Cmax AUCo_t CL 
(h) 
3 
24 
* 
** 
(mg/m2) 
150 
175 
225 
135 
175 
225 
135 
175 
(mLlm2) 
12.5 
14.6 
18.8 
11.3 
14.6 
18.8 
11.3 
14.6 
(I-lLlmL) (l-lL.h/mL) (mLlh/m2) 
4.30 48.4 258 
2 5.30, 5.70 81.6,89.9 162,179 
3 5.37±0.96 84.6±4.38 223±11.8 
3 2.32±0.34 28.9±2.40 392±32.5 
5 3.43±0.47 46.3±7.55 321±55.7 
5 4.46±0.75 59.4±10.0 322±49.2 
3 0.69±0.14 22.4±4.63 520±121 
6 1.43±0.39 43.1±12.3 364±115 
Data were obtained from cancer patients after treatment courses of 1-, 3-, or 24-h 
Lv. infusion of paclitaxel at dose levels ranging from 135 to 225 mg/m2 • The 
parameters were calculated by non-compartmental analysis, and data represent mean 
values ± SO. 
Tinf , infusion duration of drug administration; n, number of treatment courses studied; 
Cm,x, peak plasma concentrations; AUCo_" area under the plasma concentration-time 
curve up to the last time point with detectable levels; Cl, apparent plasma 
clearance. 
However, a clear time-dependency was noted in CrEL pharmacokinetics 
with the plasma clearance increasing significantly with an increase in infusion 
time [e.g. CL'h = 223±11.8 VS CL3h = 322±49.2 mLlh/m2; P= 0.02 (at 225 
168 
Pharmacokinetic interaction of pac/itaxe/ and Cremophor EL 
mg/m2) or CL3h = 392±32.5 VS CL24h = 520±121 mLlh/m2; P= 0.03 (at 135 
mg/m2)]. Accumulation effects of multiple dosing were not observed in any 
patient that had blood samples collected on two or three separate 
consecutive occasions (3-weekly schedules of 3-h or 24-h Lv. infusion), and 
the coefficient of variation in observed AUC values was typically below 10%. 
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Representative plasma concentration-time curves of CrEL in 3 patients 
treated with paclitaxel at a dose level of 175 mg/m2 given as a 1-h (+), 3-h 
(0) or 24-h Lv. infusion (e). In all cases, paclitaxel was formulated at 6 
mg/mL in a mixture of CrEL-dehydrated ethanol USP (1: 1, v/v), and diluted 
in 5% dextrose or 0.9% sodium chloride solution within 3 h prior to dosing. 
Pharmacokinetic curves were fitted to a bi-exponential equation assuming a 
2-compartmental model for distribution and elimination phases using the 
Siphar v4 software package. 
Paclitaxe/ B/ood Partitioning 
The concentration of paclitaxel in plasma and blood after a 3-h Lv. 
infusion is shown in Fig. 2 as a function of the dose administered. At the 
lowest dose tested (i.e. 135 mg/m2), the blood:plasma ratio was independent 
of the concentration (0.99±0.12 to 0.93±0.13; P> 0.15). Increasing the dose 
to 175 and 225 mg/m2, however, resulted in significant decreases in 
blood:plasma ratios toward the end of infusion to 0.68±0.08, at which 
approximately 90% of drug is distributed outside blood cells. To demonstrate 
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the comparative relationship between CrEL concentrations and alterations in 
the paclitaxel blood:plasma ratio, a simulation based on the proposed 
pharmaco-kinetic/pharmacodynamic model (eq. 1) is presented in Fig. 3. 
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Plasma (e) and blood (0) concentration-time plots of paclitaxel in patients 
treated with a 3-h Lv. infusion of paclitaxel at dose levels of 135 (panel A), 
175 (panel B) or 225 mg/m 2 (panel C). Data represent mean values 
(symbols) ± SO (error bars). 
Using the computer fitting (,-2=0.733; P=O.OOOO1), the paclitaxel 
blood:plasma ratio in the absence of CrEL was estimated as 1.09, which is in 
excellent agreement with our previous in vitro finding of 1.07±0.004 at a 
paclitaxel concentration of 1 fl9/mL (10). After increasing CrEL levels, the 
blood:plasma ratio gradually decreased to a value in which paclitaxel is 
distributed only in the water phase (corresponding to an erythrocyte:plasma 
water ratio of approx. 0.65), with an estimated [CcrEd50 value of 2.297 flLlmL 
and Hill coefficient y of 1.35. Simulations for the patients receiving 1-h or 24-
h Lv. infusions using the predicted parameter values and superposition of the 
pharmacokinetic data of CrEL are shown in Fig. 3. Based on the proposed 
model, a change in blood:plasma ratio during 24-h infusions is predicted 
between 0.911 and 1.01 (up to 16.5% decrease of initial value). The 1-h 
infusions have the lowest relative net change in the ratio (between 0.545 and 
0.650), despite having the highest CrEL concentrations. These results show 
that only with 3-h Lv. infusions substantial disproportional accumulation of 
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paclitaxel in plasma, resulting from CrEL-mediated alteration of blood 
distribution, is likely to occur. 
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Relationship between the blood:plasma concentration ratio of paclitaxel and 
the observed plasma concentration of CrEL during 3-h Lv. infusions of 
paclitaxel. Data were obtained from 5 patients (13 courses) treated at 135, 
175, or 225 mg/m2 • The solid line represents a fit of the data with a 
sigmoidal minimum-effect model using 1/(CrEL concentration) weighting 
and an integrated numerical algorithm based on the Powell method. Boxes 
with dotted lines indicate the range of CrEL peak levels associated with i.v. 
paclitaxel administration over 1, 3, or 24 h at dose levels ranging between 
135 and 225 mg/m2 (see Table 1), and the predicted paclitaxel blood: 
plasma concentration ratio obtained by interpolation of the fitted model. 
DISCUSSION 
The present study was performed to investigate the clinical 
pharmacokinetics of CrEL administered over 1-, 3-, and 24-h i.v. infusions of 
paclitaxel and to examine the interrelationships of paclitaxel disposition, 
infusion duration and CrEL kinetics. The CrEL plasma clearance was found to 
be time-dependent and increased significantly with prolongation of the 
infusion duration from 1 to 3 to 24 h. This observation is at odds with most 
literature concerning CrEL pharmacokinetics following 3-h paclitaxel 
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administration, showing linear increases in both Cmax and AUC with increasing 
dose (15,17), although some other authors have reported slower CrEL 
clearances at the lower end of paclitaxel dose ranges when using body-
surface area-based dose-calculation methods (18). Our results are in line with 
those found using an HPLC assay for CrEL described recently (19). The 
processes involved in CrEL elimination are not yet fully discerned, although 
preliminary findings indicate that the cumulative urinary excretion is very low, 
accounting for less than 0.1 % of the administered dose, despite its relatively 
high hydrophilic nature (20). Given the limited volume of distribution of CrEL 
(15) and the prominent role of serum carboxylesterase-mediated metabolic 
transformation in the elimination of the related surfactant polysorbate 80 
(21), it is possible that the underlying time-dependent mechanism is that of 
capacity-limited CrEL metabolism within the systemic circulation. Regardless 
of the processes affecting the pharmacokinetic profile of CrEL, our findings 
indicate that CrEL disposition is highly dependent on infusion duration, with 
disproportional increases in systemic exposure being associated with 
shortening of infusion. This finding may be of particular importance in view of 
the potential role of CrEL in the frequent presence of acute hypersensitivity 
reactions associated with clinical use of paclitaxel, which are characterized by 
dyspnea, flushing, rash, and generalized urticaria (22). Despite extensive 
premedication with high-dose corticosteroids and H1/H 2-receptor antagonists, 
the overall frequency of minor reactions is estimated as high as 44%, with 
major reactions, necessitating discontinuation of paclitaxel therapy, still 
occurring in approximately 1.5 to 3% of patients (23,24). Consistent with the 
pharmacokinetic selectivity of CrEL for the plasma water phase (13), Szebeni 
et al recently postulated a novel concept suggesting that an important 
contributing mechanism to hypersensitivity reactions from paclitaxel is 
complement activation due to binding of naturally occurring anti-cholesterol 
antibodies to the hydroxyl-rich surface of CrEL micelles (25). Based on an 
elegant series of in vitro experiments, it was shown that CrEL-induced 
complement activation in human serum was clearly concentration dependent 
with a minimum activating CrEL level in the order of 2 ~L!mL (25), 
concentrations readily achieved clinically in plasma (Fig. 1). It should be 
mentioned in this context that the current trend to pursue shorter schedules 
of paclitaxel administration in an attempt to simplify complex multidrug 
regimens, can have a much greater impact on complement-activating CrEL 
levels at the site of infusion and on total CrEL exposure than would be 
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expected in case of time-independent pharmacokinetics. Indeed, a recent 
clinical pilot experience in attempting to administer paclitaxel at 175 mg/m 2 
by 30- or 45-min Lv. infusion indicated symptoms and signs of significant 
adverse hypersensitivity reactions in all patients treated within 15 min after 
start of drug administration, even in the presence of standard antiallergenic 
premedication (2). 
Consistent with our previous in vitro observations (10), we found in the 
present study a distinct CrEL-concentration dependency of the paclitaxel 
blood:plasma ratio during 3-h paclitaxel infusions (Fig. 2). This finding 
demonstrates for the first time that CrEL affects the clinical pharmacokinetics 
of paclitaxel by a disproportional accumulation process in plasma, and lends 
further support to our prior supposition that the ability of CrEL to modulate 
the murine disposition of various compounds, including paclitaxel and 
doxorubicin (9,26,27) may have important clinical ramifications. Mathematical 
models able to accurately and completely describe paclitaxel concentration-
time profiles have shown that the nonlinear drug disposition is most likely 
dictated initially by saturable distribution kinetics (5,6), and is particularly 
evident with the 3-h infusion schedule. This is also in keeping with results 
obtained in mice showing that disproportional plasma levels with an increase 
in dose did not reflect higher tissue levels (8), and with evidence obtained 
from trials with prolonged (~24-h) Lv. infusions indicating that the nonlinearity 
of paclitaxel pharmacokinetics was less evident (5,28,29). Using an indirect 
response model applied in the pharmacokinetic/pharmacodynamic analysis of 
CrEL concentrations and corresponding blood distribution of paclitaxel (Fig. 
3), a change in blood:plasma ratio during 24-h infusions between 0.911 and 
1.01 (up to 16.5% decrease of initial value) was predicted, indicating a minor 
effect of CrEL on paclitaxel distribution. The model also provided additional 
information on the disposition characteristics of shorter schedules, and shed 
light on some important mechanistic aspect of the paclitaxel-CrEL interaction. 
Since the estimated Michaelis-Menten constant (Km) for paclitaxel distribution 
was previously found to be in the order of paclitaxel peak plasma 
concentrations following 24-h infusions (135 to 175 mg/m2) (6), dose and 
infusion schedules associated with high drug concentrations relative to Km 
(approx. 270 ng/mL) were expected to display the most distinct signs of 
nonlinearity. In contrast, however, no evidence of nonlinear paclitaxel 
disposition has been described in any trial using 1-h infusion schedules at 
dose levels associated with distinct deviation of linearity using 3-h schedules 
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(i.e. between 135 and 225 mg/m2) (11,30-34). This paradox can be 
understood in view of the fact that the high CrEL concentrations achieved 
early into the infusion produce only a low relative net change in the paclitaxel 
blood:plasma ratio (between 0.545 and 0.650), although the absolute 
quantitative effect is large already at low-dose input. Measurement of plasma 
concentrations of CrEL may, therefore, not be the exclusive indicator of the 
importance of the vehicle-drug interaction, but rather the combination of dose 
delivered and input-rate applied. 
CONCLUSION 
Our current study demonstrates that the pharmacokinetic behavior of 
the paclitaxel vehicle CrEL is subject to considerable variability depending on 
the duration of i.v. infusion for drug administration. We have identified CrEL-
mediated alterations of the paclitaxel blood:plasma ratio as a major 
contributing mechanism of the nonlinear paclitaxel disposition observed in 
patients with 3-h infusion schedules. In addition, a pharmacokinetic/-
pharmacodynamic model could accurately describe the biological events for 
CrEL kinetics and subsequent change in blood:plasma ratio of paclitaxel and 
predict the interrelationships between the parameters under diverse dosing 
conditions. Since CrEL is increasingly used as a formulation vehicle in 
pharmaceutical preparations of novel agents, recognition of the complex 
interplay between kinetic profiles of CrEL and paclitaxel is of particular 
significance. The present data should therefore be of importance as a guide to 
better understand the role of this drug vehicle in the future. 
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ABSTRACT 
Nonlinear disposition of paclitaxel (Taxol) in cancer patients has been 
described in several studies, but the underlying mechanism is still 
speculative. Previously, we have shown in vitro that the paclitaxel 
formulation vehicle, Cremophor El (CrEl), alters the blood distribution of 
paclitaxel as a result of entrapment of the compound in circulating CrEl 
micelles, thereby reducing the free drug fraction available for cellular 
partitioning. Based on these findings, we have prospectively re-evaluated 
the linearity of paclitaxel disposition in patients using whole blood and 
plasma analysis, and we took effort to define a new pharmacokinetic model 
to describe the data. Seven patients with solid tumors were treated with 
paclitaxel infused over 3 h, each at consecutive 3-weekly dose levels of 
225, 175 and 135 mg/m2 (CrEl dose level, 18.8, 14.6, and 11.3 mLlm2, 
respectively). Patient samples were collected up to 24 h after start of 
infusion, and analyzed by high-performance liquid chromatography. 
Paclitaxel peak levels and areas under the curve in whole blood increased 
linearly with dose, whereas plasma levels showed substantial deviation 
from linearity. This was shown to be caused by a CrEl-concentration 
dependent decrease in paclitaxel uptake in blood cells, as reflected by the 
blood :plasma concentration ratios which altered significantly from 
O.83±O.11 (at 135 mg/m2) to O.68±O.07 (at 225 mg/m2). It is concluded 
that the nonlinear disposition of paclitaxel is related to paclitaxel-dose 
related levels of the formulation vehicle CrEl, leading to disproportional drug 
accumulation in the plasma fraction. The developed pharmacokinetic model 
could accurately describe the data, and will help guide future development 
and refinement of clinical protocols, especially in defining the exposure 
measure best linked to paclitaxel effects and toxicities. 
INTRODUCTION 
Nonlinear disposition of drugs is a pharmacokinetic characteristic 
which implies that a given increase in dose may lead to a disproportional 
increase in systemic drug exposure. After Lv. drug administration, the 
phenomenon is most commonly caused by saturation of enzyme, binding or 
transporter capacity (36). Although there are many drugs that display 
nonlinear elimination kinetics, either resulting from saturable metabolic 
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pathways (e.g. phenytoin (1)) or saturable excretion pathways (e.g. 
cyclophosphamide (3)), capacity-limited distribution in humans is rare, 
although concentration dependence has been described for the binding of 
some drugs to plasma proteins, blood cells and extravascular tissue or 
binding sites (20). The pharmacokinetic behavior of the anticancer agent 
paclitaxel (Taxo!), for example, was shown to be distinctly nonlinear in 
several studies, and seemed a result of saturable distribution in combination 
with saturable elimination processes (9,15,24). Interestingly, studies in 
mice have demonstrated that in the absence of CrEL, a polyoxyethylated 
castor oil derivative used as formulation vehicle for i.v. drug administration, 
both distribution and elimination of paclitaxel appeared to be linear processes 
(26). Because plasma concentrations of CrEL in mice and humans are within 
the same range, it is likely that CrEL also plays a pivotal role in the nonlinear 
paclitaxel disposition in humans (27). The cause of the observed 
nonlinearity, however, has not yet been discovered, but possible 
explanations include CrEL-mediated inhibition of endogenous P-glycoprotein 
activity causing altered hepatobiliary secretion (10,7) and altered protein 
binding resulting from CrEL-induced lipoprotein dissociation (32). Recently, 
we have found in vitro that CrEL causes profound concentration-dependent 
alterations of paclitaxel distribution in human blood, possibly because the 
highly hydrophobic paclitaxel favors partitioning in CrEL micelles (31). Based 
on these findings, we speculated that the nonlinear kinetics of paclitaxel is 
not related to saturable tissue binding or Michaelis-Menten elimination 
kinetics, but is caused by dose and time-varying CrEL concentrations in the 
central compartment. In the present study, we carried out a comprehensive 
pharmacokinetic analysis of paclitaxel and CrEL in patients by measuring 
paired whole blood and plasma levels to discover the cause of the saturable 
kinetic processes, and present explicit modeling of the disposition of the 
compounds to permit a formal explanation of the observed phenomena. 
MATERIAL AND METHODS 
Patients and Treatment 
Patients with a histologically confirmed diagnosis of a malignant solid 
tumor for whom paclitaxel as monotherapy was a viable therapeutic option 
or for whom other treatment options were not available, were candidates 
for this study. Additional eligibility criteria were: age ~18 years; World 
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Health Organization performance status < 3; life expectancy of at least 3 
months; no previous treatment with taxanes; adequate bone marrow 
function (WBC count > 3.0x1 09/l, platelet count > 100x 1 09/L) , renal 
function (serum creatinine :::;;140 f!M and creatinine clearance ::::60 mL/min)' 
and hepatic function (serum bilirubin, alkaline phosphatase, aspartate 
aminotransfer-ase and alanine aminotransferase concentrations within 
normal limits); no pre-existing peripheral neuropathy graded > 1 according 
to NCI Common Toxicity Criteria. 
The study drug was formulated in a mixture of CrEl and dehydrated 
ethanol USP (1: 1, v/v) (Taxol; provided by Bristol-Myers Squibb, Woerden, 
the Netherlands) and diluted further into 500 ml of isotonic sodium chloride 
prior to dosing. Paclitaxel was administered every 3 weeks as a 3-h Lv. 
infusion at consecutive dose levels of 225, 175 and 135 mg/m2 (CrEl dose 
level, 18.8, 14.6, and 11.3 mL/m2 , respectively). Patients continuing 
treatment thereafter were given paclitaxel at a dose of 175 mg/m2 out of 
protocol. Premedication was uniform for all patients and consisted of (I) 
dexamethasone (10 mg Lv.), (i/) clemastine (2 mg Lv.) and (iii) ranitidine 
(50 mg Lv.), all given 30 min before start of paclitaxel administration. 
During chemotherapy, the patients did not use any other co-medication that 
might have interfered with paclitaxel disposition. The clinical protocol was 
approved by the Rotterdam Cancer Institute Review Board, and all patients 
signed informed consent before entering the study. 
Sample Collection 
Blood samples (approx. 5 ml) were obtained from all patients during 
all courses of treatment and collected in Vacutainer glass tubes containing 
143 USP units of lithium heparin as anticoagulant. Samples were obtained at 
the following time points: before dosing and at 1, 2, 3, 3.08, 3.25, 3.5, 
3.75,4,5,7,9, 11, 15, and 24 h after start of the infusion. After agitation, 
2-ml aliquots of whole blood were snap-frozen at _20DC at the patient site, 
and plasma was separated by centrifugation for 5 min at 4000xg (4 DC) and 
then stored at -80 DC. Complete stool collections were obtained from each 
patient up to 24 h after drug administration in polystyrene containers and 
stored immediately at -80DC. Weighted feces samples were homogenized 
individually in 4 volumes of deionized Milli-Q-UF water (Millipore, Milford, 
MA) using five 1-min bursts of an Ultra-Turrax T25 homogenizer OKA-
labortechnik, Dottingen, Germany) operating at 20,500 rpm. Aliquots of 
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feces homogenates (200 /-tl) were diluted 5-fold with drug-free human 
plasma prior to further sample processing. 
Drug Analysis 
Paclitaxel (batch: 494034, purity: 98.3% by reversed-phase high-
performance liquid chromatography [HPlC]) and docetaxel, used as internal 
standard, were provided by Bristol-Myers Squibb and Rh6ne-Poulenc Rorer 
(Vitry-sur-Seine, France), respectively. Reference stocks of pure 6a-
hydroxypaclitaxel, 3' -p-hydroxypaclitaxel and 6a,3' -p-dihydroxypaclitaxel 
were obtained by isolation and purification of a patient feces sample, as 
described (25). Stock solutions of each of the taxanes were prepared at 1.0 
mg/ml in dimethyl sulfoxide. Concentrations of paclitaxel in whole blood and 
plasma were determined using isocratic reversed-phase HPlC with UV 
detection (Ie = 230 nm) with a lower limit of quantitation of 10 ng/ml, as 
reported (28). The same assay methodology was also used for 
determination of paclitaxel in whole blood, and was validated as described 
(28) using spiked quality control samples containing 40, 200, 400, and 
15,000 ng of paciitaxel/mL. The within-run precision and between-run 
precision ranged from 2.23-8.74% and 1.81-8.07% (n = 14 at each of the 
concentrations), respectively, with a mean percentage deviation from 
nominal values less than ±3.30%. A potential CrEl-concentration 
dependency in extraction recovery of paclitaxel from whole blood was 
tested by repeated analysis of spiked whole blood (nominal concentration: 
1000 ng/ml) containing 0, 0.1, 0.5, 1.0, 5.0 or 10 /-tl of CrEL/mL. The 
mean (±SD) recovered concentrations in these samples were 1037±28.4, 
1067±33.7, 1064±7.91, 1074±1.90, 1041±35.1 and 1057±6.71, 
respectively, with no trend in significant deviations from the control value 
(p= 0.194; n = 16 at each CrEl concentration). The detector response of 
the internal standard docetaxel, as measured by the peak height, was also 
not significantly different during analysis of either plasma or whole blood 
samples with mean values of 44,019±4739 /-tV and 43, 728±541 0 /-tV, 
respectively (P=0.525; n=164 for each matrix). These data were 
considered acceptable for analysis of paclitaxel in whole blood samples 
obtained from patients for the conduct of the present study. 
For determination of paclitaxel and its hydroxylated metabolites in 
feces homogenates, this HPlC methodology was further modified as 
described (8). In brief, standard curves were prepared in drug-free human 
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plasma and were expanded to encompass concentrations between 0.1 and 5 
f!g/mL. A 1-mL aliquot of standard or plasma-diluted sample was mixed for 5 
min with 100 f!L of 10 f!g/mL docetaxel in 50% (v/v) methanol in water and 
5 mL of 20% (v/v) acetonitrile in n-butyl chloride. After centrifugation for 5 
min at 4000xg (4°C), the entire upper organic phase was separated and dried 
under nitrogen at 60°C. The dried residue was reconstituted in 125 f!L of 
50% (v/v) methanol in water by vortex-mixing, and following a brief 
centrifugation step, 100 f!L of the clear supernatant was injected into the 
HPLC system from low-volume glass inserts by a temperature-controlled 
Waters 717Plus autosampling device (Milford, MA). Chromatographic 
separations were performed at 60°C on an Inertsil ODS-80A column 
(150x4.6 mm internal diameter, 5 f!m particle size; GL Science, Tokyo, 
Japan) and a guard column (4.0x4.0 mm, 5 f!m) packed with LiChrospher 
100 RP-18 material (Merck, Darmstadt, Germany). The mobile phase 
consisted of methanol:tetrahydrofuran:0.2 M aqueous ammonium hydroxide 
(60:2.5:37.5, v/v/v) with the pH adjusted to 6.0 (formic acid), and was 
degassed by ultrasonication prior to use. The flow-rate was set at 1.0 
mL/min, and the eluent was monitored at an absorption wavelength of 230 
nm with a Spectra Physics UV-200 detector (San Jose, CA). Integration of 
chromatographic data and calculation of calibration graphs was performed as 
described (28). A formal method validation was performed by repeat analysis 
of quality control samples spiked to contain 0.50, 2.5, 10, and 20 f!g of 
paciitaxel/mL on 4 consecutive days along with a 7-point calibration curve 
processed in duplicate. There were no endogenous compounds in any of the 
studied patient specimens that could have interfered with the peaks of 
interest in the system. Standard curves were fitted by an equation with 
proportional weighting, and were strictly linear in the tested range, with an 
R2 value greater than 0.995 in all cases. The within-run precision and 
between-run precision ranged from 2.49-7.82% and 1.68-10.6% (n=20 at 
each of the concentrations), respectively, with a mean percentage deviation 
from nominal values less than ±8.23%. 
The analytical method for determination of CrEL concentrations in 
plasma was based on binding of the surfactant to the Coomassie Brilliant 
Blue G-250 dye in protein-free plasma extracts by measuring the change in 
ratio of absorbances at 595 nm over 450 nm (2,29). For this purpose, 5011L 
samples of plasma were deproteinized by addition of 500 ,uL of acetonitrile in 
Teflon-capped 12-mL tubes followed by vortex-mixing for 1 min. Next, 2 mL 
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of n-butyl chloride were added followed by vigorous mixing for 5 min. The 
organic layer was then separated by centrifugation for 5 min at 4000 x g, 
transferred to a clean 1 O-ml glass tube, and dried under nitrogen at 60°C for 
30 min. The residue was reconsituted in 50 pl of water by vortex-mixing, 
and a 25-pl volume was pipetted into a 96-well flat-bottom cluster (Costar 
Corp., Cambridge, MA). Finally, 250 pl of water-diluted (1 :4, v/v) Coomassie 
Brilliant Blue G-250 reagent were added, and the absorbance maximum of 
the dye at 595 nm after binding to CrEl, and the simultaneous decrease in 
absorbance at 450 nm were measured within 24 h against a reagent blank 
using a Bio-Rad Model 550 automated microplate reader (Bio-Rad 
laboratories, Hercules, CA). The lower limit of this procedure is 0.50 pLlml, 
and over the entire range studied (up to 10.0 pLlml), the method has 
excellent specificity, accuracy (S;6.33% relative error), and precision « 1 0%) 
(2). 
Pharmacokinetic Analysis 
The pharmacokinetics of paclitaxel were initially evaluated by a non-
compartmental method using the Siphar package (version 4.0; SIMEO, 
Creteil, France). The actual times of drug intake and blood sampling were 
taken into account. Peak drug levels (Cmaxl were determined by visual 
inspection of the concentration-time data. The area under the concentration-
time curve (AUC) from zero to the last sampling time point with a detectable 
concentration (Clast) was calculated by the linear trapezoidal rule. The 
apparent half-life of the terminal disposition phase (T1/2) was defined as In2/A, 
in which A was the elimination rate constant of the terminal phase, estimated 
by a least-squares regression analysis of the final 3 data points of the 
concentration-time profiles. Total body clearance (Cl) was calculated as the 
quotient of dose (expressed in mg/m2 ) and AUC extrapolated to infinity by 
dividing Clast by A. The relationships between paclitaxel dose and Cmax or AUC 
in plasma and blood were evaluated in a scattered plot with linear and 
nonlinear fitting using Graphstatics Plus (Manugistics Inc., Rockville, MA). 
The AUC of CrEl in plasma was also calculated using the Siphar package as 
described (30). 
Statistical Considerations 
All pharmacokinetic parameters are reported as mean values ± SO. 
Since multiple measurements were performed at different times on the 
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same patients, comparisons between the sets of observations were based 
on within subject differences. Therefore, variation between subjects, which 
is usually considerable, does not affect our ability to distinguish differences 
between the sets of observations, which here relate to the 3 paclitaxel dose 
levels. The effect of drug dose on the apparent paclitaxel clearance in 
plasma and blood was evaluated using a Friedman's two-way analysis of 
variance test, with the level of significance set at P< 0.05. Statistical 
analysis was performed using the Number Cruncher Statistical System 
(NCSS) software package (version 5.X; J. L. Hintze, Kaysville, UT, 1992). 
Model Development 
Paclitaxel in blood was assumed to exist in the following 
pharmacokinetically distinguishable forms: unbound (Cunbound)' bound to 
plasma protein (Cbound), in micellar form together with CrEL (Cmieellar), and 
bound to or distributed into red blood cells (Crbe). Further, Cunbound was 
assumed to be in equilibrium with tissues. For some tissues and organs, the 
rate to attain this equilibrium may be fast and therefore part of the central 
volume of distribution. For other tissues and organs it may be slow, where 
the number of peripheral compartments will reflect the heterogeneity of the 
rate of equilibration between tissues of importance for the distribution of 
paclitaxel. As neither Cunbound nor Cbound was measured separately and since 
the relationship between the two was assumed linear and instantaneous, 
there was no possibility to separately characterize these based on 
pharmacokinetic data. However, no approximation of the model was 
necessary because of this, the only consequence being that the relevant 
parameters will be based on the sum of the two concentrations rather than 
on Cunbound alone. Thus, Cnon~mieellar is the sum of Cunbound and Cbound' Cplasma is 
the sum of Cmieellar and Cnon~mieellar' whereas Cblood is the hematocrit-weighted 
average of Crbe and Cplasma' 
The only feature that distinguishes the model used from standard 
linear compartmental pharmacokinetic models is the possibility of paclitaxel 
to be included in micelles and thereby undergo a change in the 
pharmacokinetic properties. In the present model, these CrEL-paciitaxel 
micelles were assumed to exist in plasma, and with plasma rapidly 
equilibrating organs and tissues. The initial model for Cmieellar assumed it to 
be proportional to both the unbound paclitaxel concentration and the total 
CrEL concentration. Several modifications to this assumption were 
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explored, including nonlinear dependence on paclitaxel and/or CrEL 
concentrations as well as time dependent changes in the proportionality 
constant governing the relationship. The information about the relationship 
between paclitaxel, CrEL and Cmicellar as entered into the model came from 
the nonlinear behavior of the plasma concentration-time curve and the 
varying ratios of Cblood to Cplasma' Therefore, the data were best utilized in a 
simultaneous fit of the model to both. The ratio between Crbc and Cnon-micellar, 
a necessary part of the model, was estimated as the parameter 8rbc ' 
Whereas nonlinear mixed effects ('population') modeling is the accepted 
method of analyzing sparse pharmacokinetic data, rich pharmacokinetic 
data sets are more commonly analyzed by individual modeling. However, 
when complex models are used, there is a gain in analyzing data from 
several subjects together even if data are rich (11,23). Indeed, if many 
parameters are to be estimated from a single individuals pharmacokinetic 
profile, there are usually some parameters for which the information is 
slight. Thus, in a sense, with complex pharmacokinetic models, individual 
data are no longer 'rich' in information. This analysis has been performed as 
population modeling using the first-order method as implemented in the 
NONMEM program (version V; S.L. Beal and L.B. Sheiner, San Francisco, 
CA, 1998). As the number of individuals was small, there has been no 
model building in the traditional sense, where both the structural, statistical 
and covariate models are refined in an integrated process. Covariates, apart 
from the CrEL concentrations, were absent. Interindividual variability 
parameters can be expected to be poorly estimated, but will be included in 
the model as long as the termination is successful and can provide 
estimates of parameter precision. Interindividual variability was included as 
log-normally distributed and residual variability was initially modeled as 
combined additive and proportional, where either component may be 
omitted if superfluous. The assessment of statistical significance of the 
additional parameters was based on the difference between the objective 
function values (part of the output from NONMEM) between models being 
compared. This difference is minus twice the log likelihood for the models 
and is approximately x-squared distributed. A difference of greater than 
10.83 (one degree of freedom) is significant at the 0.1 % level, which was 
used in discriminating between hierarchical models. 
Introducing the CrEL concentrations into the model requires 
knowledge of CrEL at all time points, including those in-between sampled 
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CrEL observations. In the present modeling, we have used the individual 
predictions from a two-compartment model generated as a part of a 
separate analysis of CrEL pharmacokinetics in a larger population that 
included 67 complete concentration-time courses (not shown). Although 
this model is a simplification of CrEL pharmacokinetics, it adequately 
describes the individual profiles, which is what was needed for the present 
purpose. 
Table 1 Characteristics of patients undergoing concomitant blood and 
plasma sampling during and after paclitaxel infusion 
Characteristic No. of patients 
Total no. 7 
No. of courses 19 
Age (years) 
Median 54 
Range 32 - 64 
Gender 
Male 3 
Female 4 
WHO * * performance status 
0 2 
1 4 
2 1 
Primary tumor site 
Bladder 3 
Breast 1 
Lung 1 
Unknown 1 
Weak tissue (sarcoma) 1 
Pretherapy clinical chemistry * 
serum creatinine (f1M) 92 (69 - 138) 
total bilirubin (f1M) 9 (3 - 15) 
ASAT (units/L) 19(10-28) 
ALAT (units/L) 16 (6 - 31) 
total protein (mg/mL) 76 (74 - 78) 
serum albumin (mg/mL) 42 (34 - 49) 
* Mean values with range in parentheses. 
** WHO, World Health Organization; ASAT, aspartate aminotransferase; ALAT, alanine 
aminotransferase. 
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RESULTS 
Patient Characteristics 
Seven patients (3M/4F) with various malignant solid tumors were 
studied (Table 1). The median age was 54 years (range, 32-64 years), and 
all patients had normal hematopoietic and liver functions at the time of 
study. One patient had slightly increased serum creatinine values and a 
lower creatinine clearance (138 f.tM and 57 mL/min, respectively), but was 
accepted based on the known limited role of renal function in paclitaxel 
disposition (8). Two patients did not receive the last course (135 mg/m2) 
because of progressive disease after two paclitaxel courses. Eventually, 19 
courses were available for pharmacokinetic evaluation. 
Figure 1 
:e 10 A 
..:: 
c 
0 
~ 
c 
T T ., u tj~ c 0 u 0.1 ;; 
.. 
. ~ 
u 
'" ... 0.01 
0 5 10 15 20 25 30 
time (h) 
:e 10 B 
..:: 
" ~ 
f! 
C 
" u c: 
0 
u 0.1 ;; 
>< .~ 
u 
'" ... 0.01 
0 5 10 15 20 25 30 
time (h) 
Plasma (panel A) and blood (panel B) concentration-time profiles of paclitaxel in 
patients treated with paclitaxel at dose levels of 135 mg/m2 (0), 175 mg/m2 (e) 
and 225 mg/m2 (L>.). Data are presented as mean values (symbols) ± SD (error 
bars). 
187 
Chapter 8 
------------------------------------------------------------
Paclitaxel Blood Distribution 
The mean plasma and blood concentration-time profiles of paclitaxel at 
the three different dose levels tested are displayed in Fig. 1. The relationships 
between the administered dose and paclitaxel Cmax and AUC in plasma 
indicated a substantial deviation from linearity (Fig. 2A), whereas this 
disproportionality was less pronounced with data based on whole blood 
measurements (Fig. 28). 
Figure 2 
188 
14 A 12 
i' 
2: 10 
= E B (.) 
a; 
" 
6 0 
.~ 0 m 
.,. .... U 4 
"t--l' " c. 2 
0 
0 50 100 150 200 250 300 
dose (mg/m') 
40 B 
.c 
:Ii 30 
2: 
(.) 
::l 
« 20 fI 
a; 0 • 
--
" 
~ ,A __ ' 
.~ /~--r'- ~ u 10 
II! 
C. 
0 
0 50 100 150 200 250 300 
dose (mg/m') 
Relationships between the administered dose and paclitaxel Cm,x (panel A) 
and paclitaxel AUC (panel B) in plasma (0) and whole blood (A). Dotted 
lines indicate linearity of the relationships in case of proportional increases 
of Cm,x and AUC with dose. 
Disposition of pac/itaxe/ in humans 
Table 2 Summary of non-compartmental paclitaxel pharmacokinetics * 
Dose* * Matrix Cmax *** AUC Cl T1/2 
(mg/m 2) (tiM) (tlM.h) (Llh/m 2) (h) 
135 
175 
225 
* 
** 
*** 
plasma 3.04±0.493 9.62±1.43 16.7±2.54 7.70±4.15 
blood 2.63±0.387 8.06±2.92 18.8±2.30 8.15±2.92 
plasma 4.54±1.73 14.3±3.40 14.0±3.76 7 .17±1 .92 
blood 3.31±0.883 11.8±2.30 17.9±3.64 6.96±1.63 
plasma 8.75±2.76 28.7±7.04 9.75±2.78 6.77±2.45 
blood 5.58±1.32 17.9±4.81 15.7±4.34 5.99±1.67 
Data were obtained from 7 patients after treatment with a 3-h i.v. infusion of 
paclitaxel, each receiving consecutive 3-weekly doses of 225 (n = 7), 175 (n = 7) 
and 135 mg/m2 (n = 5). Pharmacokinetic parameters represent mean values ± SO. 
Corresponding dose levels of CrEl, 11.3, 14.6, and 18.8 mL/m2, respectively. 
Cmax< peak concentration; AUC, area under the concentration-time curve up to the 
last sampling-time point with detectable paclitaxel concentration; Cl, apparent 
clearance; T 1I2 , apparent half-life of the terminal disposition phase. 
In line with previous findings (9,15,24), the apparent plasma 
clearance of paclitaxel was clearly dose-dependent and significantly 
decreased from 16.7±2.53 Llh/m 2 (at 135 mg/m2) to 9. 75±2. 78 Llh/m 2 (at 
225 mg/m2; P= 0.030) (Table 2). The whole blood clearance of paclitaxel, 
however, appeared to be independent of the administered dose (P=0.063), 
and averaged 17.5±3.43 Llh/m 2 • Examination of blood:plasma concentration 
ratios (Cb/Cp) revealed that the discrepant kinetic profiles of paclitaxel in 
plasma and blood is most closely associated with a concentration-dependent 
change in movement of drug within the central compartment during the 
distribution phase. At Cmax, Cb/Cp ratios decreased in a dose-dependent 
manner from 0.83±0.11 (135 mg/m2) to 0.80±0.18 (175 mg/m2) and 
0.68±0.07 (225 mg/m2). The estimated terminal half-life was relatively 
consistent in all subjects and not different between dose levels, exhibiting 
mean values of 7.21±0.623 hand 6.91±0.485 h for plasma and blood, 
respectively (plasma versus blood, P=0.69). This finding is further 
substantiated by the fecal recovery patterns of paclitaxel and its three main 
hydroxylated metabolites during the first 24 h after initiation of the infusion, 
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that were qualitatively and quantitatively independent of the dose given. Fecal 
excretion of unchanged drug accounted for only 2.8%, 3.7% and 3.7% of 
the total dose administered at the 135, 175 and 225 mg/m2 dose levels, 
respectively. This is in line with previous findings (31 L and with murine data 
indicating that fecal excretion pathways of paclitaxel are independent of the 
administered dose and the vehicle used for drug formulation (27). 
CrEL Pharmacokinetics 
The plasma clearance of CrEL at the tested dose levels of 18.8, 14.6, 
and 11.3 mLlm2 was independent of the administered dose (P= 0.61) and 
averaged 320±53.2 mLlh/m2, which is within the same range as described 
for this compound previously when based on calculations using AUCo_t (30). 
Mean CrEL plasma concentration-time profiles at the various dose levels are 
shown in Fig. 3. 
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Figure 4 
1 
Pharmacokinetically distinguishable forms of paclitaxel in blood 
compartment assumed to exist in the proposed model for paclitaxel 
pharmacokinetics. Double-headed arrows denote processes with assumed 
instantaneous equilibrium. The star indicates a non-linear process. 
Pharmacokinetic Model 
We sought to define a pharmacokinetic model that would explain the 
nonlinearity observed in paclitaxel plasma disposition. The distribution of 
paclitaxel to tissues was best described by a three compartment model 
(based on considerations presented in Fig. 4), and was characterized by the 
following parameters (± SD): inter-compartmental clearance for peripheral 
compartment one, 30 ± 8 Llh; volume of paclitaxel for peripheral 
compartment one, 51 ± 14 L; inter-compartmental clearance of paclitaxel for 
peripheral compartment two, 34 ± 8 Llh; volume of paclitaxel for peripheral 
compartment two, 340 ± 81 L. The central volume of distribution of 
paclitaxel was 41 ± 14 L, whereas the proportionality constant relating Crbc 
to Cnon-micellar was 1.7 ± 0.2. The overall clearance of paclitaxel based on C non-
micellar was 71 ± 13 Llh. The relationship between Cmicellar and Cnon-micellar could 
be well described by the following function: 
Cmicellar = Cnon-micellar X CCrEL X 8micellar x {1 - (T x 8 time)} 
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where CCrEl is the CrEL plasma concentration in )lUmL, T is time after start 
of infusion, and Smicellar and Stime are parameters estimated to be 0.97 ± 0.22 
and 0.039 ± 0.004/ respectively. Before arriving at this final model for the 
relationship, several others were tried, including those containing functions 
with nonlinear relationships for both Cnon-micellar and CCrEl' The fit of the 
current model to the observed paclitaxel plasma and blood concentration 
gave a good description of the data without any trends in the residuals over 
time or paclitaxel concentration (Fig. 5). 
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The presently developed model gave an unbiased prediction of the 
Cb/Cp ratio over time (Fig. 6A), and it could also predict the free fraction of 
paclitaxel at any CrEL concentration compared to the free fraction in 
absence of CrEL. This estimated ratio shows good agreement with 
previously published data obtained from a single patient treated with 
paclitaxel at a dose level of 157.5 mg/m2 (31) (Fig. 6B). An example of 
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concentration-time data for the various pharmacokinetically distinguishable 
forms of paclitaxel in blood from a representative patient is given in Fig. 7. 
Figure 6 
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free fraction of paclitaxel in the presence of CrEL at various concentrations 
[i.e. Cnon.mieell" I (Cnon.mieell" + Cmicell,,)]' The continuous line is based on data 
from Ref. 31 [see Table 3 therein], whereas the squares are model based 
estimates for all observations up to 20 h after paclitaxel administration 
(panel B). 
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Paclitaxel concentration-time profiles using model-fit curves in a 
representative patient treated with paclitaxel at a dose level of 175 mg/m2 • 
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and Cboundl (0), Crnieellar (0) and C,be (II). 
DISCUSSION 
By prospectively measuring paclitaxel concentrations in whole blood 
and plasma in cancer patients given different dose levels of paclitaxel and 
serving as their own control, we demonstrated that the AUC of paclitaxel in 
whole blood is a linear function of the dose administered. By calculating 
paclitaxel Cb/Cp ratios, we found that the fraction of this drug that is bound 
in plasma changes appreciably with concentration in the concentration range 
of interest. Recently, we showed in vitro that CrEL causes a profound 
alteration of paclitaxel accumulation in erythrocytes in a concentration-
dependent manner, by reducing the free drug fraction available for cellular 
partitioning, thereby suggesting that paclitaxel trapping occurred in CrEL 
micelles (31). These findings were later independently confirmed by 
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Knemeyer, et al. (17) and Van Tellingen, et al. (33) using similar in vitro 
experiments. Yet, the findings of our present study demonstrate for the first 
time that CrEl affects the clinical pharmacokinetics of paclitaxel by a 
disproportional accumulation process in plasma, and lends further support 
to our prior supposition that the ability of CrEl to modulate the murine 
disposition of paclitaxel may have important clinical ramifications. 
Moreover, our data indicate that the nonlinear pharmacokinetics of 
paclitaxel are not related to saturable tissue binding but are caused by 
paclitaxel-dose related levels of CrEl in blood. Although our study 
population included only seven patients, the results of the paclitaxel plasma 
pharmacokinetics were highly consistent with previously described data by 
Gianni, et al. (9) obtained from a larger group of patients. For example, the 
paclitaxel plasma AUC varied from 10.9±1.1 to 1B.5±3.0 and 24.3±6.B 
/-lM.h in their study versus 9.6±1.4, 14.3±3.4 and 2B.7±7.0 /-lM.h in our 
study, at dose levels of 135, 175 and 225 mg/m2, respectively, indicating 
that our small patient population was indeed representative. 
The other speculated causes of the nonlinearity of paclitaxel as 
mentioned in the introduction became unlikely by our findings; the 
established decrease in Cb/Cp ratio of paclitaxel in our study exclude the role 
of P-glycoprotein (10), because modulation of endogenous P-glycoprotein 
expressed in certain blood cells (e.g. white blood cells) by CrEl should lead 
to an increase of this ratio. The hypothesis of altered P-glycoprotein-
mediated hepatobiliary secretion is based on experiments in an isolated 
perfused rat-liver system in which paclitaxel is administered as a bolus dose 
both in the absence of CrEl and after the administration of either BO or BOO 
/-ll of CrEl (7). Total and biliary clearance of paclitaxel decreased in a dose-
dependent manner not through alterations in the metabolism of paclitaxel 
under influence of CrEl but logically by the same principle as defined in our 
study, i.e. by micellar formation preventing paclitaxel from reaching the sites 
of metabolism and excretion. Altered protein binding as primary cause of the 
nonlinear paclitaxel pharmacokinetics (32) was already excluded as an 
explanation by our previous in vitro study, in which the CrEl-induced 
alteration of paclitaxel accumulation in erythrocytes was also observed in the 
absence of any plasma proteins (31). 
The model that we presented here accurately described the 
pharmacokinetics of paclitaxel in patients at all dose levels studied, and 
could be proven useful for prediction of paclitaxel disposition at as yet 
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untested dose levels. In the past, the first attempts to model the nonlinear 
pharmacokinetics of paclitaxel used a nonlinear distribution mechanism and 
a nonlinear elimination based on plasma measurements (24). Later a model 
where the saturable process was replaced by a saturable binding to sites 
outside plasma was shown to describe data equally well, and be more 
probable based on the known pharmacologic properties of paclitaxel (9). In 
the present report we have used an alternative approach for describing the 
nonlinear pharmacokinetics of paclitaxel. As opposed to the previous 
models, only one nonlinear component was required to describe both the 
apparent nonlinear distribution and elimination kinetics. The sequence of 
models developed for paclitaxel illustrates the strive for mechanistic models 
that is a dominant principle in contemporary modeling. It also illustrates the 
principle that to discriminate between complex models, there is often a 
necessity to obtain information on more than one component of the 
system. In this case, we have, in addition to CrEL levels, measured both 
blood and plasma concentrations. Although it cannot be excluded that the 
saturable binding of paclitaxel to tubulin may play a role in its 
pharmacokinetic behavior (14), the present model can explain not only the 
nonlinear distribution and elimination of paclitaxel, but also the changing 
Cb/Cp ratio, something that no previous model had explained. We have not 
performed a comparison between the fit of the present model to data with 
the fit that previous models might have given. One reason for this is that 
the previous models from the nature of their development had no 
component for predicting the blood concentrations. As blood concentrations 
are an integral part of the present model, without which the model cannot 
be evaluated, no direct comparison could be made. 
Our model makes several assumptions and approximations that may 
not be necessary if additional information on these processes are being 
gathered. Three assumptions regarding the micellar binding may be 
particularly approximate. Firstly, the amount of paclitaxel in micellar form is, 
at any time, assumed directly proportional to the total concentrations of the 
drug and CrEL. We know that at very low CrEL concentrations micelles 
cannot be formed, although it has been shown that in aqueous solution 
CrEL micelles can persist for several hours after dilution below the critical 
micellar concentration, estimated to be 0.009% (w/v) at equilibrium (16). It 
appeared, however, that this critical micellar concentration in plasma is low 
compared to the range of concentrations experienced during the 
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observation period of these treatments. Secondly, even above the critical 
micellar concentration there may be deviation from the simple direct 
proportionality that was postulated. Although literature data on CrEl 
micellar kinetics are lacking, preliminary experiments indicated that the in 
vitro equilibrium between paclitaxel in micelles and free paclitaxel is reached 
within 1 min,l and thus can be considered instantaneous on the time scale 
of paclitaxel pharmacokinetics. It is possible, however, that with time CrEl 
is able to form micelles with other components, such that less is available 
for forming paclitaxel micelles. Thirdly, the change in the micellar 
concentration with time is modeled as a linear relationship although it may 
well be a more complex function of both degradation of CrEl and/or binding 
to other blood constituents. Indeed, we have found recently, that 
compounds such as CrEl and polysorbate 80 are prone to a degradation 
pathway induced by serum carboxylesterases that causes a release of fatty 
acids (ricinoleic acid in case of CrEl and oleic acid in case of polysorbate 
80) (34). Although this metabolic route is likely to be very slow for CrEl, 
given the long terminal half-life of CrEl of around 80 h (30), it is likely to 
impact on the CrEl-paciitaxel interaction. Hence, the assumptions regarding 
linear plasma protein and red cell binding as well as linear tissue distribution 
and elimination may in the end prove false under further scrutiny. In the 
present data set, however, such nonlinearities were not indicated. It is also 
noteworthy in this context that plasma protein binding of paclitaxel in 
human samples, determined by both equilibrium dialysis and ultrafiltration 
techniques, has been shown previously to be independent of the paclitaxel 
concentration within the therapeutic range associated with 3-h Lv. infusions 
(18). We are currently exploring the relevance of this principle for the in 
vivo situation by defining free (unbound) area-dose relationships in cancer 
patients treated with paclitaxel. 
Our current findings will have significant implications for 
interpretation of the relationship between the pharmacokinetic parameters 
and pharmacodynamic outcome of paclitaxel treatment. Over the last few 
years, various hypotheses regarding relationships between plasma 
pharmacokinetics and hematological toxicity (e.g. neutropenia) have been 
postulated, including those using a step function (threshold model) (12,15) 
and more general models that used a nonlinear continuous function for the 
time-dissociated component (13,22). A common feature of these models 
1 Sparreboom A, Verweij J: unpublished data. 
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has been the use of the total paclitaxel plasma concentration, which is, in 
view of our current findings, unlikely to be the exposure measure best 
linked to observed toxicity profiles. Since the nonlinear pharmacokinetics of 
paclitaxel in plasma can be explained by CrEL concentration-dependent 
changes in drug movement within the central compartment, the effects of 
entrapment of paclitaxel in the plasma compartment will be less with 
prolonged (e.g. 24-h) infusion schedules associated with lower 
concentrations of CrEL (35). Thus, total plasma levels of paclitaxel 
measured in these schedules will represent a higher fraction of free 
paclitaxel, and this may, in part, explain the increased incidence of severe 
hematological toxicity seen in the 24-h infusion schedules as compared 
with infusion of the same dose over 3 h (6,9). 
The existence of CrEL in blood as large polar micelles with a highly 
hydrophobic interior may also have important consequences for other drugs 
that are formulated in this vehicle. CrEL is currently used in i.v. preparations 
of many hydrophobic drugs including other anticancer agents (e.g. 
teniposide, didemnin B, halomon), anesthetics, vitamins and immuno-
suppressive agents (e.g. cyclosporin A, tacrolimus). It is admissible that the 
pharmacokinetic behavior of these drugs will also be influenced by the 
formulation vehicle, although the impact is likely to be smaller than for 
paclitaxel, since the amounts of this vehicle co-administered are much less. 
For example, cyclosporin A is known to exhibit disproportional dose-AUC 
relationships, and it can be postulated this phenomenon is related, in part, 
to the presence of CrEL and micellar entrapment similar to that described 
here for paclitaxel, in addition to saturable binding to erythrocytes (19). It 
can also be anticipated that CrEL may alter the distribution of some 
compounds co-administered with paclitaxel. For example, clinically 
significant pharmacokinetic interactions between paclitaxel and doxorubicin 
have been reported (10), and both preclinical and clinical evidence suggests 
that these are directly attributable to CrEL (4,21,37). Similarly, differences 
in the plasma concentration-time profile of CrEL imparted by the paclitaxel 
administration schedule could also account for the apparent sequence and 
schedule-dependent effect of paclitaxel on doxorubicin pharmacokinetics 
(5). 
In conclusion, we have shown that micellar encapSUlation of 
paclitaxel in CrEL can, as a single principle, explain both the nonlinear 
distribution and nonlinear elimination processes of paclitaxel in plasma. This 
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micellar formation is likely to affect other hydrophobic drugs either those 
formulated in CrEL themselves, or those given in combination with 
paclitaxel, leading to changes in the pharmacokinetic and pharmacodynamic 
behavior of these compounds that can have significant clinical implications. 
Our pharmacokinetic model could accurately describe the generated 
paclitaxel blood and plasma data, and will help guide further development 
and refinement of clinical protocols. Future studies will focus on defining 
the exposure measure best linked to paclitaxel-induced antitumor effects 
and toxicities, not only to expand our understanding of paclitaxel 
pharmacology but to provide insight into considerations of optimal dosage 
and schedule of drug administration. Ultimately, a more rational and 
selective chemotherapy with paclitaxel should be possible and thus the 
treatment of cancer improved. 
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Over the last 10 years the taxanes paclitaxel and docetaxel, both 
belonging to the so-called naturally occurring drugs because of their origin 
from the yew trees, have obtained a prominent place in cancer treatment. 
Many publications have discussed their pharmacodynamic characteristics 
and pharmacokinetic behavior as well as attempts to increase activity by 
combining them with various other agents. Combined therapy also has to 
be evaluated on pharmacodynamic and pharmacokinetic modulations. This 
thesis highlights the last subject with specific attention to two particular 
problems: 1) the deliberate pharmacologic modulation of docetaxel by the 
new P-glycoprotein inhibitor R101933, and 2) the unintended pharmaco-
kinetic modulation of paclitaxel by its formulation vehicle Cremophor EL. 
P-glycoprotein and MRP (multidrug resistance-associated protein), 
both transmembrane transport proteins, have been identified to be involved 
in the phenomenon of multidrug resistance. The clinical relevance of these 
drug transporters and the attempts to inhibit them are reviewed in chapter 
1 with specific focus on P-glycoprotein and its intentionally designed 
'second generation' inhibitors. Potential explanations of the limited clinical 
success rate of these inhibitors are given with pharmacokinetic interaction 
as the first and maybe most important one. This interaction results in 
unintended and unacceptable increases in severity and frequency of side-
effects of the co-administered anticancer drug due to competition at the 
level of cytochrome-P450 3A isozymes, the major metabolic route of many 
drugs. Recommendations for the development of new P-glycoprotein 
inhibitors and for the design of future studies with these agents are 
provided. 
Chapter 2 describes a phase I and pharmacokinetic study with the 
new P-glycoprotein inhibitor R101933, the major metabolic pathway of 
which is cytochrome-P450 3A4 independent, in combination with 
docetaxel. Fifteen patients received oral R1 01933 alone at a dose escalated 
from 200 to 300 mg twice daily (cycle 0), an escalating intravenous dose 
of docetaxel (60, 75, 100 mg/m 2) as a 1-hour infusion (cycle 1), and the 
combination of both (cycle 2 and further). Dose limiting toxicity consisting 
of mucositis and neutropenic fever was reached at the docetaxel dose of 
100 mg/m2 combined with R1 01933 300 mg twice daily, and the maximum 
tolerated dose was set at docetaxel 100 mg/m2 with R1 01933 at a dose of 
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200 mg twice daily. Plasma concentrations of R 101933 achieved in 
patients were in the same range as those required in preclinical rodent 
models to overcome paclitaxel resistance. The plasma pharmacokinetics of 
docetaxel were not influenced by the R1 01933 co-treatment at any dose 
level tested, as indicated by plasma clearance values of 26.5 ± 7.78 Llh/m2 
and 23.4 ± 4.52 Llh/m2 (p= 0.15) in cycle 1 and 2, respectively. These 
findings indicated that the contribution of a P-glycoprotein inhibitor to the 
activity of anticancer chemotherapy can now be assessed in patients 
independent of its effect on anticancer-drug pharmacokinetics. 
In five patients, apart from plasma samples also complete stool 
collections for docetaxel analysis were obtained for up to 31 h after the 
start of drug administration during cycle 1 and 2. This way the role of P-
glycoprotein in the metabolic disposition of docetaxel in humans could be 
studied as described in chapter 3. The cumulative fecal excretion of 
docetaxel was markedly reduced from 8.47±2.14% (mean±SD) after dosing 
the single agent to less than 0.5% in the presence of R101933 
(p= 0.0016). Levels of the major cytochrome P450 3A4-mediated 
metabolites of docetaxel in feces were significantly increased following 
combination treatment with R1 01933 (P= 0.01 0), indicating very prominent 
and efficient detoxification of re-absorbed docetaxel into hydroxylated 
compounds before reaching the systemic circulation. The similarity of the 
terminal disposition phases in plasma of docetaxel between treatment 
courses as shown in chapter 2 indicated that the reduced fecal excretion of 
the parent drug in the patients receiving R101933 is unlikely related to 
diminished (P-glycoprotein-mediated) biliary secretion. It is more likely a 
consequence of intestinal P-glycoprotein playing a principal role in the fecal 
elimination of docetaxel by modulating re-absorption of the drug following 
hepatobiliary secretion. In addition, the results indicate that inhibition of P-
glycoprotein activity in normal tissues by effective modulators, and the 
physiological and pharmacological consequences of this treatment, cannot 
be predicted based on plasma drug monitoring alone. 
The study of docetaxel in combination with the orally administered 
R101933 described in chapter 2 indicated that a further increase of the 
level of P-glycoprotein inhibition could not be reached by oral administration 
due to low oral bioavailability of R 101933. Therefore, chapter 4 presents a 
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study to assess the feasibility of combining docetaxel with intravenously 
administered Rl01933. Treatment consisted of R101933 Lv. alone at a 
dose escalated from 250 to 500 mg on day 1 (cycle 0), docetaxel 100 
mg/m 2 given as a 1-hour infusion on day 8 (cycle 1) and the combination 
given every three weeks thereafter (cycle 2 and further). Twelve patients 
were entered of whom nine received the combination treatment. Single 
treatment with R 101933 Lv. was associated with minimal toxicity 
consisting of temporary drowsiness and somnolence. Dose limiting toxicity 
consisting of neutropenic fever was seen in cycle 1 as well as in cycle 2 or 
further at both dose levels of R101933, and was due to docetaxel. The 
plasma pharmacokinetics of docetaxel did not change by co-administration 
of R101933 at both dose levels tested, as indicated by plasma clearance 
values of 22.5 ± 6.2 Llh/m 2 and 24.2 ± 7.4 Llh/m 2 (P=0.38) in cycle 1 
and 2, respectively. Because of the observations ,'eported in chapter 3, 
analysis of the fecal excretion of docetaxel was performed and showed a 
significant decrease after the combination treatment from 2.54 ± 2.05% to 
less than 1 % of the administered dose of docetaxel, most likely due to 
inhibition of the intestinal P-glycoprotein also by Lv. administered R101933. 
Plasma concentrations of R1 01933 were similar in cycle 0 and cycle 2 and 
the achieved concentrations were capable of inhibiting P-glycoprotein in an 
ex vivo assay. It can be concluded that the combination of docetaxel 100 
mg/m2 Lv. and R 101933 500 mg Lv. is feasible, lacks pharmacokinetic 
interaction in plasma, and with evidence of P-glycoprotein inhibition both in 
an ex vivo assay and in vivo by the indication of inhibition of intestinal P-
glycoprotein. 
As reviewed in chapter 1, many agents are known to be inhibitors of 
P-glycoprotein and Cremophor EL, the formulation vehicle of paclitaxel, is 
known to be one of these. This feature of Cremophor EL has been 
hypothesized as one of the explanations of the nonlinear pharmacokinetics 
of paclitaxel. In the second part of this thesis we report that a completely 
different cause underlies this phenomenon. 
Chapter 5 reviews the biological and pharmacological properties of 
the non-ionic surfactants Cremophor EL and Tween 80. Both are used as 
formulation vehicles of many (anticancer) agents including paclitaxel and 
docetaxel. Their influence on the disposition of the solubilized drugs, with 
focus on Cremophor EL and paclitaxel, and of concomitantly administered 
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drugs is discussed in detail. The ability of the surfactants to form micelles 
in aqueous solution as well as biological fluids (e.g. plasma) appears to be 
of great importance with respect to the pharmacokinetic behavior of the 
formulated drugs. Due to drug entrapment in the micelles, plasma 
concentrations and clearance of free drug change significantly leading to 
alteration in pharmacodynamic characteristics. Some perspectives related to 
further studies and development of alternative methods of administration 
are given. 
To give the initial impetus to the correct explanation of the 
nonlinearity of paclitaxel the in vitro cellular distribution of paclitaxel in 
human blood and the influence of Cremophor EL was evaluated as is 
presented in chapter 6. In the absence of Cremophor EL, the blood:plasma 
concentration ratio of paclitaxel was 1.07 ± 0.004 (mean ± SD). The 
addition of Cremophor EL at concentrations corresponding to peak plasma 
levels achieved after the administration of paclitaxel (175 mg/m2 i.v. over a 
3-h period; i.e. 0.50%) resulted in a significant decrease in the 
concentration ratio to 0.690 ± 0.005 (P < 0.05). Kinetic experiments 
revealed that this effect was due to reduced erythrocyte uptake of 
paclitaxel by polyoxyethyleneglycerol triricinoleate, the major compound 
present in Cremophor EL. Using equilibrium dialysis, it was shown that the 
affinity of paclitaxel for tested matrices was (in decreasing order) 
Cremophor EL > plasma > human serum albumin, with Cremophor EL 
present at or above the critical micellar concentration (approx. 0.01 %). 
These in vitro findings demonstrated a profound alteration of paclitaxel 
accumulation in erythrocytes caused by a trapping of the compound in 
Cremophor EL micelles, thereby reducing the free drug fraction available for 
cellular partitioning. It was proposed that the nonlinearity of paclitaxel 
plasma disposition in patients reported previously should be reevaluated 
prospectively by measuring the free drug fractions and whole blood:plasma 
concentration ratios. 
Before this prospective study could be performed more had to be 
known about the pharmacokinetics of Cremophor EL. Therefore, as reported 
in chapter 7, the clinical pharmacokinetics of Cremophor EL were studied 
and the interrelationships of paclitaxel disposition, infusion duration and 
Cremophor EL kinetics were examined. The Cremophor EL plasma 
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clearance, studied in 17 patients for a total of 28 courses, was time-
dependent and increased significantly with prolongation of the infusion 
duration from 1 to 3 to 24 h (P< 0.03). An indirect response model, applied 
based on use of a Hill function for Cremophor EL concentration-dependent 
alteration of in vivo blood distribution of paclitaxel, was used to fit 
experimental data of the 3-h infusion (,-2=0.733; P=0.00001). Simulations 
for 1- and 24-h infusions using predicted parameters and Cremophor EL 
kinetic data revealed that both short and prolonged administration 
schedules induce a low relative net change in paclitaxel blood distribution. 
Our pharmacokinetic/pharmacodynamic model demonstrated that 
Cremophor EL causes disproportional accumulation of paclitaxel in plasma 
in a 3-h schedule, but is unlikely to affect drug pharmacokinetics in this 
manner with alternative infusion durations. 
In chapter 8 the prospective re-evaluation of the linearity of paclitaxel 
disposition in patients using whole blood and plasma analysis is reported, 
and a new pharmacokinetic model to describe the data is defined. Seven 
patients with solid tumors were treated with paclitaxel infused over 3 h, 
each at consecutive 3-weekly dose levels of 225, 175 and 135 mg/m2 
(Cremophor EL dose level, 18.8, 14.6, and 11.3 mLlm2, respectively). 
Blood and plasma samples were collected up to 24 h after start of infusion, 
and analyzed by high-performance liquid chromatography. Paclitaxel peak 
levels and areas under the curve in whole blood increased linearly with 
dose, whereas plasma levels showed substantial deviation from linearity. 
This was shown to be caused by a Cremophor EL-concentration dependent 
decrease in paclitaxel uptake in blood cells, as reflected by the blood:plasma 
concentration ratios which altered significantly from 0.83 ± 0.11 (at 135 
mg/m2) to 0.68 ± 0.07 (at 225 mg/m2). It is concluded that the nonlinear 
disposition of paclitaxel is related to paclitaxel-dose related levels of the 
formulation vehicle Cremophor EL, leading to disproportional drug 
accumulation in the plasma fraction. The developed pharmacokinetic model 
could accurately describe the data, and will help guide future development 
and refinement of clinical protocols, especially in defining the exposure 
measure best linked to paclitaxel effects and toxicities. 
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Final conclusions and future perspectives 
Evaluation of plasma samples to determine the pharmacokinetics of a 
drug and to exclude a potential pharmacokinetic interaction in case of 
combined treatment should be a standard procedure at least in all phase I 
studies. On the other hand the above summarized studies demonstrated 
that plasma drug monitoring alone can not predict all physiological and 
pharmacological consequences of the administered treatment. 
This is examplified in the studies combining docetaxel with an 
inhibitor of P-glycoprotein, where analysis of the fecal excretion of 
docetaxel revealed the importance of intestinal P-glycoprotein in the 
disposition of this drug. This finding confirmed the physiological role of P-
glycoprotein as one of the biochemical barriers to restrict oral bioavailability 
of xenobiotics such as the 'naturally occurring' anticancer drugs. However, 
our findings also demonstrate that inhibiting P-glycoprotein alone is not 
enough to enhance oral bioavailability due to an efficient detoxification of 
the absorbed anticancer drug by cytochrome P450 isozymes present in the 
intestinal cells. Attempts to increase the oral bioavailability of several up to 
now intravenously delivered anticancer drugs such as the taxane drugs and 
the topoisomerase I inhibitors by co-administration of a P-glycoprotein 
inhibitor, have to make use of an inhibitor known to compete with the 
metabolism of the anticancer drug at the level of cytochrome P450 
isozymes. A clinical trial to apply this concept to enhance the oral 
bioavailability of irinotecan, a topoisomerase I inhibitor, is in progress at our 
institute. 
In the past, plasma pharmacokinetics of paclitaxel revealed a 
nonlinear disposition of this drug leading to extended speculations about the 
cause and the consequences for daily clinical practice. However, we 
showed that the cause is related to the limitations of analysing plasma 
samples alone. The plasma comprises a relatively small fraction of the total 
volume available for drug distribution and we showed that paclitaxel is 
equally distributed over plasma and blood cells before delivery to tissues 
and tumor. However, above a certain plasma concentration of Cremophor 
EL, the formulation vehicle necessary to enable parenteral administration of 
paclitaxel, the uptake of the drug in blood cells decreased due to 
entrapment in Cremophor EL micelles. Consequently, evaluation of plasma 
samples will show a disproportional increase in the concentration of 
paclitaxel, but evaluation of whole blood, i.e. plasma plus blood cells, will 
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reveal a linear disposition. Based on these findings we developed a model 
that accurately described the pharmacokinetics of paclitaxel at all dose 
levels studied and that provides a basis for refinement of future clinical 
protocols such that a certain concentration-time profile of free (unbound) 
paclitaxel can be targeted. Moreover, using this model, we are presently 
involved in a re-evaluation of the relationships between free-drug 
concentration-time profiles and paclitaxel-induced toxicity profiles, to 
improve the description of the concentration-response relationship and to 
predict more accurately the ultimate effect of dose and schedule variation. 
210 
Samenvatting en conclusies 
Samenvatting en conclusies 
De taxanen paclitaxel en docetaxel zijn middelen tegen kanker 
(cytostatica) die behoren tot de 'natuurlijk voorkomende' geneesmiddelen 
omdat ze afkomstig zijn van taxusbomen. Paclitaxel werd oorspronkelijk 
onttrokken aan de bast van de Taxus brevifolia; docetaxel werd ge'isoleerd 
uit de naalden van de Taxus baccata. Sinds ongeveer tien jaar nemen beide 
taxanen een belangrijke plaats in bij de behandeling van patienten met 
kanker. Veel onderzoek is gedaan naar de werking van deze geneesmiddelen 
(farmacodynamie) en naar de verwerking van deze stoffen door het lichaam 
(farmacokinetiek). Daarnaast is uitgebreid onderzocht of de werking van 
deze geneesmiddelen verbeterd kan worden door toediening in combinatie 
met andere geneesmiddelen, al dan niet andere cytostatica. Hierbij is het 
van belang de wederzijdse be'invloeding te onderzoeken, niet aileen met 
betrekking tot de werking, maar ook ten aanzien van de verwerking van de 
gecombineerde middelen door het lichaam. Dit laatste aspect is het 
onderwerp van dit proefschrift toegespitst op twee specifieke problemen: 1) 
de gevolgen voor de farmacokinetiek van docetaxel van de bewust 
nagestreefde farmacologische be'invloeding van dit taxaan door de nieuwe 
rem mer van P-glycoprote'ine R101933 en 2) de onbedoelde invloed op de 
farmacokinetiek van paclitaxel door Cremophor EL, het middel waarin 
paclitaxel is opgelost om toediening via een infuus mogelijk te maken. 
P-glycoprote'ine speelt een belangrijke rol bij multidrugresistentie. 
Multidrugresistentie is het fenomeen dat verantwoordelijk wordt geacht 
voor de aanwezigheid of het ontwikkelen van ongevoeligheid van 
kankercellen voor met name 'natuurlijk voorkomende' cytostatica. In dat 
geval zijn er in de celmembraan eiwitten aanwezig die passief 
binnengedrongen cytostatica direct naar buiten pompen en hiermee de 
celdodende werking van de cytostatica voorkomen. Van de klinische 
relevantie van twee van deze 'uitscheidingspompen', te weten P-
glycoprote'ine en MRP (multidrug resistance-associated protein). en van de 
pogingen om deze pompen te remmen wordt een overzicht gegeven in 
hoofdstuk 1. De nadruk wordt hierbij gelegd op P-glycoprote'ine en op de 
specifiek ontwikkelde tweedegeneratie remmers van deze pomp. Mogelijke 
verklaringen voor het beperkte klinische succes van deze remmers worden 
gegeven. De belangrijkste verklaring lijkt te zijn dat behandeling met de 
combinatie van een cytostaticum en een P-glycoprote'ineremmer vrijwel 
altijd leidt tot een toename van de bijwerkingen van het cytostaticum. Dit is 
212 
Samenvatting en conclusies 
het gevolg van be'invloeding van de farmacokinetiek van het cytostaticum 
door competitie met de gelijktijdig toegediende P-glycoprote'ineremmer op 
het niveau van de enzymen die verantwoordelijk zijn voor de stofwisseling 
van vele middelen (cytochroom P450-isozymen). Dit leidt tot een 
onbedoelde toename van de concentratie van het cytostaticum in het 
lichaam. Er worden richtlijnen geformuleerd waaraan de ontwikkeling van 
nieuwe P-glycoprote'ineremmers en waaraan het ontwerp van toekomstige 
onderzoeken met deze middelen moeten voldoen. 
In hoofdstuk 2 worden de resultaten beschreven van een fase I en 
farmacokinetisch onderzoek naar de behandeling met docetaxel in 
combinatie met de nieuwe remmer van P-glycoprote'ine R101933. De 
stofwisseling van R101933 is grotendeels onafhankelijk van cytochroom 
P450 3A4. Vijftien patienten deden mee aan dit onderzoek. Voor hen was 
docetaxel op dat moment het mid del van keus of er waren geen andere 
behandelingsmogelijkheden (meer) aanwezig. In kuur 0 werd aileen 
R101933 gegeven als drank in een dosering die begon met 200 mg 
tweemaal daags gedurende vijf dagen. Toen dit goed verdragen bleek te 
worden werd de dosering verhoogd naar 300 mg tweemaal daags 
gedurende vijf dagen. In kuur 1 werd docetaxel intraveneus (iv.) toegediend 
door middel van een 1-uur durend infuus in toenemende doseringen (60, 
75, 100 mg/m2). Hierna werd elke drie weken de combinatiebehandeling 
gegeven waarbij docetaxel op de derde dag na de start van de inname van 
R 101933 werd toegediend (kuur 2 en verder). De dosisbeperkende 
bijwerkingen bestonden uit slijmvliesontsteking en koorts optredend in de 
periode van een tekort aan witte bloedlichaampjes. Deze werden bereikt bij 
een dosis docetaxel van 100 mg/m2 in combinatie met een dosis R 101933 
van 300 mg tweemaal daags. De aanbevolen doseringen voor vervolg-
onderzoek met de combinatiebehandeling werden dan ook vastgesteld op 
docetaxel 100 mg/m2 en R101933 200 mg tweemaal daags. De 
concentraties R1 01933 die bereikt werden in het plasma van de patienten 
lagen in dezelfde orde van grootte als die welke noodzakelijk waren in 
preklinische onderzoeken bij knaagdieren om de resistentie van cellen voor 
paclitaxel tegen te gaan. De plasmaklaring van docetaxel veranderde niet 
door de gelijktijdige toediening van R101933 bij de geteste doseringen en 
bedroeg 26,5 ± 7,78 l/h/m 2 en 23,4 ± 4,52 l/h/m2 (P=0,15) in 
respectievelijk kuur 1 en 2. Dit geeft aan dat de farmacokinetiek van 
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docetaxel zoals gemeten in plasma niet werd be'invloed door R1 01933, wat 
betekent dat nu voor het eerst zuiver kan worden beoordeeld wat de 
bijdrage kan zijn van een rem mer van P-glycoprote'ine aan de activiteit van 
een cytostaticum. 
Bij vijf patienten werden niet aileen plasma monsters onderzocht, 
maar werd ook de ontlasting gespaard vanaf de start van het infuus met 
docetaxel tot 31 uur hierna tijdens kuur 1 en 2. Hiermee kon een meer 
volledig beeld verkregen worden van de rol die P-glycoprote'ine heeft in de 
distributie in en eliminatie uit het lichaam van docetaxel, zoals blijkt uit de 
resultaten beschreven in hoofdstuk 3. De cumulatieve fecale uitscheiding 
van onveranderd docetaxel bedroeg na kuur 1 (docetaxel aileen) 8,47 ± 
2,14% (gemiddelde ± SD) van de dosis en nam duidelijk af tot minder dan 
0,5% na toediening van docetaxel in combinatie met R101933 
(p= 0,0016). De concentraties in de ontlasting van de belangrijkste 
stofwisselingsproducten van docetaxel, die ontstaan door omzetting via 
cytochroom P450 3A4, waren significant toegenomen na de combinatie-
behandeling (p= 0,01 0). Dit laatste betekent dat er sprake lijkt te zijn van 
een efficiente ontgifting van het via de darm heropgenomen onveranderde 
docetaxel voordat het de algemene circulatie bereikt. In samenhang met 
eerdere bevindingen in plasma, beschreven in hoofdstuk 2, betekent dit dat 
de verminderde fecale uitscheiding van onveranderd docetaxel onder invloed 
van R1 01933 niet het gevolg is van vermindering van de (P-glycoprote'ine-
afhankelijke) uitscheiding via de galwegen, maar vooral veroorzaakt wordt 
door de aanwezigheid van P-glycoprote'ine in de darmen, Op grond van deze 
resultaten kon dan ook geconcludeerd worden dat de aanwezigheid van P-
glycoprote'ine in de darmen een belangrijke rol speelt bij de eliminatie van 
docetaxel via de darmen omdat het de heropname van docetaxel remt nadat 
het is uitgescheiden via de galwegen. Meer in het algemeen betekenen deze 
bevindingen dat de fysiologische en farmacologische gevolgen van remming 
van P-glycoprote'ine in normaal weefsel niet kan worden voorspeld louter op 
basis van metingen in plasma, 
Uit het onderzoek naar de combinatiebehandeling van docetaxel met 
R101933 oraal, zoals beschreven in hoofdstuk 2, bleek dat sprake was van 
een lage biologische beschikbaarheid van R 10 1933, Dit betekende dat geen 
verdere remming van P-glycoprote'ine bereikt kon worden door middel van 
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verhoging van de orale dosering. Daarom werd een nieuwe studie opgezet 
naar de haalbaarheid van behandeling met docetaxel gecombineerd met 
intraveneus toegediend R1 01933. De resultaten hiervan worden beschreven 
in hoofdstuk 4. De behandeling bestond uit toediening van aileen R101933 
iv. in een dosering die in de loop van het onderzoek toenam van 250 tot 
500 mg op dag 1 (kuur 0), docetaxel 100 mg/m2 als 1-uursinfuus op dag 8 
(kuur 1) en de combinatiebehandeling elke drie weken hierna (kuur 2 en 
verder). Twaalf patienten deden mee aan dit onderzoek van wie negen de 
combinatiebehandeling kregen. Na toediening van aileen R 101933 werden 
geringe bijwerkingen gezien voornamelijk bestaande uit voorbijgaande 
slaperigheid. De dosisbeperkende bijwerking bestond uit koorts, optredend 
in de periode van een tekort aan witte bloedlichaampjes, en werd zowel in 
kuur 1 als in kuur 2 en de vervolgkuren gezien en zowel na R101933 250 
mg als na 500 mg. De farmacokinetische parameters van docetaxel in 
plasma veranderden niet onder invloed van R101933 zoals onder andere 
bleek uit de klaring die gelijk bleef met waarden van 22,5 ± 6,2 l/h/m2 en 
24,2 ± 7,4 IIh/m2 (P=0,38) in respectievelijk kuur 1 en 2. Naar aanleiding 
van de bevindingen beschreven in hoofdstuk 3, werd ook nu de fecale 
uitscheiding van docetaxel en zijn stofwisselingsproducten gemeten. 
Overeenkomstig de eerdere resultaten nam de uitscheiding van onveranderd 
docetaxel significant af na de combinatiebehandeling van 2,54 ± 2,05 % 
van de toegediende dosis docetaxel na kuur 1 tot minder dan 1 % na kuur 2. 
Dit betekent dat waarschijnlijk ook na intraveneuze toediening van 
R1 01933 remming van P-glycoprote'ine in de darmen wordt bewerkstelligd. 
De plasmaconcentraties van R101933 verschilden niet tussen kuur 0 en 
kuur 2 en waren voldoende om P-glycoprote'ine te rem men zoals bleek uit 
een ex vivo assay. Geconcludeerd kon worden dat de behandeling met de 
combinatie docetaxel 100 mg/m 2 en R101933 500 mg iv. haalbaar was. 
Hierbij werd er geen wederzijdse be'invloeding gevonden van de 
plasmafarmacokinetiek. Een ex vivo assay en de aanwijzing dat P-
glycoprote'ine in de darm geremd werd bevestigden dat remming van P-
glycoprote'ine bereikt werd. 
In de literatuur zijn vele remmers van P-glycoprote'ine beschreven 
zoals samengevat is in hoofdstuk 1. Ook Cremophor EL, het oplosmiddel 
van paclitaxel, staat bekend als een rem mer van P-glycoprote'ine. Deze 
eigenschap is aangedragen als een van de verklaringen voor het feit dat er 
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voor paclitaxel in plasma geen rechtlijnig verband bestaat tussen de 
toegediende dosis paclitaxel en de farmacokinetische parameters (niet-
linea ire kinetiek). In de verdere hoofdstukken laten wij echter zien dat er een 
heel ander mechanisme aan dit fenomeen ten grondslag ligt. 
In hoofdstuk 5 wordt een overzicht gegeven van de biologische en 
farmacologische eigenschappen van de oppervlaktespanning-verlagende 
stoffen Cremophor EL en Tween 80. Beide worden gebruikt als oplosstoffen 
voor vele (antikanker-) geneesmiddelen inclusief paclitaxel (Cremophor EL) 
en docetaxel (Tween 80), maar beide stoffen zijn niet fysiologisch neutraal. 
Gedetailleerd wordt hun invloed op de farmacokinetiek en farmacodynamie 
van het opgeloste geneesmiddel besproken met nadruk op 
paclitaxel/Cremophor EL en op gelijktijdig hiermee toegediende andere 
geneesmiddelen. De eigenschap van Cremophor EL om micellen te vormen 
in zowel waterige oplossingen als biologische vloeistoffen (bv. plasma) lijkt 
van groot belang te zijn voor het farmacokinetische gedrag van het 
opgeloste geneesmiddel of een gelijktijdig toegediend ander geneesmiddel. 
Ten gevolge van opsluiting van het geneesmiddel in de micellen veranderen 
de plasmaconcentraties en de klaring van de vrije fractie van het 
geneesmiddel. Oit leidt aantoonbaar tot verandering in de farmaco-
dynamische karakteristieken. Aan het eind van het overzicht worden enkele 
overwegingen gegeven met betrekking tot verdere ontwikkeling van en 
onderzoek naar alternatieve methoden voor de toediening van genees-
middelen die nu opgelost moeten worden in Cremophor EL of Tween 80. 
Ais eerste aanzet voor het vinden van de juiste verklaring voor de 
niet-lineaire kinetiek van paclitaxel werd, lOals beschreven in hoofdstuk 6, 
in een 'reageerbuis' (in vitro) de verdeling van paclitaxel over de diverse 
componenten van bloed en de invloed van Cremophor EL hierop onderzocht. 
Het bleek dat de verhouding van de concentraties van paclitaxel in bloed en 
plasma 1,07 ± 0,004 (gemiddelde ± SO) was in afwezigheid van 
Cremophor EL. Na toevoeging van Cremophor EL, tot concentraties die 
overeenkwamen met de maximale plasmaconcentraties die bereikt worden 
na toediening van paclitaxel (175 mg/m2 iv. in 3-h; d.i. 0,50%) aan 
patienten, daalde de verhouding significant tot 0,690 ± 0,005 (P< 0,05). 
Kinetiekexperimenten lieten zien dat dit effect veroorzaakt werd door 
vermindering van de opname van paclitaxel in de rode bloedlichaampjes 
(erythrocyten) ten gevolge van polyoxyethyleneglyceroltriricinoleaat, de 
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belangrijkste component van Cremophor EL. Door middel van 
evenwichtsdialyse werd duidelijk dat de affiniteit van paclitaxel voor de 
onderzochte bestanddelen als voigt was weer te geven (in afnemende orde): 
Cremophor EL > plasma > menselijk serum albumine, waarbij de 
concentratie Cremophor EL gelijk was aan of groter was dan de kritische 
micelconcentratie (ongeveer 0,01 %). Deze in vitro-bevindingen bevestigden 
dat de verandering van de opname van paclitaxel in de erythrocyten werd 
veroorzaakt door opsluiting van het geneesmiddel in Cremophor EL-micellen. 
Dit heeft tot gevolg dat de vrije fractie van paclitaxel afneemt zodat minder 
geneesmiddel beschikbaar is voor cellulaire verdeling. Om te laten zien dat 
dit ook bij patienten een rol speelt en dat dit de verklaring is voor het 
bestaan van niet-lineaire kinetiek van paclitaxel wordt de aanbeveling 
gedaan prospectief onderzoek op te zetten waarin de bloed:plasma 
verhouding van de concentratie paclitaxel opnieuw prospectief bepaald 
moet worden en waarin zo mogelijk de vrije fractie paclitaxel in bloed wordt 
gemeten. 
Voordat deze prospectieve studie kon plaatsvinden was het van 
belang meer kennis te verkrijgen van de farmacokinetiek van Cremophor EL. 
In hoofdstuk 7 wordt dan ook het onderzoek beschreven naar de farmaco-
kinetiek van Cremophor EL en naar de samenhang tussen deze kinetiek, de 
duur van het infuus en de verdeling van paclitaxel in het bloed. De klaring 
van Cremophor EL, bestudeerd in 17 patienten die totaal 28 kuren paclitaxel 
kregen, bleek afhankelijk te zijn van de infusieduur en significant toe te 
nemen met een toename van de infusieduur van 1 naar 3 naar 24 uur 
(P<O,03). Door middel van een mathematisch model gebaseerd op de 
Cremophor EL concentratieafhankelijke verandering van de verdeling van 
paclitaxel in bloed konden de experimentele gegevens van de 3-uursinfusie 
beschreven worden (,-2=0,733; P=O,00001). Simulaties voor 1- en 24-
uursinfusies, gebruikmakend van voorspelde parameters en gegevens van 
de kinetiek van Cremophor EL, gaven aan dat deze beide infusieduren 
leidden tot een relatief lage nettoverandering in de verdeling van paclitaxel 
over de bloedbestanddelen. Het model laat dus zien dat, indien er sprake is 
van toediening van paclitaxel/Cremophor EL in drie uur, Cremophor EL een 
onevenredige ophoping van paclitaxel in plasma veroorzaakt. 8ij alternatieve 
infusieduren wordt de farmacokinetiek van het geneesmiddel waarschijnlijk 
niet op deze manier be'lnvloed. 
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In hoofdstuk 8 wordt de voorgestelde prospectieve studie beschreven 
naar de verklaring voor de niet-lineaire kinetiek van paclitaxel bij patienten. 
Hierbij werd gebruikgemaakt van bloed en plasma analyses. Tevens wordt 
een nieuw farmacokinetisch model gedefinieerd om de gegevens te kunnen 
beschrijven. Zeven patienten met een solide tumor werden behandeld met 
paclitaxel toegediend in drie uur, in de opeenvolgende dosering van 225, 
175 en 135 mg/m2 (Cremophor EL-concentratie respectievelijk 18,8, 14,6 
en 11,3 ml/m2) in een driewekelijks schema. Bloed- en plasmamonsters 
werden verzameld gedurende de 24 uur na de start van het infuus en 
werden geanalyseerd met behulp van hogedrukvloeistofchromatografie 
(HPLC). In bloed nam de maxima Ie concentratie en de oppervlakte onder de 
curve van paclitaxel rechtlijnig toe met de toegediende dosis, terwijl de 
waarden in plasma van de kinetiekparameters een duidelijke afwijking van 
de rechte lijn vertoonden. Door berekening van de bloed/plasma-
concentratieverhoudingen van paclitaxel, die significant daalden van 0,83 ± 
0,11 (bij 135 mg/m2) naar 0,68 ± 0,07 (bij 225 mg/m 2), werd duidelijk dat 
de niet-lineaire kinetiek in plasma werd veroorzaakt door een vermindering 
van de opname van paclitaxel in bloedcellen, die afhankelijk is van de 
aanwezige concentratie Cremophor EL. Dit leidt tot een onevenredige 
ophoping van het geneesmiddel in het plasma. Met het ontwikkelde 
farmacokinetische model konden nauwkeurig de gegevens worden 
weergegeven. 
Conclusies en vooruitzichten 
Onderzoek naar de farmacokinetiek van een geneesmiddel, op grond 
van analyse van afgenomen plasmamonsters, en het uitsluiten van een 
eventuele farmacokinetische interactie tussen geneesmiddelen onderling 
dient een ge'integreerd onderdeel van fase I-studies te zijn. Uit de 
onderzoeken beschreven in dit proefschrift blijkt echter ook dat het 
analyseren van louter plasmamonsters niet het gehele beeld van 
fysiologische en farmacologische gevolgen van de behandeling kan 
weergeven. Indien docetaxel gecombineerd wordt met een rem mer van P-
glycoprote'ine blijkt onderzoek van de fecale uitscheiding van docetaxel een 
aanwijzing te geven veer het belang van de aanwezigheid van P-
glycoprote'ine in de darmen voer de distributie in en eliminatie uit het 
lichaam van dit geneesmiddel. Daarmee bevestigt deze bevinding de 
fysiologische rol van P-glycoprote'ine als een van de barrieres van het 
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lichaam die opname tegengaan van oraal binnengekregen giftige stoffen 
zoals de 'natuurlijk voorkomende' cytostatica. Daarnaast laten de 
beschreven onderzoeken echter zien dat het omzeilen van deze barriere door 
het toedienen van remmers van P-glycoprote'ine niet voldoende is om de 
orale beschikbaarheid van cytostatica te vergroten. Indien er wei opname 
plaatsvindt voigt namelijk een efficiente ontgifting van de opgenomen stof 
door cytochroom P450-isozymen die aanwezig zijn in de darmcellen. Voor 
studies naar het verbeteren van de orale biologische beschikbaarheid met 
behulp van een rem mer van P-glycoprote'ine van tot op heden intraveneus 
toegediende cytostatica, bijvoorbeeld taxanen en topo'isomerase I-remmers, 
moet dan ook gekozen worden voor een remmer die ook ingrijpt op de 
stofwisseling van het cytostaticum. Dit gebeurt indien er sprake is van 
competitie tussen rem mer en cytostaticum op het niveau van de 
cytochroom P450-isozymen. Binnenkort zal in ons ziekenhuis een onderzoek 
uitgevoerd worden waarin dit principe zal worden toegepast om verbetering 
van de orale biologische beschikbaarheid van irinotecan, een topoisomerase 
I-remmer, te bereiken. 
Uit vroegere onderzoeken naar de farmacokinetiek van paclitaxel was 
duidelijk geworden dat bij dit geneesmiddel sprake was van niet-Iineaire 
kinetiek. Dit leidde tot uitgebreide discussies in de Iiteratuur over de 
mogelijke oorzaak hiervan en over de gevolgen voor de klinische toepassing 
van paclitaxel. De studies beschreven in dit proefschrift laten echter zien 
dat de verklaring in verband staat met de beperkingen van het louter 
evalueren van plasmamonsters. Plasma omvat een relatief klein gedeelte 
van het totale volume dat een stof voor zijn verdeling over het Iichaam ter 
beschikking heeft. Wij toonden aan dat paclitaxel tot aflevering aan 
weefsels en tumor gelijkelijk is verdeeld over plasma en bloedcellen. 
Wanneer echter de concentratie van Cremophor EL, de oplosstof van 
paclitaxel die nodig is om intraveneuze toediening mogelijk te maken, boven 
een bepaalde grens komt, vermindert de opname van paclitaxel in de 
bloedcellen ten gevolge van het ontstaan van Cremophor EL-micellen waarin 
paclitaxel wordt opgesloten. Als gevolg hiervan laten plasmamonsters, 
waarin de micellen zich bevinden, een onevenredige toename zien van de 
concentratie paclitaxel. Evaluatie van bloedmonsters - dit is plasma plus 
bloedcellen - laat echter een met de dosis evenredige toename van de 
concentratie paclitaxel zien. Gebaseerd op deze bevindingen werd een 
model ontwikkeld waarmee de farmacokinetiek van paclitaxel op de juiste 
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manier kon worden beschreven en waarmee protocollen voor toekomstige 
studies verbeterd kunnen worden zodat de vrije (niet-gebonden) fractie van 
paclitaxel het doel van de farmacokinetische studies gaat worden. 
Daarnaast vindt momenteel een herevaluatie plaats van de relatie tussen de 
vrije concentratie paclitaxel en de bijwerkingen van dit middel, zodat 
uiteindelijk het effect van veranderingen in dosis en toedieningsschema's 
beter voorspeld kan worden. 
220 
DANKWOORD 
De afronding van het promotieonderzoek beschreven in dit 
proefschrift vindt plaats kort voor mijn veertigste verjaardag. Onwillekeurig 
leidt het bereiken van deze twee mijlpalen, de een bewust nagestreefd, de 
ander ongemerkt genaderd, tot een moment van bezinning. Ik ervaar het 
verkrijgen van de titel 'doctor' als het resultaat van de vorming door en de 
hulp van velen een heel leven lang. Ik kan hier daarom nooit volledig 
weergeven aan wie ik dank verschuldigd ben. Desalniettemin wil ik een 
aantal mensen noemen. De scheiding tussen werk en persoonlijk leven die 
ik daarvoor aanbreng is bedoeld om het overzicht te bewaren. Gelukkig kan 
ik constateren dat je ook op je werk vrienden kunt maken. 
Allereerst dank ik mijn promotor professor J. Verweij. Beste Jaap, jij 
hebt me de ruimte geboden om vanuit twijfel te groeien naar overtuiging. 
Oat dit proces zich in de korte tijd van drie jaar kon voltooien is te danken 
aan je kwaliteiten als wetenschapper en leermeester. Je voortdurende 
positieve stimulatie en een enkel streng woord op het juiste tijdstip hebben 
me behouden door deze periode geloodst met dit proefschrift als resultaat. 
Voor mij stond vanaf het begin vast dat, aile voorschriften ten spijt, dr. A. 
Sparreboom ook officieel mijn copromotor zou moeten zijn. Beste Alex, 
zonder jouw aanwezigheid en bereikbaarheid zou dit proefschrift nooit 
geschreven zijn. Het belang van het beschreven onderzoek werd voor mij 
geleidelijk duidelijk door je onvermoeibare uitleg van kleine details en grote 
lijnen. Daarnaast had je altijd een open oor voor persoonlijke hoogte- en 
dieptepunten. Ik hoop in de toekomst veel met je te blijven delen. Professor 
G. Stoter, beste Gerrit, mijn achting voor jou is groot. Jij schept op 
onnavolgbare wijze een sfeer van vrijheid en gelijkheid. Vanaf mijn eerste 
werkdag bij de afdeling Interne Oncologie van AZR-Daniel gaf dit me de 
gelegenheid tot innerlijke groei als internist en tot ontplooiing van mijn 
mogelijkheden als wetenschapper. Daarnaast maakte jij het mij mogelijk om 
in mijn persoonlijk leven de grote stap naar moederschap in rust te maken. 
Mijn collegae van heden en verleden ben ik aile dank verschuldigd. 
Zonder hun luisterend oor en meeleven in momenten van vreugde en twijfel 
had ik niet bereikt waar ik nu ben aangekomen. Walter Loos, Eric Brouwer 
en Peter de Bruijn, ana listen, wil ik bedanken voor al het (denk-}werk dat zij 
voor mij hebben verricht in het laboratorium. Zonder jullie ideeen, inzet en 
221 
bereidheid tot vaak lastige en tijdrovende metingen was de inhoud van dit 
proefschrift een stuk minder interessant geweest. Linda Ouwens, Anita 
Bras, Vera van Beurden, Maureen de Boer, Agnes Klaren en Corine Nierop, 
researchverpleegkundigen, wil ik bedanken voor hun inzet om de 
beschreven studies op de werkvloer te introduceren en te begeleiden, de 
data te verzamelen en de deelnemende patienten te begeleiden. De 
data managers en met name Gerda de Heus-Colijn en Judith ter Steeg wil ik 
bedanken voor de nauwgezette verwerking van aile studiegegevens, 
waardoor het beschrijven van de resultaten een betrekkelijk eenvoudige 
zaak werd. Aline Treuren-den Braber en Petra Bos ben ik zeer dankbaar voor 
hun hulp bij de opmaak van dit proefschrift. Aline, tegenslag en stress 
horen blijkbaar bij dit proces, maar hebben door jouw doorzettingsvermogen 
en bereidheid tot overleg nooit de overhand gekregen. Je collegae van het 
secretariaat dank ik niet aileen voor hun flexibiliteit waardoor jij de ruimte 
kon krijgen om dit proefschrift te redigeren, maar ook voor hun al jaren 
aanwezige ondersteuning in de zorg voor de patienten. Marijke Westerhout-
Kersten en de andere medewerksters van de medische bibliotheek ben ik 
aile dank verschuldigd voor de niet aflatende en snelle verstrekking van 
oude en nieuwe artikelen. Hun (klant-)vriendelijkheid is een voorbeeld voor 
velen. Aile verpleegkundigen, afdelingssecretaressen, doktersassistenten en 
andere medewerk(st)ers van De Daniel wil ik zeer bedanken voor de 
geboden ondersteuning in patientenzorg en onderzoek en voor het scheppen 
van een goede en bijzondere werksfeer. Op onnavolgbare wijze droeg Sonja 
de Cauwer-Louman hieraan bij, en het blijft onvoorstelbaar dat zij nooit 
meer op haar vertrouwde plaats zal zitten. 
Ik wil niet nalaten de verpleegkundigen en (afdelings-)secretaressen 
te bed an ken met wie ik in het veri eden op andere plaatsen heb 
samengewerkt. Van hun praktische en soms ook persoonlijke ondersteuning 
heb ik veel geleerd. Voor deze periode ben ik ook dank verschuldigd aan Dr. 
J.M. Werre, mijn opleider. Beste Jan, jou zie ik zeker in terugblik als mijn 
beroepsmatige 'vader'. Jouw inzicht in de problematiek van de patient was 
zeer leerzaam en van blijvende waa.rde. Daarnaast heb je minstens zo veel 
bijgedragen aan mijn persoonlijke vorming door je levenswijsheid. Jan Thies, 
Herman Lamers, Jaap Mol en Bian Tan, internisten en mijn bazen van het 
eerste uur, jullie wil ik bedanken voor de ooit geboden mogelijkheid 
daadwerkelijk dokter te worden. In het toenmalige Elisabeth Gasthuis 
ontstond mijn wens internist te worden mede door jullie voorbeeld. Ook 
222 
Loek van Kempen, cardioloog, wil ik bedanken voor het toen geschonken 
vertrouwen aan een echte beginneling. 
De patienten vormen een onlosmakelijk deel van mijn bestaan. De 
band die ik met velen van hen kon opbouwen is voor mij van grote 
betekenis. Zonder hun vertrouwen en bereidheid tot samenwerking had ook 
dit proefschrift niet tot stand kunnen komen. Ik dank hen daarvoor. 
Ik ben nu aangekomen bij mijn persoonlijk leven. Mijn moeder ben ik 
onuitsprekelijk dankbaar voor de basis die zij gelegd heeft en het is 
verdrietig dat zij al jaren geen getuige meer is van mijn verdere vorming. Zij 
en mijn vader hebben mij altijd gestimuleerd tot kennisverwerving en 
hebben mij geleerd te volharden op de ingeslagen wegen. Pa, ik wil je 
hiervoor bedanken en hieraan toevoegen dat ik jou en tante Riet dankbaar 
ben voor jullie steun en praktische hulp geboden de laatste jaren. Marja en 
Bram, dierbare zus en broer, jullie wil ik danken voor de onvoorwaardelijke 
band die wij met elkaar hebben. Thea en Max Livingston-Buijs, mijn tante en 
oom, zijn vanaf mijn vroegste jaren op de achtergrond en zo nodig op de 
voorgrond aanwezig geweest. Tante Thea en oom Max, veel dank hiervoor. 
Bian en Rineke Tan-Coumans, mijn schoonouders, hebben mij direct en met 
liefde in hun gezin opgenomen. Bian en Rineke, ik ben jullie hier dankbaar 
voor evenals voor jullie praktische en inhoudelijke ondersteuning. 
Mijn kinderjaren worden gekleurd door de vriendschap met Lenny 
Guyt, mijn tienerjaren zijn onlosmakelijk verbonden met Judith de Wilde. 
Lenny en Judith, jullie vriendschap heeft een blijvende betekenis gehad voor 
mijn leven en ik ben jullie en jullie ouders dankbaar voor de betrokkenheid 
die er nog steeds is. Irene Kunst-Janssens, Liesbeth Botden en Anneke 
Zaalberg, de vriendschap met ieder van jullie is voor mij van onnoemelijk 
belang. Zij heeft ervoor gezorgd dat ik niet vergeten ben waar het in het 
leven echt om gaat. Otto van Eysden, jouw aandacht heeft een blijvende 
waarde gekregen, je hulp heeft mij door menige periode heen geholpen. 
Marius van der Marel, zonder jouw verrassende aanwezigheid lOU mijn 
leven minder kleurrijk zijn. Marjo ,van Kasteren en Maja de Jonge, de 
vriendschap met jullie ontstond tijdens het werk en geeft daardoor steun die 
onvervangbaar is. 
De laatste woorden richt ik tot twee mensen die lo allesbepalend zijn 
voor mijn leven dat woorden van dank niet kunnen omvatten wat zij voor 
mij betekenen. Minke, lieve dochter, je bent pas kort in ons leven, maar je 
223 
levensvreugde en evenwichtigheid hebben mij ge'inspireerd en geholpen dit 
proefschrift tot een goed einde te brengen. Marcel, mijn man, de 
vanzelfsprekendheid waarmee jij gelijkwaardigheid vorm geeft is essentieel 
geweest voor mijn professionele ontwikkeling, maar is slechts een van de 
vele aspecten die ik in je bewonder. 
224 
CURRICULUM VITAE 
Lia van Zuijlen werd op 16 januari 1961 geboren te Katwijk (ZH). In 
1979 behaalde zij het VWO-diploma aan het Pieter Groen College te 
Katwijk. Na uitloting van de studie Geneeskunde begon zij in dit jaar met de 
studie Psychologie aan de Rijksuniversiteit Leiden. Hoewel zij de colleges 
van deze studie met plezier volgde, besloot zij toch na inloting in 1980 
Geneeskunde te gaan studeren aan voornoemde universiteit. Tijdens de 
studie was zij werkzaam als student-assistent bij de vakgroep 
Kindergeneeskunde en als wetenschappelijk assistent bij de vakgroep 
Interne Geneeskunde. In augustus 1988 behaalde zij haar artsexamen. 
Gedurende 2 jaar werkte zij als arts-assistent bij de afdelingen Interne 
Geneeskunde en Cardiologie van Ziekenhuis Rijnstate, locatie EG, te 
Arnhem (H. Lamers, L. van Kempen). In oktober 1990 startte zij haar 
opleiding tot internist in hetzelfde ziekenhuis op de locatie DH (Dr. J.M. 
Werre, Dr. L. Verschoorl, welke in januari 1995 werd voortgezet in het Sint 
Radboud Ziekenhuis te Nijmegen (Prof. dr J. van der Meer). In oktober 1996 
begon zij haar vervolgopleiding in het aandachtsgebied Medische Oncologie 
in het Academisch Ziekenhuis Rotterdam, locatie Daniel (Prof. dr G. Stoter). 
In deze periode kwam dit proefschrift tot stand. Momenteel is zij werkzaam 
als internist-oncoloog in dit ziekenhuis. 
225 
PUBLICATIONS 
1. Van Wouwe JP, Van Zuijlen C: Changes of zinc values in children during 
malignant disease. Biological Trace Element Res 30: 197-204, 1991 
2. Van Zuijlen C, Oostendorp FMGM, Van Beusekom BR, Cools HJM, Bolk JH, 
Ligthart GJ: Increasing drug use in nursing homes. Neth J Med 132: 1692-
1695, 1988 
3. Van Zuijlen C, Essink AWG, Van Leusen R, Bosch FH: Severe lactate acidosis 
due to treatment with metformine. Intensive Care Rev 10:86-89, 1995 
4. Van Zuijlen L, Schellens JHM, Goey SH, Pronk LC, de Boer-Dennert MM, 
Loos WJ, Ma J, Stoter G, Verweij J: Phase I and pharmacologic study of the 
arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients 
with non-small cell lung cancer. Anti-Cancer Drugs 10:361-368, 1999 
5. Sparreboom A, Van Zuijlen L, Brouwer E, Loos WJ, De Bruijn P, Gelderblom 
H, Pillay M, Nooter K, Stoter G, Verweij J: Cremophor EL-mediated alteration 
of paclitaxel distribution in human blood: Clinical pharmacokinetic 
implications. Cancer Res 59: 1454-1457, 1999 
6. Loos WJ, De Bruijn p, Van Zuijlen L, Verweij J, Nooter K, Stoter G, 
Sparreboom A: Determination of 5-fluorouracil in microvolumes of human 
plasma by solvent extraction and high-performance liquid chromatography. J 
Chromatogr B 735:293-297, 1999 
7. Van Zuijlen L, Sparreboom A, Van Der Gaast A, Van Der Burg MEL, Van 
Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J: The orally 
administered P-glycoprotein inhibitor R 1 01933 does not alter the plasma 
pharmacokinetics of docetaxel. Clin Cancer Res 6: 1365-1371, 2000 
8. Eskens FALM, Greim GA, Van Zuijlen L, Wolff I, Denis LJ, Planting ASTh, 
Muskiet FA, Wanders J, Barbet NC, Choi L, Capdeville R, Verweij J, 
Hanauske A-R, Bruntsch U for the EORTC Early Clinical Studies Group: Phase 
I and pharmacologic study of weekly administration of the polyamine 
synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. 
Clin Cancer Res 6:1736-1743,2000 
9. Van Zuijlen L, Nooter K, Sparreboom A, Verweij J: Development of 
multidrug-resistance convertors: Sense or nonsense? Invest New Drugs 
18:205-220, 2000 
10. Van Zuijlen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A: Role 
of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in 
humans. Clin Cancer Res 6:2598-2603, 2000 
11. Van Zuijlen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, 
Sparreboom A: Interrelationships of paclitaxel disposition, infusion duration 
and Cremophor EL kinetics in cancer patients. Anti-Cancer Drugs 11 :331-
337, 2000 
12. Van Zuijlen L, Verweij J, Sparreboom A: Role of formulation vehicles in 
taxane pharmacology. Invest New Drugs (in press) 
13. Van Zuijlen L, Karlsson MO, Verweij J, Brouwer E, De Bruijn P, Nooter K, 
Stoter G, Sparreboom A: Pharmacokinetic modeling of paclitaxel 
encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol (in 
press) 
14. Van Zuijlen L, Sparreboom A, van der Gaast A, Eskens FALM, Brouwer E, Bol 
CJ, de Vries R, Palmer PA, Verweij J: Disposition of docetaxel in the 
presence of P-glycoprotein inhibition by intravenous administration of 
R101933. Submitted 
226 
Abstracts 
1. Van Zuijlen L, Sparreboom A, Bol CJ, Van Der Gaast A, Van Der Burg MEL, 
Palmer PA, Verweij J: R1 01933, an oral MDR-reversing agent that does not 
alter the pharmacokinetics of docetaxel in patients with solid tumors. Proc 
Am Ass Cancer Res #4376, 1999 
2. Van Zuijlen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A: Role 
of intestinal MDR1 P-glycoprotein in the plasma disposition and fecal 
elimination pathways of docetaxel in humans. Clin Cancer Res 5(S):518, 
1999 
3. Sparreboom A, Van Zuijlen L, Verweij J, Mross K, Brouwer E, Gianni L: 
Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL 
kinetics in cancer patients. Proc AACR-NCI-EORTC Int Conf 1: 112, 1999 
4. Van Zuijlen L, Eskens FALM, Bridgewater J, Sparreboom A, Sklenar I, Planting 
AST, Choi L, Mueller C, Capdeville R, Ledermann JA, Verweij J: The 
polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in 
metastatic colorectal cancer (MCC): Results of a phase I and pharmacokinetic 
study. Proc Am Soc Clin Oncol #751, 2000 
5. Sparreboom A, Verweij J, Van Zuijlen L, and Karlsson MO: A pharmacokinetic 
model for micellar encapsulation of paclitaxel in Cremophor EL. Proc Am 
Assoc Cancer Res 41 :522,2000 
6. Van Zuijlen L, Sparreboom A, Brouwer E, Van Der Gaast A, Eskens FALM, 
Bol CJ, De Vries R, Palmer PA, Verweij J: Disposition of docetaxel in the 
presence of confirmed P-glycoprotein inhibition through intravenous 
R1 01933 administration. Proc AACR-NCI-EORTC Int Conf #187, 2000 
227 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
j 
I 
j 
